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Aim and outline of this thesis 
Optically pure aspartic acid derivatives are highly valuable as tools for biological research and as 
chiral building blocks for pharmaceuticals, nutraceuticals, and peptidomimetics. The preparation of 
these amino acids remains a difficult and laborious task with conventional organic synthesis, and 
the use of a biocatalytic methodology can be an important and highly competitive alternative 
option. In recent years, the enzyme methylaspartate ammonia lyase (MAL), which in nature 
catalyzes the conversion of 3-methylaspartate to ammonia and mesaconate, has gained a lot of 
interest because of its potential for application in the asymmetric synthesis of substituted aspartic 
acids. However, the biocatalytic applicability of MAL is limited by its poor diastereoselectivity and 
narrow substrate scope. Therefore, the aim of the work described in this thesis was to engineer 
MAL, guided by the crystal structure of the enzyme in complex with its natural substrate, in order 
to enhance its diastereoselectivity and to broaden its substrate scope, making this lyase more 
suitable for biocatalytic applications.  
In Chapter 1, we review the current knowledge on aspartate ammonia lyases and methylaspartate 
ammonia lyases. The main focus of this chapter is on the three-dimensional structures of these 
lyases in complex with their natural substrates, their catalytic mechanisms, and the recent progress 
in the engineering and application of these enzymes to prepare enantiopure L-aspartic acid 
derivatives. 
In Chapter 2, we describe the engineering of MAL with the aim to alter its diastereoselectivity. 
Based on the crystal structure of the enzyme complexed with substrate, the residues Lys-331, His-
194 and Gln-329 are suggested to be involved in the formation and stabilization of the enolate anion 
intermediate. The roles of these active site residues in the diastereoselectivity of the MAL-catalyzed 
reaction were investigated by using site-directed mutagenesis. Substitutions at these positions 
resulted in mutant enzymes that show strongly enhanced diastereoselectivity in the amination of 
mesaconate. It is suggested that the high diastereo- and enantioselectivity of the most active mutant 
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(H194A) can be exploited for the selective synthesis of the desired threo isomers of various 3-
substituted aspartic acids. 
In Chapter 3, we describe the engineering of MAL for the asymmetric synthesis of valuable 
aspartic acid derivatives. The engineering strategy was based on saturation mutagenesis at carefully 
chosen sites lining the binding pocket for the substrate’s amino or methyl group, with a view to 
expanding both the nucleophile and electrophile spectrum of MAL. Engineering of the amine-
binding pocket yielded a mutant enzyme (Q73A) that exhibits a very broad nucleophile scope in the 
addition reaction to mesaconate. Engineering of the methyl-binding pocket resulted in a mutant 
enzyme (L384A) that has a very broad electrophile scope in the ammonia addition reaction. These 
engineered MALs have exciting potential as biocatalysts for the asymmetric synthesis of a large 
variety of substituted aspartic acids. 
In Chapter 4, we report the synthesis of a large variety of N-substituted aspartic acids by the 
addition of structurally diverse amines to fumaric acid, using the Q73A mutant enzyme as 
biocatalyst. The enzyme-catalyzed addition reactions are highly enantioselective, only yielding the 
L-enantiomers of the corresponding amino acid products.  
In Chapter 5, we describe kinetic resolutions and asymmetric synthesis of various 3-substituted 
aspartic acids using the H194A and H194A\L384A mutant enzymes as biocatalysts. The enzyme-
catalyzed reactions are highly stereoselective, which allows the preparation of various 3-substituted 
aspartic acids with a high diastereo- and enantiomeric excess.  
In Chapter 6, we describe the roles of active site residues in the catalytic mechanism of MAL. 
Based on the crystal structure of the enzyme in complex with the natural substrate, the residues that 
contribute towards substrate binding were selected and subjected to site-directed mutagenesis. The 
mutant enzymes were characterized for their structural integrity and ability to catalyze the 
amination of mesaconate. On the basis of the observed properties of the mutant enzymes, we 
propose a detailed catalytic mechanism for the MAL-catalyzed reaction. 
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In Chapter 7, we report the cloning, recombinant expression and purification of methylaspartate 
ammonia lyase from the thermophilic bacterium Carboxydothermus hydrogenoformans Z-2901. 
Heat-inactivation assays showed that the purified enzyme is stable at 50°C for several hours. The 
enzyme shows a broad substrate scope, accepting various substituted amines and fumarates, and 
displays high regio- and stereoselectivity. This makes this newly identified thermostable MAL an 
attractive biocatalyst for the asymmetric synthesis of aspartic acid derivatives and a promising 
target for future engineering experiments. 
In Chapter 8, the work described in this thesis is summarized, final conclusions are drawn, and 
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Ammonia lyases catalyze the formation of α,β-unsaturated bonds by the elimination of ammonia 
from their substrates. This conceptually straightforward reaction has been the emphasis of many 
studies, with the main focus on the catalytic mechanism of these enzymes and/or the use of these 
enzymes as catalysts for the synthesis of enantiomerically pure α-amino acids. In this review 
aspartate ammonia lyase and 3-methylaspartate ammonia lyase, which represent two different 
enzyme superfamilies, are discussed in detail. In the last few years, the three-dimensional structures 
of these lyases in complex with their natural substrates have revealed the details of two elegant 
catalytic strategies. These strategies exploit similar deamination mechanisms that involve general-
base catalyzed formation of an enzyme-stabilized enolate anion (aci-carboxylate) intermediate. 
Recent progress in the engineering and application of these enzymes to prepare enantiopure L-
aspartic acid derivatives, which are highly valuable as tools for biological research and as chiral 





Ammonia lyases are capable of cleaving carbon-nitrogen bonds without employing hydrolysis or 
oxidation mechanisms.
[1]
 Various ammonia lyases exist in nature, with three types of lyases specific 
for aspartate or its derivatives as substrates: aspartate ammonia lyase (aspartase), 3-methylaspartate 
ammonia lyase (MAL) and 3-hydroxyaspartate ammonia lyase.
[1]
 
Aspartate ammonia lyase (aspartase; EC 4.3.1.1) plays an important role in microbial 
nitrogen metabolism by catalyzing the reversible deamination of L-aspartate (1) to yield fumarate 
(2) and ammonia (Scheme 1A). This enzyme was discovered in the early twentieth century after it 
was established that bacteria could transform aspartate to succinate.
[2, 3]
 It was shown in 1926 that 
an equilibrium between L-aspartate, fumarate and ammonia exists in the presence of resting 
bacterial cells, and further investigation indicated that a deaminase was responsible for the 
reversible elimination of ammonia from L-aspartate to give fumarate.
[4]
 Since then, extensive 
investigations have resulted in the identification and characterization of aspartase from various 
organisms, including Escherichia coli, Pseudomonas fluorescens, Hafnia alvei (formerly known as 
Bacterium cadaveris), Bacillus subtilis, and Bacillus sp. YM55-1.
[5-13]
 
3-Methylaspartate ammonia lyase (MAL; EC 4.3.1.2) catalyzes the reversible α,β-
elimination of ammonia from L-threo-3-methylaspartate (3) and L-erythro-3-methylaspartate (4) to 
yield mesaconate (5) (Scheme 1B). MAL activity was first detected by Barker et al.
[14]
 in cell-free 
extracts of the anaerobic bacterium Clostridium tetanomorphum H1. In this bacterium, the MAL-
catalyzed deamination reaction forms the second step in the catabolic pathway in which L-
glutamate is metabolized via L-threo-3-methylaspartate to finally yield acetyl-coenzyme A.
[14, 15]
 
MAL has subsequently been identified in several other facultative anaerobic organisms, including 
Morganella morganii, Citrobacter amolonaticus, Fusobacterium varium and Hafnia alvei, which 
form part of the Enterobacteriaceae family.
[15-19]
 MAL also forms part of the anabolic 





 In addition to the MALs that have been isolated and characterized from these 
sources, there are more than hundred putative MAL sequences available in various databases. Raj et 





Scheme 1. Reactions catalyzed by ammonia lyases specific for aspartate and its derivatives. (A) 
Aspartate ammonia lyase catalyzes the reversible deamination of L-aspartate (1) to yield fumarate (2) and 
ammonia. (B) 3-Methylaspartate ammonia lyase catalyzes the reversible deamination of L-3-methylaspartate 
(threo isomer 3 and erythro isomer 4) to yield mesaconate (5) and ammonia. (C) 3-Hydroxyaspartate 
ammonia lyases catalyze the deamination of threo- or erythro-3-hydroxyaspartate (6) to yield oxaloacetate 
(7) and ammonia. 
 
Two other enzymes, which are classically known as hydratases, have been classified as 
ammonia lyases by NC-IUBMB: threo-3-hydroxyaspartate ammonia lyase (or threo-3-
hydroxyaspartate dehydratase, EC 4.3.1.16) and erythro-3-hydroxyaspartate ammonia lyase (or 
erythro-3-hydroxyaspartate dehydratase, EC 4.3.1.20).
[1]
 As indicated by their names, these 
enzymes catalyze the deamination of different epimers (threo or erythro) of 3-hydroxyaspartate (6) 
to yield oxaloacetate (7) and ammonia (Scheme 1C). Furthermore, there are two distinct threo-3-
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hydroxyaspartate ammonia lyases known which exhibit specificity toward either the D- or L-
enantiomer of threo-3-hydroxyaspartate. These pyridoxal-phosphate- and divalent cation-dependent 
enzymes were first identified in the 1960s and are involved in the glycolate and glyoxylate 
degradative pathways.
[22, 23]
 The first enzyme to be identified was erythro-3-hydroxyaspartate 
dehydratase from Micrococcus denitrificans (Paracoccus denitrificans).
[23, 24]
 Almost 35 years later 
L-threo-3-hydroxyaspartate dehydratase was identified in Pseudomonas sp. T62 and a few years 
later in Saccharomyces cerevisiae.
[25, 26]
 Recently, enzyme activity towards D-threo-3-
hydroxyaspartate was identified in Delftia sp. HT23 and the enzyme was named D-threo-3-
hydroxyaspartate dehydratase.
[27]
 As these enzymes are classically characterized as hydratases and 
since limited information is available for them, they will not be further discussed in this review. 
 
ASPARTATE AMMONIA LYASE (ASPARTASE) 
Properties and catalytic mechanism 
Aspartases have been isolated and characterized from different Gram-negative and Gram-positive 
bacteria, with the aspartase from E. coli (AspA) being the focus of most studies. Originally AspA 
was isolated in a seven-step purification process from E. coli with an overall yield of 20%.
[5]
 As 
science evolved, the isolation of AspA became easier with the enzyme being overexpressed and 
purified to homogeneity with a yield of ~100 mg per 10 g of cell pellet.
[2]
 This 52 kDa protein is 
allosterically activated by L-aspartate and Mg
2+
 ions, which are essential for catalytic activity at 
alkaline pH.
[28-30]
 AspA shows maximum activity at 55°C and pH 8.0, but prolonged incubation of 
the enzyme at this temperature resulted in total loss of activity after 30 minutes.
[2, 12]
 
In recent years, aspartase from the thermophilic bacterium Bacillus sp. YM55-1 (AspB) has 
also been in the spotlight due to its possible use as a biocatalyst for amino acid synthesis. The 
purification of AspB was reported in 1999, and it was the first thermostable aspartase identified and 
characterized.
[12]
 AspB has similar subunit molecular weight (51 kDa) and oligomeric state as other 




Figure 1. Crystal structures of aspartate and methylaspartate ammonia lyases. A1) The structure of the 
AspB monomer.
[39]
 The three domains are labeled and the SS-loop is indicated in red. AspA has a similar 
structure as shown here for AspB.
[31]
 A2) Structure of the functional AspB tetramer.
[39]
 The four monomers 
forming the homotetramer are indicated in magenta, yellow, cyan and green. The location of one of four 
active sites is indicated by the bound L-aspartate (1) molecule, with the SS-loop indicated in red. A3) A 
close-up of the active site of AspB in complex with L-aspartate (1). The different conformations of the SS-
loop are shown, with the closed conformation in green and the open conformation in yellow. The amino acid 
residues which are most important for substrate binding and catalysis are shown. B1) Structure of the MAL 
monomer.
[60]
 The bound Mg
2+
 ion is shown as a red ball. B2) Structure of the functional MAL homodimer, in 
complex with Mg
2+
 (red ball) and L-threo-3-methylaspartate (3).
[60]
 The two monomers are indicated in 
green and cyan. The location of one of the two active sites is indicated by the bound ligand. B3) A close-up 
of the active site of CaMAL in complex with Mg
2+
 (red ball) and L-threo-3-methylaspartate (3).
[60]
 The 
amino acid residues which are most important for substrate binding and catalysis are shown. 
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temperatures as well as in the presence of guanidine hydrochloride.[12] AspB shows maximum 
activity at 65°C and at pH 8.0.[12] In contrast to its E. coli and P. fluorescence counterparts, AspB is 
 not allosterically activated by substrate and does not require Mg
2+




The crystal structure of unliganded AspA was elucidated in 1997 to 2.8 Å resolution,
[31]
 and 
showed that each monomer of AspA contains three structurally distinct domains (Figure 1A1). The 
C-terminal domain is the smallest domain in the subunit and consists mainly of two helix-turn-helix 
motifs which are orientated approximately 90° relative to each other. The central helix domain is 
formed from five long α-helices and contains more than half of the total residues of the subunit. 
Finally, the N-terminal domain consists of a short, two stranded anti-parallel β-sheet followed by 
five -helices.
[31]
 AspA belongs to the aspartase/fumarase superfamily, which also includes 
fumarase C, adenylosuccinate lyase, argininosuccinate lyase, δ-crystallin and 3-carboxy-cis-cis-
muconate lactonizing enzyme.
[32-37]
 The members of the aspartase/fumarase superfamily have a 
similar active site architecture and share a common tertiary and quaternary fold, although they can 
show pairwise sequence identities as low as 15%. AspA functions as a homotetramer, which 
contains four composite active sites, each of which is generated by conserved motifs from three 
monomers (Figure 1A2). A flexible loop of ~10 amino acid residues forms part of one of these 
conserved motifs with a signature sequence of GSSxxPxKxN. This specific loop, also called the 
SS-loop, has been shown to be important for substrate binding and catalysis in some of the enzymes 
of this superfamily.
[32, 33, 38, 39]
 
Kinetic studies have shown that AspA displays non-Michaelis-Menten kinetics for the 
deamination reaction at high pH, and there is a time lag before the linear steady-state rate is 
achieved in time-course kinetics for the amination reaction at high pH.
[28, 29]
 From these results it 
was concluded that AspA is subjected to allosteric activation, in which L-aspartate and Mg
2+
 bind to 
a separate activator-binding site that is different from the active site. The role of L-aspartate is 
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therefore two-fold: it acts as substrate and it serves as an activator for AspA. The location of the 
activator-binding site has not been identified by the crystal structure of unliganded AspA, but 
Cys430 has been proposed to be located close to the activator-binding site.
[28, 31]
 From the crystal 
structure of fumarase C, a second binding site was identified and the amino acid residues that form 
part of this putative activator-binding site include Arg126 and Asn135.
[40]
 A comparison of the 
crystal structure of AspA with that of fumarase C indicated Gln129 and Asn138, which are found in 
a short helix segment, as the corresponding residues in AspA.
[31]
 
A general acid-base reaction mechanism was proposed for aspartases as illustrated in 
Scheme 2A.
[2, 11, 31, 41-43]
 The active site general base abstracts the pro-R proton from the C3 
position of 1 resulting in a carbanion, which is stabilized as an aci-carboxylate intermediate (8). 
This proposed enolate anion intermediate can rearrange to eliminate ammonia and form the product, 
fumarate (2). The rate determining step is the cleavage of the Cα-N bond, which may be facilitated 
by a general acid that donates a proton to the leaving group (NH3) to form an ammonium ion.
[31, 41, 
43]
 Inhibition studies using 3-nitro-2-aminopropionate as inhibitor also supported the formation of 
an enzyme-stabilized enolate anion (aci-carboxylate) as intermediate, since the resonance-stabilized 
nitronate (aci-form) state of this inhibitor binds very tightly to aspartase as a transition state 
analogue.
[44]
 pH-rate profiles for AspA and the H. alvei aspartase differ from each other, thus 
making it unclear whether the protonation state of the leaving group is that of the ammonia or the 
ammonium ion.
[11, 45]
 It has been argued that if the amino group is released as ammonia, there might 
not be the need for a general acid catalyst.
[41, 46]
 
Numerous studies involving site-directed mutagenesis, chemical modification, and 
mechanism-based inactivation have been done to identify the catalytically important residues of 
AspA.
[2, 47, 48]
 Until recently, however, several major issues remained unresolved.
[39]
 For example, 
the identity of the general base catalyst that abstracts the C3 proton, as well as the identity of other 
catalytic and substrate-binding residues, was still unclear. The question of whether or not substrate 




Scheme 2. Schematic representations of the proposed catalytic mechanisms of aspartate and 
methylaspartate ammonia lyases. (A) Proposed general reaction mechanism for aspartase and 
metylaspartase. A base in the active site abstracts the proton from the substrate’s C3 position. Consequently, 
a carbanion (enolate anion intermediate) is formed which is stabilized as the aci-acid resonance form. 
Collapse of the intermediate is followed by Cα-N bond cleavage, which results in the elimination of ammonia 
and may be facilitated by a general acid in some aspartases. (B) Schematic representation of the catalytic 
mechanism of AspB. Residue Ser318 acts as the catalytic base and abstracts the pro-R proton from the C3 
position of 1. The formed enolate anion intermediate (8) is stabilized through hydrogen bonding interactions 
with amino acid residues that line the active site of AspB. The collapse of 8 results in the cleavage of the Cα-
N bond and the formation of 2 and ammonia. (C) Schematic representation of the catalytic mechanism of 
MAL. Residue Lys331 acts as the catalytic base and abstracts the C3 proton from 3 to form the enolate anion 
intermediate 9. This intermediate is stabilized by interactions with both the Mg
2+
 ion and amino acid residues 




Scheme 3. Biocatalytic preparation of aspartate derivatives. (A) Structure of the artificial sweetener N-
(L-α-aspartyl)-L-phenylalanine 1-methylester (10) with the L-aspartic acid backbone highlighted. (B) 
Different combinations of electrophiles and nucleophiles are used with aspartase or methylaspartase as 
biocatalyst to yield various N-, 3-, and N,3-(di)substituted aspartate derivatives. 
 
active site was also not answered.
[39]
 The structural work on AspA did not address these questions 
because no crystal structure of AspA in complex with substrate or product was available.
[31]
 In 
order to resolve these issues recent studies have focused on AspB, since this is a simpler system to 
work on because of the lack of allosteric activation.
[12]
 In addition, the crystal structure of 
uncomplexed AspB was already solved at this stage and the location of the putative active site was 
predicted based on comparisons with AspA and other superfamily members.
[49]
 Manual docking of 
L-aspartate (1) into the putative active site of AspB suggested that the α-carboxylate group of 1 
forms hydrogen-bonding interactions with Thr187 and Lys324 (Scheme 2B). On the opposite end 
of the molecule, the β-carboxylate group forms hydrogen bonds with the hydroxyl groups of Ser140 
and Thr141, whereas the amino group of 1 forms hydrogen bonds with the side chains of Thr101, 
Asn142 and His188.
[49]
 To further verify the role of each residue and to determine the exact 
mechanism of catalysis, site-directed mutagenesis, pH-rate profile experiments, and inhibition 
studies were carried out on AspB.
[46]
 Despite all these efforts, the specific residue that acts as 
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catalytic base in the first step of the proposed mechanism eluded investigators. The SS-loop in the 
unliganded AspB structure 
[49]
 was also highly disordered and therefore its possible role in substrate 
binding and catalysis was unclear. 
Advances in the elucidation of the catalytic mechanism of aspartase were recently achieved 
by Fibriansah et al.
[39]
 They were successful in solving (2.6 Å resolution) the crystal structure of 
AspB in complex with L-aspartate (1) (Figure 1A1-3), providing the first detailed view of the 
substrate-bound active site of an aspartase. This allowed the identification of all active site residues 
as well as an (improved) understanding of their roles in substrate binding and catalysis (Scheme 
2B). Remarkably, AspB forces the bound substrate to adopt a high-energy enolate-like (aci-
carboxylate-like) conformation that is stabilized by an extensive network of hydrogen bonds 
between the substrate’s β-carboxylate group and residues Thr101, Ser140, Thr141, and Ser319. 
Furthermore, a large conformational change of the SS-loop takes place from an open conformation 
in the absence of substrate to one where it closes over the active site in the presence of substrate 
(Figure 1A3). The open conformation of the SS-loop is stabilized by hydrophobic interactions of 
Ile320 and Met321, which are part of the loop, with a hydrophobic surface patch on the neighboring 
C-terminal domain. Binding of the substrate is needed in order to close the SS-loop.
[39]
 This 
conformational change provides additional substrate binding interactions and safeguards the 
substrate from the solvent during catalysis. As a result the SS-loop, in combination with the C-
terminal domain, plays a vital role in the catalytic mechanism of AspB. Most importantly, the 
closure of the SS-loop positions Ser318 in close proximity to the C3 proton of 1 to enable proton 
abstraction (Figure 1A3 and Scheme 2B). Indeed, mutation of the strictly conserved Ser318 to an 
alanine resulted in complete loss of AspB activity, suggesting that Ser318 is essential for 
activity.
[39]
 The exact mechanism by which the intrinsically high pKa value of Ser318 is lowered to 
function as a catalytic base is still unclear. 
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The results of this structural work on AspB
[39]
 thus provide strong support for a catalytic 
mechanism involving general base-catalyzed formation of the enzyme-stabilized enolate anion 
intermediate 8 (Scheme 2B). In fact, the highly structured active site environment, the high-energy 
conformation of the bound substrate, the closed SS-loop conformation, and the extensive hydrogen-
bonding network with the β-carboxylate group of the substrate (Scheme 2) show how the active site 





Biocatalytic applications  
In industry, aspartase is used as biocatalyst for the preparation of enantiopure L-aspartic acid, an 
important starting compound for the synthesis of artificial sweeteners such as N-(L-α-aspartyl)-L-
phenylalanine 1-methylester (10, Scheme 3A), which is also known as aspartame.
[50, 51]
 Notably, N- 
and 3-substituted derivatives of L-aspartic acid are highly valuable as tools for biological research 
and as chiral building blocks for a range of pharmaceuticals.
[52-54]
 However, the synthesis of these 
L-aspartic acid derivatives in enantiopure form remains a major challenge in synthetic chemistry. In 
principle, the stereo- and regioselective addition of amine nucleophiles to the double bonds of 
fumarate and its derivatives catalyzed by aspartases appears to be a very attractive strategy for the 
synthesis of these compounds (Scheme 3B). This strategy, however, is limited by the narrow 
substrate range of aspartases.
[2, 55]
 
A wide spectrum of compounds (11-63, Scheme 4A and 4B) has been tested as potential 
substrates or inhibitors of AspA.
[2, 30, 56]
 Only L-aspartate-β-semialdehyde (11) is deaminated by 
AspA, but this compound functions as a suicide substrate and its deamination leads to the 
irreversible inactivation of the enzyme.
[2, 56]
 Compounds 12-31 have been found to act as 
competitive inhibitors of AspA (Scheme 4A), with all of them containing a carboxylic acid or 
similarly charged functional group, which seems to be a requirement for enzyme binding.
[2, 30]
 
Compounds 32-63 did not act as substrate nor as inhibitor of the enzyme. Some of these compounds 
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(57-63; Scheme 4B), as well as additional amino acids (64-76, Scheme 4C), have also been tested 
as alternative substrates for AspB in order to determine if this aspartase exhibits a different 
substrate scope. It was found that AspB displays similar substrate specificity as AspA and does not 
process these nonnative amino acids.
[55]
 
In 1963 it was reported by Emery that hydroxylamine can be used as an alternative 
nucleophile in the addition reaction catalyzed by AspA.
[57]
 This observation prompted Weiner and 
co-workers to test various alternative nucleophiles as potential substrate in the AspB-catalyzed 
addition reaction.
[55]
 It was found that AspB accepts hydroxylamine, methoxylamine, hydrazine, 
and methylamine in the addition to fumarate, yielding L-N-hydroxyaspartic acid (77), L-N-
methoxyaspartic acid (78), L-2-hydrazinosuccinic acid (79), and L-N-methylaspartic acid (80) 
(Scheme 5). Whereas compounds 78-80 could be isolated in excellent yields, compound 77 could 
not be isolated due to the instability of the compound.
[55]
 Based on the structurally distinct 
nucleophiles tested, the authors concluded that the nucleophile binding pocket of AspB is designed 




3-METHYLASPARTATE AMMONIA LYASE (MAL) 
Properties and catalytic mechanism 
The MAL enzyme was purified from cell free extracts of several facultative anaerobic bacteria, and 
characterized with regard to its biocatalytic properties
[14, 16-19]
 The best studied MALs are those 
from C. tetanomorphum (CtMAL) and C. amalonaticus (CaMAL), the corresponding genes of 
which have been cloned, sequenced, and functionally expressed in E. coli.
[18, 58]
 MAL (45 kDa) is a 
homodimeric protein and depends on divalent (Mg
2+
) and monovalent (K
+
) cations for activity.
[58-60]
 




 revealed that the enzyme is not structurally 
related to aspartases (Figure 1B1-3). Instead, the structures showed that MAL belongs to the enolase 
superfamily, the members of which share a characteristic TIM barrel fold. The monomer of MAL 
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has a small N-terminal domain that wraps around the larger C-terminal domain, which is an 8-fold 
α/β (TIM) barrel (Figure 1B1).
[59, 60]
 
 The most recent addition to the library of characterized MALs is MAL from C. 
hydrogenoformans Z-2901 (ChMAL).
[21]
 This organism was isolated from a hot spring in Kunashir 
Island (Russia) and has an optimal growth temperature of 78°C.
[61, 62]
 The protein (subunit is 46.5 
kDa) has a length of 420 amino acids and the sequence is 53% identical and 73% similar to that of 
CtMAL. The biological function of this protein in C. hydrogenoformans is still unknown. Like 
CtMAL, ChMAL has an optimum pH for activity of 9. However, whereas CtMAL is active from 
10-70°C with an optimum temperature for activity of 50°C, ChMAL is active between temperatures 
of 10-90°C with an optimum temperature for activity of 70°C.
[21]
 The thermostability of the 
enzymes also varies dramatically. ChMAL has been shown to be stable at 50°C for up to 4 h, 
retaining >95% of its original activity. In contrast, CtMAL retained only half of its original activity 
after a 30 minute incubation period at 50°C.
[21]
 This study indicated that ChMAL is the most 
thermostable MAL purified and characterized to date. 
MAL catalyzes the reversible anti- and syn-addition of ammonia to mesaconate (5) to give 
L-threo-(2S,3S)-3-methylaspartate (3) as major product and L-erythro-(2S,3R)-3-methylaspartate (4) 
as minor product, respectively (Scheme 1B). The mechanism of action has been debated over the 
last ~50 years with various studies aiming to demonstrate the deamination mechanism of MAL.
[63-
69]
 Early investigations postulated that MAL catalyzes the deamination reaction through a carbanion 
mechanism similar to aspartase (Scheme 2A), with cleavage of the Cα-N bond as the rate-limiting 
step.
[63, 64]
 This hypothesis was supported by the fact that C3 hydrogen-exchange with solvent 
occurs more rapidly than cleavage of the Cα-N bond. Also, the C3-deuterated substrate 3 used to 







Scheme 4. Compounds investigated as potential inhibitors or substrates for aspartase. (A) L-aspartate-
β-semialdehyde (11) acts as a suicide substrate for AspA.[56] Compounds 12-31 were shown to act as 
competitive inhibitors of AspA.
[2, 30]
 (B) Compounds 32-63 were shown not to act as competitive inhibitors 
nor as alternative substrates for AspA.
[30]
 Compounds 57-63 in the dashed box have also been tested on 
AspB, but were also not accepted as substrates by this enzyme.
[55]
 (C) Compounds 64-76 were shown not to 






Other studies have questioned this carbanion mechanism by suggesting that MAL is 
mechanistically similar to phenylalanine ammonia lyase (PAL) and histidine ammonia lyase 
(HAL), and may catalyze the reaction via a covalent enzyme-substrate complex which utilizes an 
electrophilic dehydroalanine prosthetic group.
[58, 69, 70]
 MAL is irreversible inactivated by N-
ethylmaleimide and phenylhydrazines, and substrate protects the enzyme from inactivation by these 
compounds. On the basis of these findings, combined with sequence analysis, it has been suggested 
that post-translational dehydration of an active site serine (Ser173) may be the origin of this 
prosthetic group.
[58, 69, 70]
 However, it was later discovered that PAL and HAL do not form a 
dehydroalanine group through post-translational dehydration, but instead form a MIO-group (4-
methylene imidazole-1-one) by cyclization and elimination of water in the active site tripeptide Ala-
Ser-Gly.
[71, 72]
 The crystal structures of uncomplexed CtMAL and CaMAL in complex with the 
natural substrate 3 were reported in 2002 and proved to be essential for the determination of the 
exact mechanism of the enzyme.
[59, 60]
 It was clear from the structures that MAL is not structurally 
related to HAL or PAL, and electron density maps did not indicate posttranslational modification of 
any active site residues. Instead, MAL shows structural homology to the enolase superfamily, the 
members of which share a common mechanism that involves the general-base catalyzed formation 
of an enolate anion (aci-carboxylate) intermediate. The MAL-substrate complex structure,
[60]
 in 
combination with structural alignment of MAL with other members of the enolase superfamily,
[59]
 
suggested that Lys331 functions as the S-specific base catalyst that is responsible for proton 
abstraction from C3 of substrate 3 (Figure 1B3 and Scheme 2C). It was further postulated that 
His194 may act as the R-specific base catalyst and abstracts the C3 proton from substrate 4. This 
hypothesis was based on structure comparisons between MAL and other enolase superfamily 
members where the main chain of His194 superimposes on Lys164 of mandelate racemase (a 







Scheme 5. L-Aspartic acid derivatives obtained from preparative reactions. L-aspartic acid analogs 77-
95 were prepared using MAL as biocatalyst.
[74-76]







 investigated the importance of these two proposed catalytic base residues in 
CtMAL. First, Lys331 was shown to be an essential residue for catalysis, because enzyme activity 
was lost completely when this amino acid was mutated to a glycine, alanine, histidine, glutamine, or 
arginine.
[73]
 Second, computer modeling of 4 into the active site of MAL indicated that the C3 
proton of 4 is indeed facing towards the imidazole nitrogen atom (Nε2) of His194. Moreover, an 
alanine mutation at this position disables the protein from accepting 4 as a substrate, but the H194A 
mutant still has the ability to catalyze the deamination of 3. It is of synthetic importance that the 
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H194A mutant is completely diastereoselective, and aminates 5 to give 3 as the sole product.
[73]
 
These studies thus showed that MAL catalyzes the reversible deamination reaction by using Lys331 
as the S-specific general base/acid catalyst and His194 as the R-specific base/acid catalyst. It was 
also shown that MAL does not catalyze the direct epimerization reaction from 3 to 4, and therefore 
the two products form exclusively as a result of the anti- and syn-addition of ammonia to 5.
[73]
 
The structure of MAL in complex with substrate
[60]
 further showed that specific hydrogen 
bonds are made between the substrate’s β-carboxylate group and the nitrogen atoms (Nε2) of 
Gln329 and His194 (Figure 1B3, Scheme 2C). The importance of these residues for MAL activity 
was confirmed by site-directed mutagenesis.
[73]
 Importantly, the active site Mg
2+
 ion assists these 
two residues in binding of the substrate’s β-carboxylate group, thereby providing efficient 
stabilization of the enolate anion intermediate. The Mg
2+
 binding site of MAL is located in the 
mouth of the TIM barrel and consists of Asp238, Glu273 and Asp307.
[59, 60]
 Each of these amino 
acids contributes a single oxygen atom as ligand, and in combination with three water molecules (in 




 In the substrate 
bound active site, one of the six ligands to the Mg
2+
 ion is provided by one of the β-carboxyl 
oxygen atoms of the substrate, replacing a water molecule.
[60]
 The α-carboxylate of the substrate has 
hydrogen bond interactions with the main chain NH of Cys361, the oxygen atom (Oγ) of Thr360, 
and the nitrogen atom (Nε2) of Gln172 (Scheme 2C). The C2 amino group fits nicely into a 
nucleophile binding pocket and has hydrogen bond interactions with the oxygen atom (Oε1) of 
Gln172 and, via a water molecule, with the nitrogen atom (Nε2) of Gln73. The substrate is further 
stabilized in the active site by favorable Van der Waals packing interactions between its 3-methyl 
group and the side chains of Leu384 and Gln172 (60). This detailed view of the substrate-bound 
active site of MAL thus allowed the identification of the active site residues (Figure 1B3) as well as 
an understanding of their roles in catalysis (Scheme 2C). In conclusion, the MAL structures
[59, 60] 
and recent mutagenesis experiments
[73]
 provide strong support for a catalytic mechanism involving 




Several studies have focused on the usefulness of CtMAL as a biocatalyst for asymmetric synthesis 
of aspartic acid derivatives.
[74-76]
 Gani and co-workers showed that CtMAL accepts different 
fumarate derivatives in the ammonia addition reaction, yielding a range of 3-substituted aspartic 
acid derivatives (Scheme 5).
[74, 75]
 The same group reported that MAL can also catalyze the addition 
of a few small amines to fumarate and several 2-alkylfumarates to yield various N- and N,3-
disubstituted aspartic acid derivatives (Scheme 5).
[76]
 Hence, CtMAL has a broader substrate 
spectrum than the aspartases AspA and AspB, and can be used to synthesize amino acids 77-95 
(Scheme 5). Like CtMAL, the thermostable ChMAL also accepts various substituted fumarates and 
amines, and exhibits high regio- and stereoselectivity.
[21]
 This makes Ch-MAL an attractive enzyme 
for biocatalytic applications, as well as a promising scaffold for protein engineering. 
 
ENGINEERING OF ASPARTATE AND METHYLASPARTATE AMMONIA LYASES  
A synthetic strategy in which aspartate and methylaspartate ammonia lyases are used as biocatalysts 
for the preparation of enantiomerically pure L-aspartic acid derivatives is of high interest (Scheme 
3B). However, this strategy is currently limited by the narrow substrate range of these enzymes. It 
would therefore be very attractive to extend the accessible range of aspartic acid derivatives by the 
redesign of these lyases to convert new unnatural substrates, which would enlarge their biocatalytic 
applicability.
[77]
 In fact, aspartase has been subjected to protein engineering by various 
investigators, but with limited success. Asano et al.
[78]
 used directed evolution in an attempt to 
enlarge the substrate scope of AspA. Interestingly, they found that mutation of Lys327 to an 
asparagine enables AspA to catalyze the deamination of L-aspartic acid α-amide (β-asparagine), 
albeit at a very low level.
[78]
 Unfortunately, no other AspA variants with a modified substrate scope 
have been reported. In our laboratory, we have attempted to broaden the substrate scope of 
aspartase AspB by rational design and structure-based saturation mutagenesis. However, we were 
unsuccessful in these engineering attempts, which may have to do with the complex movement of 
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the SS-loop upon substrate binding, making protein engineering of aspartases a formidable 
challenge. 
In contrast to aspartases, where substrate-dependent closure of the SS-loop positions 
catalytic and substrate-binding residues in a suitable orientation for catalysis, MAL has an intact 
catalytic machinery in the uncomplexed enzyme and does not undergo large conformational 
changes upon substrate binding. This implies that MAL is a more promising template for redesign 
to convert new unnatural substrates.
[79]
 Raj et al.
[73]
 have shown that the diastereoselectivity of the 
enzyme can be altered by mutation of active-site residues, allowing the preparation of exclusively 
L-threo-3-methylaspartate (3, Scheme 1B). The crystal structure of substrate-bound MAL shows 
that the surface lining of the 3-methyl binding pocket, which is formed in part by Leu384, Phe170 
and Tyr356, is composed almost entirely of side chains with little or no interaction between the 
substrate’s 3-methyl group and the main chain atoms.[60] Recently, Poelarends and co-workers have 
engineered this alkyl binding pocket of MAL and obtained a single active site mutant (L384A) that 
has a wide electrophile scope including fumarate derivatives with alkyl, aryl, alkoxy, aryloxy, 
alkylthio and arylthio substituents at the C2 position (Scheme 6).
[80]
 These investigators also 
engineered the nucleophile (amine) binding pocket of MAL, which is formed in part by Gln73 and 
Gln172, yielding a single active site mutant (Q73A) that exhibits a broad nucleophile scope 
including various structurally diverse linear and cyclic alkylamines (Scheme 7).
[80]
 Hence, MAL 
appears to be the most attractive enzyme to create new biocatalysts for the asymmetric synthesis of 





Scheme 6. Electrophile spectrum of an engineered MAL variant. The MAL-L384A mutant as catalyst in 
the ammonia addition to fumarate and its 2-substituted derivatives. 
 
 
Scheme 7. Nucleophile spectrum of an engineered MAL variant. The MAL-Q73A mutant as catalyst in 
the amine addition to mesaconate. 
 
CONCLUDING REMARKS  
Aspartase and MAL have been under investigation extensively for a number of decades, but the 
details of their catalytic mechanisms have only been elucidated in recent years. Information on the 
properties of these enzymes has been extended and the isolation and characterization of enzymes 
from thermophilic organisms have added more robust enzymes to the arsenal of researchers. There 
are still limitations around the range of substrates that can be accepted. Hence, there is a need to 
apply directed evolution techniques to provide biocatalysts with a much broader substrate scope. 
However, the complex movement of the SS-loop from an open conformation to one that closes over 
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the active site upon substrate binding makes engineering of the substrate specificity of aspartases a 
difficult task. We will therefore continue our efforts to further expand the substrate spectrum of 
MAL, which appears to be a more promising template for protein engineering. 
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ABSTRACT  
3-Methylaspartate ammonia-lyase (MAL) catalyzes the reversible amination of mesaconate to give 
both (2S,3S)-3-methylaspartic acid and (2S,3R)-3-methylaspartic acid as products. The deamination 
mechanism of MAL is likely to involve general base catalysis, in which a catalytic base abstracts 
the C-3 proton of the respective stereoisomer to generate an enolate anion intermediate that is 
stabilized by coordination to the essential active site Mg
2+
 ion. The crystal structure of MAL in 
complex with (2S,3S)-3-methylaspartic acid suggests that Lys-331 is the only candidate in the 
vicinity that can function as a general base catalyst. The structure of the complex further suggests 
that two other residues, His-194 and Gln-329, are responsible for binding the C-4 carboxylate group 
of (2S,3S)-3-methylaspartic acid, and hence are likely candidates to assist the Mg
2+
 ion in 
stabilizing the enolate anion intermediate. In this study, the importance of Lys-331, His-194 and 
Gln-329 for the activity and stereoselectivity of MAL was investigated by site-directed 
mutagenesis. His-194 and Gln-329 were replaced with either an alanine or arginine, whereas Lys-
331 was mutated to a glycine, alanine, glutamine, arginine or histidine. The properties of the mutant 





The CD spectra of all mutants were comparable to that of wild-type MAL indicating that these 
mutations did not result in any major conformational changes. Kinetic studies demonstrated that the 
mutations have a profound effect on the values of kcat and kcat/Km, implicating Lys-331, His-194 and 
Gln-329 as mechanistically important. 
1
H NMR spectra of the amination and deamination reactions 
catalyzed by the mutant enzymes K331A, H194A, and Q329A showed that these mutants have 
strongly enhanced diastereoselectivities. In the amination direction, they catalyze the conversion of 
mesaconate to yield only (2S,3S)-3-methylaspartic acid, with no detectable formation of (2S,3R)-3-
methylaspartic acid. The results are discussed in terms of a mechanism in which Lys-331, His-194 
and Gln-329 are involved in positioning the substrate, and in formation and stabilization of the 
enolate anion intermediate. 
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INTRODUCTION 
3-Methylaspartate ammonia-lyase (MAL) catalyzes the reversible amination of mesaconate (1) to 
give (2S,3S)-3-methylaspartic acid (2) as a major product and (2S,3R)-3-methylaspartic acid (3) as a 
minor product (Scheme 1).
[1, 2]
 The enzyme is used by the anaerobic bacterium Clostridium 
tetanomorphum as part of a degradative pathway that converts (S)-glutamic acid via 2 to finally 
yield acetyl-CoA.
[1, 2]
 MAL is of considerable biocatalytic interest because it also catalyzes the 
stereo- and regioselective addition of ammonia to several derivatives of 1 to form a number of 3-
alkyl- and 3-halo-substituted aspartic acids.
[3]
 Moreover, the broad nucleophile specificity of MAL 
enables the use of a range of alternative nucleophiles such as methylamine, ethylamine, hydrazine, 
and methoxylamine in the conjugate addition reaction.
[4]
 These properties make MAL a promising 
biocatalyst for the enantiospecific synthesis of both 3- and N-substituted aspartic acids, which are 
interesting building blocks for pharmaceutical synthesis. 
 
Scheme 1. MAL-catalyzed reversible amination of mesaconate to yield (2S,3S)- and (2S,3R)-3-
methylaspartic acid. 
 
MAL is a homodimeric enzyme (molecular mass of ~45.5 kDa) that requires both 
monovalent (i.e., K
+
) and divalent (i.e., Mg
2+
) cations for activity.
[1, 2]
 Several studies have been 
aimed at demonstrating the deamination mechanism of MAL.
[5-11]
 Some of these have suggested 
that MAL operates via a carbanion mechanism with rate-limiting C-N bond cleavage.
[5, 6]
 This 
proposed mechanism is supported by the observation that C-3 hydrogen exchange of the C3-
deuterated substrate (2, Scheme 1) with solvent occurs more rapidly than C-N bond cleavage. 
Moreover, no primary isotope effect was observed for the deamination of the C3-deuterated 




 Nonetheless, other reports have questioned this carbanion mechanism,
[7-11]
 and up 
until the structure of MAL was reported, the catalytic mechanism of the enzyme remained 
unresolved. 
  
Figure 1. (A) Ribbon diagram of the functional homodimeric structure of C. amalonaticus MAL.
[13]
 The 
location of the active site in each monomer is indicated by the bound Mg
2+
 ion, which is shown as a red 
sphere. The figure was prepared with PyMOL.
[27]
 (B) A close-up of the active site of C. amalonaticus MAL 
in complex with (2S,3S)-3-methylaspartic acid.
[13]
 For clarity, only the Mg
2+
 ion (magenta sphere) and the 
active site residues His-194, Gln-329, and Lys-331 are shown. The roles of these residues and their 
interactions are discussed in the text. Observed distances (in Å) between active site residues and substrate are 
indicated. The figure was prepared with PyMOL.
[27] 
 
The crystal structure of MAL from C. tetanomorphum
[12]
 and that of the isozyme from 
Citrobacter amalonaticus
[13]
 were reported a few years ago. These structures showed that within the 
functional homodimer, each MAL monomer consists of two domains (Figure 1A). The larger C-
terminal domain is an 8-fold α/β-barrel, and the smaller N-terminal domain mainly consists of β-
strands. The active site carrying the essential Mg
2+
 ion is located in a large cleft between the two 
domains. Structure comparisons identified MAL as a member of the enolase superfamily.
[12, 13]
 
Despite little sequence identity, the overall α/β-barrel topology and the active site architecture of 
MAL are strikingly similar to those of enolase, the title enzyme of this superfamily. Interestingly, 
the members of the enolase superfamily catalyze different reactions but share a common catalytic 
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step: the metal ion assisted, general-base catalyzed abstraction of the α-proton of a carboxylic acid 
substrate to generate an enzyme-stabilized enolate anion intermediate.
[14]
 On the basis of the 
structural homology to the enolase superfamily, coupled with the earlier results of kinetic isotope 
studies, it was proposed that MAL functions via the common enolase catalytic step, and thus 




Scheme 2. Proposed enolate anion intermediate along the reaction pathway of MAL. 
 
Although a general base catalyst for the deamination activity of MAL has not been 
determined, Lys-331 appears to be a likely candidate because it occupies a similar position to the 
general base Lys-345 in enolase.
[12, 13]
 Moreover, the crystal structure of C. amalonaticus MAL in 
complex with 2 shows that Lys-331 is the only candidate in the vicinity of C-3 that can function as 
a general base catalyst (Figure 1B).
[13]
 Two other residues, His-194 and Gln-329, are implicated in 
binding the C-4 carboxylate group of 2 (Figure 1B),
[13]
 and thus are likely candidates for assisting 
the Mg
2+
 ion in stabilizing the enolate anion intermediate. It was further postulated that His-194 
may also function as the second base (in addition to Lys-331) that abstracts the C-3 proton of the 
stereoisomer 3 (Scheme 1).
[12]
 
The objective of the present work is two-fold. First, we demonstrate the importance of His-
194, Gln-329, and Lys-331 for the MAL-catalyzed reactions. Second, we show that mutations of 
these active-site residues alter the diastereoselectivity of MAL. This led to a single amino acid 
MAL variant (H194A) that has useful properties for the stereoselective synthesis of isomerically 
pure (2S,3S)-3-methylaspartic acid. The results are discussed in terms of a mechanism in which 
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His-194, Gln-329, and Lys-331 are involved in binding and positioning of the substrate, and in 
formation and stabilization of the enolate anion intermediate. 
 
RESULTS 
Expression and purification of MAL 
The gene coding for MAL was amplified from genomic DNA of C. tetanomorphum and fused into 
the start codon of the expression vector pBAD/Myc-His A, resulting in the construct pBAD(MAL-
His). Sequencing of the cloned MAL gene verified that no mutations had been introduced during 
the amplification and cloning procedures. The MAL gene in pBAD(MAL-His) is under 
transcriptional control of the araBAD promoter and the recombinant enzyme was produced upon 
induction with arabinose in E. coli TOP10 as a C-terminal hexahistidine fusion protein. Production 
of soluble and active MAL was most efficient when cells were cultivated at 17°C and when 0.004% 
(w/v) arabinose was used. The recombinant enzyme was purified by a one-step Ni-based 
immobilized metal affinity chromatography protocol, which typically provides 10-15 mg of 
homogeneous enzyme per liter of culture. 
 
Kinetic and 1H NMR analysis of the MAL-catalyzed amination of 1 
A mixture containing MAL, mesaconate (1), and ammonium chloride was monitored by 
1
H NMR 
spectroscopy to verify that the products of the reaction are (2S,3S)-3-methylaspartic acid (2) and 
(2S,3R)-3-methylaspartic acid (3), as has been previously reported.
[2]
 Indeed, the enzymatic 
amination of 1 yields 2 and 3, as indicated by signals in the NMR spectra consistent with the 
structures of these amino acid products (Figure 2A).
[15]
 Although the 
1
H NMR spectra showed 
signals for both 2 and 3, those corresponding
 
to 2 predominated in the initial spectra whereas 
signals for 3 appeared only in the later spectra. These observations confirm that
 
MAL catalyzes the  
 





H NMR spectra monitoring the amination of 1 by MAL (A) and the H194A mutant (B). The 
1
H 
NMR signals for compounds 1, 2, and 3 are indicated (see Supporting Information for assignment of the 
signals). Spectra were recorded after 1 h, 7 days, and 13 days, respectively. The 
1
H NMR spectra of the 
K331A and Q329A mutants (not shown) were comparable to those of the H194A mutant; that is, there was 
no detectable formation of 3 in the incubation mixtures. The less prominent singlets at 1.20 and 2.11 ppm 
correspond to impurities resulting from multiple additions of protein. 
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rapid conversion of 1 to the natural substrate 2, as well as the slow conversion of 1 to 3. After a 13 
day-incubation period, the MAL-catalyzed reaction was complete, resulting in 45% 2 and 35% 3. 
A previously described assay
[3]
 was used to measure the kinetic parameters for MAL in the 
amination direction. Accordingly, the rate of amination of 1 was monitored by following the 
depletion of 1 at 270 nm in 500 mM Tris-HCl buffer (pH 9.0) containing 20 mM MgCl2 and 400 
mM NH4Cl at 30°C. A kcat of 61 (± 1) s
-1
 and a Km of 0.7 (± 0.02) mM were found, which results in 






 (Table 1). 
 
Table 1. Apparent kinetic parameters for the MAL-, K331A-, H194A-, and Q329A-catalyzed 














61 ± 1 
ND 
8.4 ± 0.3 
0.25 ± 0.02 
0.7 ± 0.02 
ND 
14 ± 1 












The steady state kinetic parameters were determined in 500 mM Tris-HCl buffer (pH 9.0) containing 20 
mM MgCl2 and 400 mM NH4Cl at 30°C. Errors are standard deviations. ND, not determined. 
 
Kinetic and 1H NMR analysis of the MAL-catalyzed deamination of 2 
The rate of deamination of 2 by MAL was monitored by following the formation of 1 at 240 nm in 
500 mM Tris-HCl buffer (pH 9.0) containing 20 mM MgCl2 and 1 mM KCl at 30°C.
[3]
 For the 
deamination of 2, a kcat of 89 (± 4) s
-1
 and a Km of 1.0 (± 0.1) mM were found, which results in a 






 (Table 2). 
A mixture containing MAL and 2 was also monitored by 
1
H NMR spectroscopy to verify 
that the product of the reaction is 1. The enzymatic conversion of 2 yields 1, as indicated by a 
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singlet at 1.74 ppm and a singlet at 6.28 ppm (Figure S4, Supporting Information), which 
correspond to the protons at the C-3 methyl group and C-2, respectively. In addition, signals 
corresponding to 3 are also present. After a 13 day-incubation period, the MAL-catalyzed reaction 
results in 41% 1 and 2% 3.
[16]
 Hence, 1 is the major product of the MAL-catalyzed conversion of 2. 
 
1H NMR analysis of the MAL-catalyzed deamination of 3 
1
H NMR analysis of the diastereoisomer 3 revealed that the provided material contains 94-95% of 
the required diastereoisomer 3 and 5-6% of the unwanted diastereoisomer 2. This finding precluded 
the use of the material in kinetic experiments. Nevertheless, it was possible to monitor the 
deamination of 3 by 
1
H NMR spectroscopy and identify the products of the reaction. The 
1
H NMR 
spectra showed the disappearance of signals corresponding to 3 and the
 
appearance of new signals 
corresponding to 1 and 2. Signals corresponding
 
to 1 predominated in the initial spectra whereas 
signals for 2 increased in the later spectra. After a lengthy incubation period (~2 weeks), the MAL-
catalyzed reaction was complete, resulting in 79% 1 and 12% 2 (Figure S5, Supporting 
Information). 
 
Mutagenesis of His-194, Lys-331, and Gln-329 
In order to investigate the importance of His-194, Lys-331, and Gln-329 for the activity and 
stereoselectivity of MAL, single site-directed mutants were constructed in which His-194 and Gln-
329 were replaced with either an alanine or arginine (H194A, H194R, Q329A, and Q329R) and 
Lys-331 with a glycine, alanine, glutamine, histidine, or arginine (K331G, K331A, K331Q, K331H, 
and K331R). DNA sequencing verified that only the intended mutations had been introduced into 
each mutant gene. The mutants were overexpressed in E. coli strain TOP10 and purified to >95% 
homogeneity (as assessed by SDS-PAGE) using the Ni-based immobilized metal affinity 
chromatography protocol described for wild-type MAL. The yields (in milligrams of homogeneous 
protein per liter of cell culture) of the mutants varied from 10 mg to 20 mg. 
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It was shown by non-denaturing PAGE (data not shown) that the native molecular mass for 
each mutant is comparable to that of wild-type, indicating that the oligomeric association of the 
mutants was still intact. The structural integrity of the mutants was also assessed by circular 
dichroism (CD). The CD spectra of the mutants were comparable to that of the wild-type indicating 
that these mutations did not result in any major conformational changes (Figure S6, Supporting 
Information). 
 
Kinetic and 1H NMR analysis of the deamination of 2 by the MAL mutants 
The activities of the MAL mutants were initially assayed using the natural substrate 2. It was found 
that substitution of Lys-331 by a glycine, alanine, histidine, glutamine, or arginine essentially 
abolished enzymatic activity, underscoring the importance of this residue for the MAL-catalyzed 
deamination of 2. Under the conditions of the kinetic assays, no activity could be detected for these 
mutants. Substitution of either His-194 or Gln-329 by an arginine also resulted in mutant enzymes 
that were inactive. The H194A and Q329A mutants, however, deaminate 2 although at a reduced 
catalytic efficiency (Table 2). For the H194A mutant, there is a slight (1.8-fold) increase in Km and 
a ~160-fold decrease in kcat, which results in a ~290-fold reduction in kcat/Km. For the Q329A 
mutant, there is a ~8900-fold decrease in kcat, whereas the Km is not affected. Hence, this results in a 
~8900-fold reduction in kcat/Km. 
The deamination activities of the three alanine mutants (H194A, K331A, and Q329A) were 
also assessed by 
1
H NMR spectroscopy after a lengthy (~2 weeks) incubation period. Using 2, the 
H194A- and Q329A-catalyzed reactions resulted in 40% 1 and 3% 3, whereas the K331A-catalyzed 
reaction showed only a trace amount of product (2% 1 and 2% 3).
[16]
 These observations parallel 
those of the kinetic assays and suggest that Lys-331 is more critical for the deamination activity of 
MAL than His-194 and Gln-329. 
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89 ± 4 
ND 
0.55 ± 0.01 
0.01 ± 0.001 
1.0 ± 0.1 
ND 
1.8 ± 0.2 












The steady state kinetic parameters were determined in 500 mM Tris-HCl buffer (pH 9.0) containing 20 
mM MgCl2 and 1 mM KCl at 30°C. Errors are standard deviations. ND, not determined. 
 
pH dependence of the kinetic parameters of MAL and the H194A mutant using 2 
In order to determine the pKa of the basic group on the enzyme important for catalysis (the 
presumed general base catalyst) and to evaluate the effect of the alanine mutation on this pKa, the 
pH dependence of the kcat/Km for the MAL- and H194A-catalyzed deamination of 2 was determined 
over the pH range 6.0-9.5. The other two alanine mutants, K331A and Q329A, were not active 
enough with 2 and thus could not be measured. The log (kcat/Km) vs pH profiles of MAL and 
H194A both show a single ascending limb with a slope of 1 (Figure 3).
[17]
 For wild-type MAL, a 
pKa value of 7.8  0.1 was found. For the H194A mutant, a pKa value of 8.2  0.1 was found. 
Hence, within the estimated errors, there is no significant effect of the H194A substitution on the 
pKa for the ascending limb. 
 
1H NMR analysis of the K331A-, H194A-, and Q329A-catalyzed deamination of 3 
The deamination of the non-natural substrate 3 by the alanine mutants was monitored by 
1
H NMR 
spectroscopy. After a 13 day-incubation period, the Q329A-catalyzed reaction resulted in 10% 1. 
The contaminant 2, which is the natural substrate for the enzyme, was selectively processed by 
Q329A at a rate much faster than for 3. The H194A mutant also processed the contaminant 2, 
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resulting in 6% 1, but showed no detectable activity towards 3. The mixture containing the K331A 
mutant showed no product. 
 
 
Figure 3. pH-dependence of log (kcat/Km) for the deamination of 2 by wild-type MAL (A) and the H194A 
mutant (B). The pKa values are discussed in the text. 
 
Kinetic and 1H NMR analysis of the amination of 1 by the MAL mutants 
The kinetic parameters for the amination reactions catalyzed by the MAL mutants were determined 
and compared to those measured for the wild-type MAL-catalyzed amination of 1 (Table 1). For the 
Q329A mutant, there is a slight increase in Km (~2.4-fold) and a ~240-fold decrease in kcat, which 
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results in a ~600-fold reduction in kcat/Km. For the H194A mutant, there is a 20-fold increase in Km 
and only a ~7-fold decrease in kcat, which results in a ~140-fold reduction in kcat/Km. Under the 
conditions of the kinetic assay, no activity could be detected for the other mutants (H194R, Q329R, 
K331G, K331A, K331Q, K331H, and K331R). 
The amination of 1 by the three alanine mutants (H194A, Q329A, and K331A) was also 
monitored by 
1
H NMR spectroscopy to identify the diastereoisomeric products of the reaction. 
After a 13 day-incubation period, the K331A-, Q329A-, and H194A-catalyzed reactions resulted in 
30%, 58%, and 85% diastereoisomer 2, respectively (Figure 2B; data not shown). Interestingly, and 
in contrast to the wild-type MAL-catalyzed amination of 1 (Figure 2A), there was no detectable 
formation of diastereoisomer 3 in the incubation mixtures. [For comparison, conversion of 35% of 1 
by wild-type MAL results in 19% 2 and 16% 3.] These observations indicate that the H194A, 
Q329A, and K331A mutants have enhanced diastereoselectivities and catalyze the highly 
stereoselective conversion of 1 to 2, with no detectable conversion of 1 to 3. 
 
DISCUSSION 
Previous studies of the stereoselectivity of C. tetanomorphum MAL indicated that the wild-type 
enzyme catalyzes the reversible anti- and syn-addition of ammonia to mesaconate (1) to yield 
(2S,3S)-3-methylaspartic acid (2) and (2S,3R)-3-methylaspartic acid (3), respectively.
[2, 9]
 The 
determination of the X-ray structure of C. amanolaticus MAL in complex with the natural substrate 
2 has provided the essential structural information for the identification of the substrate interactions 
within the enzyme-substrate complex.
[13]
 Guided by the structure of this complex, we have selected 
three active site residues in C. tetanomorphum MAL
[12]
 for mutagenesis to provide insight into the 
structural determinants of the reactivity and stereoselectivity of MAL.
[18]
 The results of these 
studies are interpreted here and discussed in terms of a two-base mechanism, in which the proton 
abstraction/addition steps are effected by (S)- and (R)-specific general base/acid catalysts 
juxtaposed on either side of the (chiral) C-3 carbon of the substrate. 
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We first verified that both 2 and 3 are formed as products of the MAL-catalyzed amination 
of 1 by 
1
H NMR spectroscopy. It was found that stereoisomer 2 is formed at a rate much faster than 
stereoisomer 3. [At equilibrium, the ratio of 2:3 is ~1.3.] Second, we confirmed that MAL does not 
catalyze the direct epimerization of the two stereoisomers. This was evident from a prolonged 
incubation of MAL with 2, which yielded 1 as the major product and gave only a trace amount of 3. 
Another notable observation is that the incubation of MAL with 3 finally gives 2 (in 12% yield), but 
only after a significant amount of 1 had accumulated in the reaction mixture. This suggests that 
MAL first catalyzes the syn-elimination of ammonia from 3 to yield 1, followed by the anti-
addition of ammonia to 1 to give 2. These observations indicate that the formation of 2 and 3 as 
products of the MAL-catalyzed amination of 1 is not the result of the MAL-catalyzed amination of 
1 to 2 followed by the slow direct epimerization of 2 to 3. Hence, MAL indeed catalyzes the rapid 
anti-addition and the much slower syn-addition of ammonia to 1 to give 2 and 3, respectively. 
The crystal structure of C. amalonaticus MAL in complex with 2
 
shows that Lys-331 is the 
only candidate in the vicinity of C-3 that can function as the (S)-specific base/acid catalyst (Figure 
1B).
[13]
 This lysine residue is conserved in all characterized 3-methylaspartate ammonia lyases. 
Moreover, a comparison of the active site structures of MAL and enolase shows that Lys-331 in 
MAL superimposes to within 1 Å of the previously identified general base Lys-345 in enolase.
[13]
 
To assess its role in catalysis, we have mutated Lys-331 to a glycine, alanine, histidine, glutamine, 
or arginine. Examination of the kinetic properties for these mutants clearly shows that Lys-331 is an 
essential residue in the MAL-catalyzed reactions because all five mutations at this position result in 
a dramatic loss of activity (there is a >10
7
-fold drop in the value of kcat/Km using 2). The mutant 
enzymes appear to retain an intact overall structural integrity as shown by CD spectroscopy. It is 
therefore reasonable to conclude that Lys-331 is crucial for catalysis because it functions as the (S)-
specific base catalyst in the deamination of 2 and, hence, as the acid catalyst (the conjugate acid of 
Lys-331) in the corresponding reverse anti-addition reaction (Scheme 3). 
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From the ascending limb of the log (kcat/Km) vs pH profile of MAL, a residue with a pKa of 
~7.8, which must be deprotonated for optimal activity, may be the general base catalyst involved in 
abstraction of the C-3 proton of 2. While the pKa value of Lys-331 in MAL has not been directly 
measured by NMR spectroscopy, it can be inferred from these results that the kinetic pKa value of 
7.8 is likely due to Lys-331. 
 
Figure 4. Close-up view of two superimposed active sites of C. amalonaticus MAL, one in complex with the 
natural substrate (2S,3S)-3-methylaspartic acid (2)
[13]
 (shown in grey) and the other with the most favored 
conformation of the modeled non-natural substrate (2S,3R)-3-methylaspartic acid (3) (shown in cyan). The 
orientation of 2 suggests that its C-3 proton is abstracted by Lys-331, whereas the orientation of 3 suggests 
that its C-3 proton is abstracted by His-194. The Figure was prepared with Discovery Studio 1.7. 
 
In the structure of the MAL-substrate complex, His-194 and Gln-329 are hydrogen bonded 
to the C-4 carboxylate group of 2 (Figure 1B).
[13]
 This suggests roles for these residues in binding 
the substrate, and possible intermediates, in the reaction mechanism of MAL. In this study, His-194 
and Gln-329 were mutated to assess their role in catalysis. The best characterized mutants are the 
H194A and Q329A mutants, which have measurable activity and show no significant differences in 
their CD spectra compared to that of wild-type MAL. Examination of the kinetic properties for the 
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two mutants in the deamination direction (using 2) shows that there is a small effect on Km and a 
much larger effect on kcat. This suggests important roles for His-194 and Gln-329 in catalysis. The 
somewhat larger effect of these mutations on the value of Km in the amination direction may 
suggest a more important role for His-194 and Gln-329 in binding 1 than 2. 
A major part of the loss in activity of the H194A and Q329A mutants is likely due to the 
removal of optimal hydrogen-bonding interactions with the proposed enolate anion intermediate 
formed at the C-4 carbonyl position of 2 (or 1 in the corresponding reverse reaction), making the 
abstraction of a proton from the C-3 position less favorable. Presumably, His-194 and Gln-329, 
together with the essential Mg
2+
 ion, polarize the C-4 carboxylate group and stabilize the enolate 
anion intermediate (4) formed upon abstraction of the C-3 proton (Scheme 3). An electrophilic 
residue whose role is to assist the Mg
2+
 ion in providing the charge neutralization that is essential 
for the activation of the α-proton and for stabilization of the enolate anion intermediate has also 





Scheme 3. A schematic representation of the proposed catalytic mechanism of MAL, showing the key 
participants in the deamination of (2S,3S)-3-methylaspartic acid. 
 
In addition to its presumed role as electrophilic residue, His-194 may also function as the 
(R)-specific base/acid catalyst. Naismith and co-workers first proposed this role for His-194 based 
on structure comparisons of enolase superfamily members.
[12]
 The side chain of His-194 
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superimposes on that of the second base Lys-166 in mandelate racemase and the principal base Lys-
213 in glucarate dehydratase.
[12]
 Moreover, if the three-dimensional structure of 3 is modeled into 
the active site of MAL, using the X-ray structure of MAL in complex with 2 as a guide, then the C-
3 proton of 3 is faced towards the imidazole nitrogen (Nε2) of His-194 (Figure 4). Our experiments 
clearly show that His-194 is an important determinant of the stereoselectivity of MAL because an 
alanine mutation at this position results in a mutant enzyme that appears to have lost its ability to 
catalyze proton abstraction/addition from the (R) face (the His-194 side) of the substrate. Indeed, 
the H194A mutant has no detectable deamination activity with 3 and catalyzes the highly 
stereoselective conversion of 1 to 2, with no detectable formation of 3. Taken together, these 
observations are consistent with a role of His-194 as the (R)-specific general base catalyst for the 
deamination of 3 and, hence, as the acid catalyst (the conjugate acid of His-194) in the 
corresponding reverse syn-addition reaction. 
 In view of the presumed role of His-194 as the (R)-specific general base/acid catalyst, 
mutation of Lys-331 or Gln-329 to an alanine gave results that were somewhat unexpected. 
Initially, it was thought that mutation of Lys-331 would only effect proton abstraction/addition from 
the (S) face (the Lys-331 side) of the substrate. Surprisingly, however, the K331A mutant lost its 
ability to catalyze proton abstraction/addition from the (R) face of the substrate, while retaining a 
very low-level proton abstraction/addition activity from the (S) face of the substrate. Like K331A, 
the Q329A mutant also catalyzes the highly stereoselective conversion of 1 to 2 with no detectable 
formation of 3. But, in contrast to K331A, the Q329A mutant still has a detectable low-level 
deamination activity with 3. 
 One potential explanation for the alteration in diastereoselectivity of the K331A and Q329A 
mutants is that mutation of Lys-331 or Gln-329 to an alanine causes different interactions between 
substrate and enzyme and may influence the geometry of a Michaelis complex that undergoes 
proton abstraction/addition from the (R) face of the substrate. In this scenario, the removal of the 
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native interactions with the substrate locate the substrate in an unfavorable position to undergo 
proton abstraction/addition by His-194, the presumed (R)-specific base/acid catalyst. Another 
explanation for the loss in proton abstraction/addition activity from the (R) face of the substrate is 
that mutation of Lys-331 or Gln-329 by an alanine directly influences the orientation of the His-194 
side chain. Crystallographic studies of the H194A, K331A and Q329A mutants, and of wild-type 
MAL in complex with 3, would be an important step toward understanding how these mutations 
affect the stereochemical properties of MAL. 
The current investigation has clearly demonstrated that the stereoselectivity of MAL can be 
enhanced by mutation of the active site residues His-194, Lys-331 and Gln-329. Interestingly, the 
mutation of Gln-73 or Gln-172, two residues implicated in binding the C-2 amino group of 2 
(Figure 4), to an alanine has a profound effect on the values of kcat and kcat/Km (using 2) but no 
significant effect on the stereoselectivity of MAL. Like wild-type MAL, the Q73A and Q172A 
mutants catalyze the amination of 1 to give both 2 and 3 as products [H. Raj and G.J. Poelarends 
(2009), unpublished results]. Hence, His-194, Gln-329, and Lys-331 appear to be the major 
determinants of the stereoselectivity of MAL. The enhancement of the stereoselectivity should 
make it possible to utilize single amino acid variants of MAL (e.g., H194A) in stereo- and 
regioselective amination reactions to produce 3-substituted aspartic acid isomers with a very high 
diastereomeric excess. Such efforts are being pursued in our laboratories. 
  




DL-threo-3-methylaspartic acid, mesaconic acid, and L-arabinose were purchased from Sigma-
Aldrich Chemical Co. (St. Louis, MO). (2S,3R)-3-Methylaspartic acid (95% purity) was purchased 
from Syncom (Groningen, The Netherlands). Ingredients for buffers and media were obtained from 
Duchefa Biochemie (Haarlem, The Netherlands) or Merck (Darmstadt, Germany). Molecular 
biology reagents, including restriction enzymes, PCR reagents, T4 DNA ligase, DNA ladders, 
agarose, and protein molecular weight standards were obtained from F. Hoffmann-LaRoche, Ltd. 
(Basel, Switzerland), Promega Corp. (Madison, WI), Invitrogen Corp. (Carlsbad, CA), Finnzymes 
(Espoo, Finland) or New England Biolabs (Ipswich, MA). PCR purification, gel extraction, and 
Miniprep kits were provided by Macherey-Nagel (Düren, Germany). Pre-packed PD-10 Sephadex 
G-25 columns were purchased from GE Healthcare Bio-Sciences AB (Uppsala, Sweden). 
Oligonucleotides for DNA amplification were synthesized by Operon Biotechnologies (Cologne, 
Germany). 
 
Bacterial strains, plasmids, and growth conditions 
E. coli strain XL1-Blue (Stratagene, La Jolla, CA) was used for cloning and isolation of plasmids. 
E. coli strain TOP10 (Invitrogen) was used in combination with the pBAD/Myc-His A vector 
(Invitrogen) for recombinant protein production. C. tetanomorphum ATCC 15920, the genomic 
DNA source for the MAL gene, was purchased from DSMZ GmbH (Braunschweig, Germany). E. 
coli cells were grown in Luria-Bertani (LB) media. When required, Difco agar (15 g/L), ampicillin 
(Ap, 100 g/mL), and/or arabinose (0.004% w/v) were added to the medium. 
 
General methods 
Techniques for restriction enzyme digestions, ligation, transformation, and other standard molecular 
biology manipulations were based on methods described elsewhere
[20]
 or as suggested by the 
manufacturer. The PCR was carried out in a DNA thermal cycler (model GS-1) obtained from 
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Biolegio (Nijmegen, The Netherlands). DNA sequencing was performed by ServiceXS (Leiden, 
The Netherlands) or Macrogen (Seoul, Korea). Protein was analyzed by polyacrylamide gel 
electrophoresis (PAGE) under either denaturing conditions using sodium dodecyl sulfate (SDS) or 
native conditions on gels containing polyacrylamide (7.5-10%). The gels were stained with 
Coomassie brilliant blue. Protein concentrations were determined by the Waddell method.
[21]
 
Kinetic data were obtained on a V-650 spectrophotometer from Jasco (IJsselstein, The 
Netherlands). The cuvettes were mixed using a stirr/add cuvette mixer (Bel-Art Products, 
Pequannock, NJ). The kinetic data were fitted by nonlinear regression data analysis using the Grafit 
program (Erithacus, Software Ltd., Horley, U.K.) obtained from Sigma Chemical Co. The CD 
spectra were recorded on a model 62A-DS spectropolarimeter from AVIV Biomedical Inc. 
(Lakewood, NJ). 
1
H NMR spectra were recorded on a Varian Inova 500 (500 MHz) spectrometer 
using a pulse sequence for selective presaturation of the water signal. Chemical shifts for protons 
are reported in parts per million scale (  scale) downfield from tetramethylsilane and are referenced 
to protium in the NMR solvents (H2O:  = 4.67). 
 
Construction of the expression vector for the production of MAL 
The MAL gene was amplified by the PCR using two synthetic primers, a small amount of biomass 
from C. tetanomorphum as the genomic DNA source, and the PCR reagents supplied in the Expand 
High Fidelity PCR system following the protocol supplied with the system (F. Hoffmann-La Roche, 
Ltd.). The forward primer (5’-ATACATATGAAAATTGTTGACGTACTTTG-3’) contains a NdeI 
restriction site (in bold) followed by 20 bases corresponding to the coding sequence of the MAL 
gene. The reverse primer (5’-CATAAGCTTTTTTCTTCTTCCTACAAG-3’) contains a HindIII 
restriction site (in bold) followed by 18 bases corresponding to the complementary sequence of the 
MAL gene. The resulting PCR product and the pBADN/Myc-His A vector were digested with NdeI 
and HindIII restriction enzymes, purified, and ligated using T4 DNA ligase. The pBADN/Myc-His 
A vector is a variant of the commercially available pBAD/Myc-His A vector in which the unique 
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NcoI site is replaced with NdeI.
[22]
 Aliquots of the ligation mixture were transformed into 
competent E. coli TOP10 cells. Transformants were selected at 37°C on LB/Ap plates. Plasmid 
DNA was isolated from several colonies and analyzed by restriction analysis for the presence of the 
insert. The cloned MAL gene was sequenced to verify that no mutations had been introduced during 
the amplification of the gene. The newly constructed expression vector was named pBAD(MAL-
His). 
 
Construction of MAL mutants 
Mutants of MAL were generated by the overlap extension PCR method
[23]
 using plasmid 
pBAD(MAL-His) as the template. The final PCR products were gel purified, digested with NdeI 
and HindIII restriction enzymes, and ligated in frame with both the initiation ATG start codon and 
the sequence that codes for the polyhistidine region of the expression vector pBADN/Myc-His A. 
All mutant genes were completely sequenced (with overlapping reads) to verify that only the 
intended mutation had been introduced. 
 
Expression and purification of MAL wild-type and mutants 
The MAL enzyme, either wild-type or mutant, was produced in E. coli TOP10 using the pBAD 
expression system. Fresh TOP10 cells containing the appropriate expression plasmid were collected 
from a LB/Ap plate using a sterile loop and used to inoculate LB/Ap medium (15 mL). After 
growth for 8 h at 37°C, a sufficient quantity of the culture was used to inoculate fresh LB/Ap 
medium (300 mL), containing arabinose (0.004%, w/v), in a 1 L Erlenmeyer flask to an initial A600 
of ~0.1. Cultures were grown for 4 days at 17°C with vigorous shaking. Cells were harvested by 
centrifugation (6000g, 15 min) and stored at -20°C until further use. 
In a typical purification experiment, cells of three 300-mL cultures were thawed, combined, 
and suspended in lysis buffer (10 mL, 50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole, pH 8.0). 
Cells were disrupted by sonication for 4 x 1 min (with 4-6 min rest in between each cycle) at a 60 
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W output, after which unbroken cells and debris were removed by centrifugation (10,000g, 45 min). 
The supernatant was filtered through a 0.45 μM-pore diameter filter and incubated with Ni-NTA (1 
mL slurry in a small column at 4°C for 18 h), which had previously been equilibrated with lysis 
buffer. The non-bound proteins were eluted from the column by gravity flow. The column was first 
washed with lysis buffer (10 mL) and then with buffer A (50 mM NaH2PO4, 300 mM NaCl, 20 mM 
imidazole, pH 8.0; 10 mL). Retained proteins were eluted with buffer B (50 mM NaH2PO4, 300 
mM NaCl, 250 mM imidazole, pH 8.0; 2.0 mL). Fractions (~0.5 mL) were analyzed by SDS-PAGE 
on gels containing acrylamide (10%), and those that contained purified MAL were combined and 
the buffer was exchanged against Tris buffer (50 mM, pH 8.0), containing MgCl2 (2 mM) and KCl 
(0.1 mM), using a pre-packed PD-10 Sephadex G-25 gel filtration column. The purified enzyme 
was stored at +4°C or −80°C until further use. 
 
Circular dichroism spectroscopy 
Circular dichroism spectra of the wild-type protein and the purified mutants were measured in Tris-
HCl buffer (10 mM, pH 8.0), containing MgCl2 (2 mM) and KCl (0.1 mM), at a concentration of 
approximately 3.2 µM in a CD cell with a 1.0-mm optical path length. 
 
Kinetic assays 
The assays used for the spectrophotometric determination of the deamination of 2 and to follow the 
amination of 1 are based on protocols reported elsewhere.
[3]
 Accordingly, the deamination of 2 by 
MAL was monitored by following the formation of 1 at 240 nm (ε = 3850 M-1 cm-1) in Tris-HCl 
buffer (500 mM, pH 9.0) containing MgCl2 (20 mM) and KCl (1 mM) at 30°C. An aliquot of MAL, 
either wild-type or mutant, was diluted into buffer (20 mL) and incubated for 30 min at 30°C. The 
30 min equilibration period results in more reproducible kinetic data. Subsequently, a 1-mL portion 
was transferred to a 10 mm quartz cuvette and the enzyme activity was assayed by the addition of a 
small quantity (1-10 μL) of 2 from a stock solution. The stock solutions were made up by 
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dissolving the appropriate amount of DL-threo-3-methylaspartic acid, a 1:1 mixture of the 
enantiomers  (2S,3S)-3-methylaspartic acid and (2R,3R)-3-methylaspartic acid, in Tris-HCl buffer 
(500 mM, pH 9.0) to obtain the desired concentration of 2. The (2R,3R)-enantiomer is not a 
substrate nor an inhibitor of MAL. The concentrations of 2 used in the assay ranged from 0.5 to 20 
mM. 





) in Tris-HCl buffer (500 mM, pH 9.0) containing MgCl2 (20 mM) and NH4Cl (400 mM) 
at 30°C.
[3]
 An aliquot of MAL, either wild-type or mutant, was diluted into buffer (20 mL) and 
incubated for 30 min at 30°C. Subsequently, a 1-mL portion was transferred to a 1 or 10 mm quartz 
cuvette and the enzyme activity was assayed by the addition of a small quantity (1-10 μL) of 1 from 
a stock solution. The stock solutions were made up in Tris-HCl buffer (500 mM, pH 9.0). The 
concentrations of 1 used in the assay ranged from 0.1 to 50 mM. 
 
pH dependence of the kinetic parameters of MAL and H194A 
The pH dependence of the steady-state kinetic parameters was determined in Tris buffer (500 mM) 
containing MgCl2 (20 mM) and KCl (1 mM) with pH values ranging from 6.0 to 9.5. For each pH 
value, a sufficient quantity of enzyme (from a stock solution in Tris buffer (50 mM, pH 8.0) 
containing 2 mM MgCl2 and 0.1 mM KCl) was equilibrated in buffer (20 mL) for 30 min at 30°C. 
The addition of enzyme did not significantly change the pH. Subsequently, aliquots (1 mL) were 
removed and assayed for activity using concentrations of 2 ranging from 0.5 to 50 mM. Stock 
solutions of 2 were made in Tris buffer (500 mM). The pH of the stock solutions was adjusted to 
each desired pH value (6.0-9.5). The volume of substrate added was 20 µL or less in all 
experiments. 
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1H NMR spectroscopic product analysis of the amination of 1 by MAL wild-type and mutants 
The products of the amination of 1 by wild-type MAL and the MAL mutants were identified by 
1
H 
NMR spectroscopy using a procedure described elsewhere
[2]
 with the following modifications. In 
separate experiments, MAL, K331A, H194A or Q329A was incubated with 1, and the reactions 
were followed by 
1H NMR spectroscopy. Reaction mixtures consisted of 350 μL of Na2HPO4 
buffer (100 mM, containing 20 mM MgCl2 and 1 mM KCl, pH 9.0), D2O (50 µL), NH4Cl (100 µL, 
5 M), and an aliquot of 1 (100 µL) from a 500 mM stock solution. The stock solution of 1 was 
made in Na2HPO4 buffer (100 mM), and the pH of the solution was adjusted to 9.0 with aliquots of 
an aqueous NaOH solution (1 M). A quantity of enzyme (50 μL) was added from a stock solution 
and the reaction mixtures were incubated at 22°C. The concentrations of the protein stock solutions 
were 12.3 mg/mL for MAL, 13.4 mg/mL for K331A, 10.7 mg/mL for H194A, and 14.4 mg/mL for 
Q329A. Additional aliquots of enzyme (50 μL) were added to the individual mixtures after 3, 6, 9, 
and 12 days. 
1
H NMR spectra were recorded 1 h, 3 days, 7 days, and 13 days after the first addition 
of enzyme. Product amounts were estimated by integration of the signals corresponding to 2 and 3, 
if present. The 
1
H NMR signals for 1, 2, and 3 are given in the Supporting Information (Figures S1, 
S2 and S3). 
 
1H NMR spectroscopic product analysis of the reaction of wild-type and mutant MAL with 2 
or 3 
The products of the deamination of 2 or 3 by wild-type MAL and the MAL mutants were identified 
by 
1
H NMR spectroscopy. In separate experiments, MAL, K331A, H194A or Q329A was 
incubated with 2 or 3. Reaction mixtures consisted of 400 μL of Na2HPO4 buffer (100 mM, 
containing 20 mM MgCl2 and 1 mM KCl, pH 9.0), D2O (40 µL), and an aliquot of 2 or 3 (150 µL) 
from a 500 mM stock solution. The stock solutions of 2 and 3 were made in Na2HPO4 buffer (100 
mM), and the pH of the solutions was adjusted to 9.0 with aliquots of an aqueous NaOH solution (1 
M). A quantity of enzyme (50 μL) was added from a stock solution and the reaction mixtures were 
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incubated at 22°C. The concentrations of the protein stock solutions were 15.7 mg/mL for MAL, 
12.8 mg/mL for K331A, 7.4 mg/mL for H194A, and 8.8 mg/mL for Q329A. Additional aliquots of 
enzyme (50 μL) were added to the individual mixtures after 3, 6, 9, and 12 days. The eight reaction 
mixtures were examined by 
1
H NMR spectroscopy after a 13 day-incubation period, and the 
product amounts were estimated by integration of the signals corresponding to 1, 2 and 3, if present. 
 
Molecular docking 
Comparative docking simulations were performed using Discovery Studio 1.7 (Accelrys, San 
Diego, CA, USA). Models for the enzymes were based on the structures of C. amanolaticus MAL 
in complex with 2
[13]
 and C. tetanomorphum MAL in the absence of a bound ligand
[12]
 (Protein 
Data Bank ID 1KKR and 1KCZ, respectively). Hydrogens were added automatically. Models of the 
substrates were constructed and energy minimized using the CHARMm (Momany and Rone) 
forcefield.
[24]
 Minimization was done using a dielectric constant of 1 and a non-bonded cutoff 
distance of 12 Å. The substrates were docked using the grid-based approach CDOCKER, a 
molecular dynamics (MD) simulated-annealing-based algorithm,
[25, 26]
 using as coordinates the 
experimentally determined binding site for 2 in C. amanolaticus MAL. Initially, the enzyme active 
site was fixed and the atoms of the substrate, either 2 or 3, were allowed to move. For subsequent 
rounds of minimization, the constraints on the amino acids forming the active site were removed 
and replaced by distance constraints based on the reported distances observed in X-ray structure of 
MAL complexed with 2. A final minimization step was applied to each ligand docked pose, 
consisting of 300 steps of steepest descent followed by 2500 iterations of the adopted basis-set 
Newton–Raphson algorithm using an energy tolerance of 0.001 Kcal mol-1. 
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H NMR spectrum of the material used as substrate 2, which is a 1:1 mixture of the enantiomers 
(2S,3S)- and (2R,3R)-3-methylaspartic acid. The (2R,3R)-enantiomer is not a substrate nor an inhibitor of 
MAL.  = 0.94 (s, 3H; CH3), 2.74 (s, 1H; CH), 3.81 (s, 1H; CH). 
  







H NMR spectrum of (2S,3R)-3-methylaspartic acid (3).  = 1.08 (d, 
3
J = 7.0 Hz, 3H; CH3), 2.63-
2.70 (m, 1H; CH), 3.46 (d, 
3







H NMR spectrum identifying the products of the MAL-catalyzed deamination of 2. The 
spectrum was taken after a 13 day-incubation period. Ratio 1 : 2 : 3 = 41 : 57 : 2.  = 0.93 (d, 
3
J = 6.5 Hz, 
3H; CH3), 1.08 (d, 
3
J = 7.5 Hz, 3H; CH3), 1.74 (s, 3H; CH3), 2.71-2.78 (m, 2H; CH), 3.46-3.48 (m, 1H; CH), 
3.81 (s, 1H; CH), 6.28 (s, 1H; CH3). Impurity  = 1.13 (s), 2.24 (d), 2.54 (d). 
  







H NMR spectrum identifying the products of the MAL-catalyzed deamination of 3. The 
spectrum was taken after a 13 day-incubation period. Ratio 1 : 2 : 3 = 79 : 12 : 9.  = 0.93 (d, 
3
J = 6.5 Hz, 
3H; CH3), 1.08 (d, 
3
J = 7.5 Hz, 3H; CH3), 1.74 (s, 3H; CH3), 2.65-2.78 (m, 2H, CH), 3.47 (s, 1H; CH), 3.81 
(s, 1H; CH), 6.28 (s, 1H; CH3). Impurity  =1.13 (s), 2.24 (d), 2.54 (d). 
  




















Figure S6. Superimposed far-UV CD spectra of wild-type and mutant enzymes. The CD spectra of all the 
mutants were comparable to that of wild-type MAL, but for clarity only the CD spectra of the K331A, 
H194A, and Q329A mutants are shown. Spectra were measured in 10 mM Tris buffer (pH 8.0), containing 2 
mM MgCl2 and 0.1 mM KCl, at a protein concentration of approximately 3.2 µM. 
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The redesign of enzymes to produce catalysts for a pre-defined transformation remains a major 
challenge in protein engineering. Here, we describe the structure-based engineering of 
methylaspartate ammonia lyase - which, in nature, catalyses the conversion of 3-methylaspartate to 
ammonia and 2-methylfumarate - to accept a variety of substituted amines and fumarates and 
catalyse the asymmetric synthesis of aspartic acid derivatives. We obtained two single active site 
mutants, one exhibiting wide nucleophile scope including structurally diverse linear and cyclic 
alkylamines and one with broad electrophile scope including fumarate derivatives with alkyl, aryl, 
alkoxy, aryloxy, alkylthio and arylthio substituents at the C2 position. Both mutants have an 
enlarged active site that accommodates the new substrates while retaining the high stereo- and 
regioselectivity of the wild-type enzyme. As an example we demonstrate a highly enantio- and 
diastereoselective synthesis of threo-3-benzyloxyaspartate - an important inhibitor of neuronal 





Optically pure α-amino acids are highly valuable as tools for biological research and as chiral 
building blocks for pharmaceuticals and (agro)chemicals.
[1]
 The industrial and academic interest in 
these compounds, combined with the potential advantages of replacing conventional chemical 
processes by biocatalysis, has fueled the development of enzymatic synthesis routes for 
enantiomerically pure α-amino acids. Various enzymatic synthesis routes have been developed 
using e.g. hydantoinases, dehydrogenases, acylases, aminotransferases, ammonia lyases and 
amidases,
[1-5]
 with the most attractive ones being those that are based on asymmetric synthesis in 
which a prostereogenic substrate is converted to an optically pure α-amino acid with 100% 
theoretical yield. For example, the asymmetric addition of ammonia to the double bonds of 
unsaturated acids catalyzed by ammonia lyases is a very attractive strategy for the synthesis of 
chiral α-amino acids.[5] This strategy makes use of readily available starting substrates without the 
need for cofactor recycling, the implementation of dynamic kinetic resolution strategies, or 
additional catalysts. However, it is limited by the narrow substrate range of ammonia lyases. 
3-Methylaspartate ammonia lyase (MAL) catalyzes the reversible addition of ammonia (2a) to 
mesaconate (1b) to yield threo-(2S,3S)-3-methylaspartate (threo-3a) and erythro-(2S,3R)-3-
methylaspartate (erythro-3a) as products (Table 1).
[6-10]
 MAL is used by the bacterium Clostridium 
tetanomorphum as part of a degradative pathway that converts (S)-glutamic acid via threo-3a to 
yield acetyl-CoA.
[6, 11]
 The crystal structure of MAL and that of the isozyme from Citrobacter 
amalonaticus have been solved by X-ray crystallography.
[12, 13]
 Based on kinetic isotope 
measurements,
[14, 15]
 the structural studies
[12, 13, 16]
 and mutagenesis experiments,
[8]
 a mechanism has 
emerged for the MAL-catalyzed reaction. In this proposed mechanism, an (S)- or (R)-specific 
catalytic base abstracts the C-3 proton of the respective stereoisomer of 3a to generate an enolate 
intermediate that is stabilized by coordination to the essential active site Mg
2+
 ion. Collapse of this 




Figure 1. Crystal structure of wild-type MAL in complex with the natural substrate threo-(2S,3S)-3-
methylaspartate. (a), A close up of the active site showing the hydrogen bond interactions between the 
substrate’s amino group and the side chains of Gln73 (via a water molecule) and Gln172. The carbon atoms 
of the active site residues are shown in green, whereas those of the substrate are shown in cyan. Hydrogen 
bonds are represented as dashed lines. The magnesium ion and water molecule are shown as magenta and 
yellow spheres, respectively. (b) A close up of the active site showing the observed distances (in Å, atoms 
connected by solid lines) between the substrate’s methyl group and the side chains of the three residues 
(Phe170, Tyr356 and Leu384) that are involved in formation of the alkyl binding pocket. The coloring 
scheme is the same as in Fig. 1a. The figures were prepared with PyMOL (http://www.pymol.org). 
 
Unfortunately, the substrate scope of MAL is very narrow, reasonable activity being observed 
only with a few small substituted amines and fumarates, yielding a limited number of substituted 
aspartic acids.
[17-19]
 Hence, it would be very attractive to extend the accessible range of aspartic acid 
derivatives by the redesign of MAL to convert various unnatural substrates, which would enlarge its 
biocatalytic applicability. In this report, we describe the use of an efficient engineering strategy, 
which is based on saturation mutagenesis at carefully chosen sites lining the substrate binding 
pocket,
[20-24]
 to expand both the nucleophile and electrophile spectrum of MAL. We have obtained 
two single active site mutants, one that accepts a large set of non-native amines and one that accepts 
various non-native fumarate derivatives. These engineered MALs have potential as catalysts for 
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asymmetric synthesis of a large variety of substituted aspartic acids, which are valuable as tools for 
biological research and as building blocks for chemical and pharmaceutical synthesis.
[25-31]
 This 
potential is illustrated by the mutant MAL-catalyzed synthesis of threo-3-benzyloxyaspartate, a 






Expansion of the nucleophile spectrum of MAL 
The crystal structure of MAL complexed with the natural substrate threo-(2S,3S)-3-methylaspartate 
(threo-3a)
[13]
 suggests that the side chains of Q73 and Q172 are involved in formation of the 
binding pocket for the substrate’s amino group (Fig. 1a). To engineer this putative amine binding 
pocket, three focused libraries were generated by saturation mutagenesis at positions 73, 172 and 
73/172, using NNS degeneracy.
[32]
 As the model reaction for activity screening, the addition of 
methylamine (2b) to mesaconate (1b) was chosen (Table 1). This small alkylamine is a poor 
substrate for wild-type MAL. We reasoned that if mutants displaying substantial activity were to be 
found in any of the libraries, then they could be tested for their ability to process larger and more 
challenging amines as well (e.g., amines 2c-2u). 
The three libraries were used to transform Escherichia coli cells. The double-site library was 
screened by evaluating ~1200 transformants, whereas ~400 transformants were evaluated for each 
single-site library. While the library at position 172 failed to contain any active mutants, screening 
of the libraries corresponding to positions 73 and 73/172 resulted in the identification of six mutants 
with pronounced activity towards methylamine addition. DNA sequencing revealed that all positive 
hits carry mutations at position 73, namely Q73A, Q73G, Q73N, Q73P, Q73S, and Q73T. These 
mutants and the wild-type enzyme were overexpressed, purified to homogeneity, and assayed for 
their ability to catalyze ammonia or methylamine addition to mesaconate. When compared to wild-
type MAL, all mutants display a significant decrease in ammonia addition activity and a large 
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Table 1. Q73A-catalyzed amine (2a-2u) addition to mesaconate (1b). 
 
Entry nucleophile R-group product conv. 
(%)
a 
de (%) ee (%) 







2 2b methyl 3b 74 >95 (threo)
c
 ND 














6 2f pentyl 3f 29 >95 (threo)
c
 ND 
7 2g hexyl 3g 17 >95 (threo)
c
 ND 










10 2j cyclopentyl 3j 36 >95 (threo)
c
 ND 
11 2k cyclohexyl 3k 21 >95 (threo)
c
 ND 





13 2m benzyl 3m 6 >95 (threo)
c
 ND 
14 2n cyclopropyl 3n 75 >95 (threo)
d 
ND 
15 2o ethoxy 3o 99 >95 (threo)
d
 ND 





17 2q 3-hydroxypropyl 3q 56 80 (threo)
d 
ND 
18 2r 2-methoxyethyl 3r 60 >95 (threo)
d
 ND 
19 2s N-methyl-2-aminoethyl 3s 80 >95 (threo)
d
 ND 
20 2t 2-aminoethyl 3t 90 >95 (threo)
d
 ND 




Reactions were allowed to proceed for 7 days in order to detect formation of low amounts of erythro 
product isomers, if present. 
b
Reaction was allowed to proceed for 14 days. 
c
The diastereomeric excess 
(defined as excess of threo isomer over erythro isomer) of the amino acid product was determined by 
comparison of its 
1
H NMR signals in the crude reaction mixture to those of synthesized authentic standards 
with known threo or erythro configuration. 
d
The purified amino acid product could be tentatively assigned 
the threo configuration on the basis of analogy. 
e
ND, not determined. 
f
The enantiomeric excess of the 





Figure 2. Enzyme-catalyzed transformations under optimized reaction conditions. (a) Progress curves 
of the Q73A-catalyzed (0.05 mol%) addition of methylamine (2b, 3 M), cyclobutylamine (2i, 2 M) or 
ethoxyamine (2o, 3 M) to mesaconate (26 mM) as monitored by 
1
H NMR spectroscopy. (b) Progress curves 
of the L384A-catalyzed (0.05 mol%) addition of ammonia (5 M) to fumarate (1a), 2-hexylfumarate (1g) or 
2-(benzyloxy)fumarate (1j) (each at 30 mM) as monitored by 
1
H NMR spectroscopy. 
 
increase in methylamine addition activity (Supplementary Fig. 1). The Q73A mutant showed the 
highest catalytic rate for methylamine addition to mesaconate and was therefore selected for further 
study. 
A comparison of the kcat/Km values shows that the Q73A mutant is at least 140-fold more 
efficient in the addition of methylamine than wild-type MAL (Supplementary Table 1). Wild-type 
MAL, however, is ~500-fold more efficient in the ammonia addition reaction. Hence, the Q73A 
mutation moved the specificity of MAL away from ammonia and towards methylamine (>70,000-
 86 
 
fold shift in nucleophile specificity as defined by kcat/Km values). 
1
H NMR spectroscopic analysis 
showed that the Q73A-catalyzed ammonia and methylamine additions to mesaconate lead to the 
same amino acid products as the corresponding wild-type MAL-catalyzed reactions (Supplementary 
Fig. 2). This demonstrates that the Q73A mutation does not affect the regio- or diastereoselectivity 
of the enzyme. Whereas the enzyme-catalyzed ammonia addition reaction yields an ~1:1 mixture of 
threo and erythro isomers of 3-methylaspartate (Table 1, 3a),
[8]
 the enzyme-catalyzed methylamine 
addition reaction is highly diastereoselective and gives exclusively the threo isomer of N,3-
dimethylaspartate (3b) (Table 1, Supplementary Fig. 2).
[19]
 
To investigate its nucleophile scope, we used 
1
H NMR spectroscopy to determine the ability 
of the Q73A mutant to add a variety of structurally different amines (2c-2u, Table 1) to mesaconate 
(10-fold molar excess of amine over mesaconate, 0.01 mol% of biocatalyst, room temperature). 
These amines are not accepted as substrates by wild-type MAL, with the exception of 2c, 2n, 2p 
and 2t which show minimal conversion (<3%) upon prolonged (2 weeks) incubation. Given that 
MAL catalyzes the fast anti-addition and much slower syn-addition of ammonia to mesaconate,
[8]
 
leading to threo and erythro isomers of the corresponding product, respectively, we allowed the 
unnatural amine addition reactions to run for 7 days in order to detect formation of low amounts of 
erythro product isomers, if present. Remarkably, the Q73A mutant processed all amines tested 
(Table 1), including those having bulky substituents such as hexyl, cyclohexyl and benzyl, which 
demonstrates its surprisingly broad nucleophile scope. Control experiments showed that the amines 
do not react with mesaconate in the absence of enzyme. 
For amines 2c-2m (Table 1, entries 3-13), the single products of the Q73A-catalyzed 
additions to mesaconate were identified as the threo isomers of the corresponding N-substituted 3-
methylaspartic acids (3c-3m) by comparison of their 
1
H NMR signals in the crude reaction mixtures 
to those of chemically synthesized authentic standards with known relative configuration 
(Supplementary Fig. 3). No other regio- or diastereoisomers were observed. For a few selected 
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amines (2c-2e, 2h, 2i and 2l), preparative scale reactions were performed (1.2 mmol 1b). 
Purification of the amino acid products and analysis by HPLC on a chiral stationary phase 
(Supplementary Fig. 4) revealed that the Q73A mutant is also highly enantioselective, producing 
3c-3e, 3h, 3i and 3l with >99% ee (Table 1). In the case of the other amines (Table 1, entries 14-
21), the Q73A-catalyzed addition reactions were performed on a 3.1 mmol scale (1b). The products 
were isolated and identified as the corresponding N-substituted 3-methylaspartic acids (3n-3u). 
While the relative configuration of products 3n-3u has not been determined by comparison to 
authentic standards, we assume the relative configuration to be threo for all products 3b-3u. 
To further demonstrate the preparative usefulness of the Q73A mutant, we optimized the 
reaction conditions for a few structurally distinct amines (2b, 2i and 2o). With 0.05 mol% 
biocatalyst and a 115-fold molar excess of 2b or 2o (3 M each) over mesaconate (26 mM), the 
reactions are complete within 20 to 60 min at 25 C, achieving final conversions of almost 100% 
(Fig. 2a). For amine 2i, a lower concentration (2 M) had to be used to avoid protein precipitation. 
Nevertheless, the reaction reaches equilibrium (~65% conversion) in just a few hours. These results 
clearly demonstrate the potential of the Q73A mutant for application in selective synthesis of 
various N-substituted 3-methylaspartic acids. 
 
Expansion of the electrophile spectrum of MAL 
The structure of MAL in complex with threo-(2S,3S)-3-methylaspartate
[13]
 suggests that the side 
chains of F170, Y356 and L384 are involved in formation of the binding pocket for the substrate’s 
methyl group (Fig. 1b). To engineer this putative alkyl binding pocket, three focused libraries were 
generated by saturation mutagenesis at positions 170, 356 and 384, using NNS degeneracy. As the 
model reaction for activity screening, the addition of ammonia to 2-hexylfumarate (Table 2, 1g) was 
chosen. Compound 1g is not at all converted by wild-type MAL, even after an incubation period of 
several weeks. The hope was that active mutants with the ability to aminate electrophiles with large 
substituents at the C-2 position (e.g., 1e-1g, 1i, 1j, 1l-1n) can be identified in this way.  
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Table 2. MAL- and L384A-catalyzed ammonia addition to fumarates 1a-1n. 
 





























































































Yield (%) of isolated product after ion 
exchange chromatography. 
d
The diastereomeric excess (de) is defined as excess of threo-isomer over erytho-
isomer. 
e
The relative configuration of the isolated product(s) was assigned by 
1
H NMR using the product(s) 





The relative configurations have not been determined. 
g
The relative configuration of the 




The relative configuration of isolated 
product was assigned by 
1
H NMR spectroscopy using an authentic standard with known threo configuration 




The isolated amino acid products were first esterified and acetylated, 
after which the relative configuration of the products could be tentatively assigned by 
1
H NMR spectroscopy 
on the basis of comparison to chemically synthesized reference molecules (see Supplementary Methods).
 
j
The ee value of isolated product was determined by chiral HPLC using authentic standards with known R or 
S configuration. 
k
ND, not determined. 
l
The ee value of isolated product was determined by chiral HPLC 
using authentic threo-(DL)-4j as standard. 
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The three libraries were introduced into E. coli cells, after which the library corresponding to 
position 384 was screened by evaluating ~400 transformants and ~200 transformants were 
evaluated for each of the other two libraries. Whereas the libraries corresponding to positions 170 
and 356 failed to give any active mutants, screening of the library corresponding to position 384 
resulted in several positive hits. Analysis by DNA sequencing revealed that all positive hits carry 
either an alanine or glycine mutation at position 384. These two mutants and the wild-type enzyme 
were overexpressed, purified to homogeneity, and tested for their ability to catalyze the addition of 
ammonia to either mesaconate or 2-hexylfumarate. Gratifyingly, the L384G and L384A mutants 
exhibit pronounced amination activity towards 2-hexylfumarate (Supplementary Fig. 5). Both 
mutants display a significant decrease in amination activity towards mesaconate when compared to 
wild-type MAL. Hence, the mutations moved the electrophile specificity of MAL away from the 
natural substrate mesaconate and towards the unnatural substrate 2-hexylfumarate. Because the 
L384A mutant showed higher activity towards a range of fumarate derivatives, it was selected for 
further study. 
Kinetic parameters were determined for the L384A mutant using substrates 1a-1g, which have 
varying 2-alkyl chain length (Table 2), and compared to those measured for the wild-type enzyme 
(Supplementary Table 2). As previously reported,
[17, 18]
 wild-type MAL only displays activity 
towards fumarates with a short alkyl substituent (1a-1d). Mutant L384A, however, shows activity 
for all tested substrates. It displays both higher affinity (lower Km values) and higher activity (larger 
kcat values) for substrates with a long alkyl chain (1d-1g) than for those with a short alkyl chain (1a-
1c). While wild-type MAL is at least 100-fold more efficient in the amination of 1a-1c, the L384A 
mutant is ~13-fold more efficient in the amination of 1d. In the case of the large substrates 1e-1g, 
which are not at all converted by wild-type MAL, it was not possible to determine the rate 
enhancement, but it must be much higher than that observed for 1d. 
 90 
 
To further explore the electrophile scope of the L384A mutant, its ability to catalyze the 
amination of substrates with aryl, alkoxy, aryloxy, alkylthio, and arylthio substituents at the C-2 
position (1h-1n) was tested by using 
1
H NMR spectroscopy (Table 2). The wild-type enzyme only 
displays amination activity for compounds 1h and 1k, which, like substrates 1a-1d, have small R-
groups at the C-2 position (Table 2, entries 1-4, 8, 11). Strikingly, the L384A mutant exhibits 
activity towards all substrates tested (Table 2), demonstrating its broad electrophile scope. Control 
experiments showed that the fumarate derivatives do not undergo amination in the absence of 
enzyme. 
The L384A-catalyzed aminations of 1a-1n were also performed on a preparative (3.1 mmol) 
scale (Table 2). Reactions (10-fold molar excess of ammonia over unsaturated acid, 0.01 mol% of 
biocatalyst, room temperature) were allowed to run for 7 days in order to detect formation of low 
amounts of erythro product isomers, if present. The products were isolated and identified as 
aspartate (4a) and its 3-substituted derivatives 4b-4n, respectively. While these L384A-catalyzed 
amination reactions provided high regioselectivities, varying degrees of diastereoselectivity were 
obtained with the single or predominant diastereoisomer having the threo configuration (Table 2). 
Analysis of products 4a and 4j by chiral HPLC revealed that the L384A-catalyzed amination 
reactions are highly enantioselective, producing these amino acids with >99% ee (Table 2). 
The preparative usefulness of the L384A mutant was further demonstrated by transformations 
using 0.05 mol% biocatalyst, 5 M ammonia, and 30 mM of the structurally distinct unsaturated 
acids 1a, 1g or 1j (167-fold molar excess of ammonia over unsaturated acid). Under these 
optimized conditions, the reactions are complete within 10 to 60 min at 25 C, achieving final 
conversions of ~85 to 100% (Fig. 2b). These results clearly demonstrate the potential of the L384A 




Structural basis for the expanded substrate spectrum 
To obtain insight into how the active sites of the Q73A and L384A mutants are remodelled to 
accommodate the new substrates, we determined their X-ray crystal structures at 2.0 Å and 1.9 Å 
resolution, respectively (Supplementary Table 3). A comparison of the Q73A and L384A structures 
with that of wild-type MAL revealed no significant changes in overall structure nor in main chain 
and side chain conformations of the active site residues (Fig. 3). These results demonstrate that the 
expanded substrate spectrum of the Q73A and L384A mutants is not due to major structural 
changes but is related to the replacement of a large active site residue by a smaller one, resulting in 
an enlarged active site that can accommodate the new substrates (Fig. 3). 
 
Figure 3. Structural comparison of wild-type MAL and the Gln73Ala and Leu384Ala mutants. (a) 
Overlay of the structures of wild-type MAL (cyan ribbons) and the Gln73Ala (green ribbons) and Leu384Ala 
(orange ribbons) mutants. The structures of the Gln73Ala (PDB code 3ZVH) and Leu384Ala (PDB code 
3ZVI) mutants can be superimposed to the wild-type MAL structure
[12]
 (PDB code 1KCZ) with a root-mean-
square-deviation (RMSD) of 0.53-0.74 Å, considering all atoms in the two subunits that occupy the different 
crystallographic asymmetric units. When considering only the atoms of residues that are within 5 Å of the 
residues at positions 73 and 384, the RMSD is 0.19-0.50 Å. (b) Overlay of the active sites of wild-type MAL 
and the Gln73Ala mutant. The coloring scheme is the same as in Fig. 3a. (c) Overlay of the active sites of 
wild-type MAL and the Leu384Ala mutant. The coloring scheme is the same as in Fig. 3a. In all three 
figures, the residues at positions 73 and 384 are shown as sticks. For clarity, these sticks are shown in grey 




To further demonstrate that the active sites of the Q73A and L384A mutants can 
accommodate larger substrates than the active site of wild-type MAL, we performed comparative 
docking simulations. Figure 4a shows an overlay of the docking model of wild-type MAL in 
complex with the natural substrate threo-(2S,3S)-3-methylaspartic acid (threo-3a) and the docking 
model of mutant Q73A complexed with the unnatural substrate threo-(2S,3S)-2-(cyclohexylamino)- 
3-methylbutanedioic acid (3k), respectively. This comparison clearly shows that compound 3k does 
not fit into the active site of wild-type MAL because residue Q73, instead of the shorter A73, 
partially fills the volume that is occupied by the cyclohexylamino moiety of substrate 3k in the 
Q73A-substrate complex. The observation that residue Q73 occludes the amine binding pocket thus 
explains why cyclohexylamine 2k and other large amines are not accepted as substrates by wild-
type MAL. An overlay of the docking model of wild-type MAL complexed with threo-3a and that 
of mutant L384A in complex with the unnatural substrate threo-(2S,3S)-3-pentylaspartic acid (4f) is 
shown in Fig. 4b. This comparison shows that the mutation of residue L384 to the shorter A384 
prevents a clash between the substrate’s pentyl group and the large leucine residue found at position 




Wild-type MAL accepts only a few amines as alternative nucleophiles for ammonia and a few 
fumarate derivatives as alternative electrophiles for mesaconate.
[17-19]
 Therefore, the goal of this 
study was to expand both the nucleophile and electrophile scope of MAL. This goal was achieved 
by using an engineering strategy that involves randomization at carefully chosen sites lining the 
substrate binding pocket of the enzyme. The major benefit of this structure-guided engineering 






Engineering of the amine binding pocket (Fig. 1a) yielded a mutant (Q73A) that has a very 
broad nucleophile scope and excellent regio- and stereoselectivity, producing the threo isomers of 
the N-substituted 3-methylaspartic acids 3b-3u with very high diasteromeric and enantiomeric 
excess (Table 1). These results demonstrate that the high regio- and stereoselectivity of the Q73A-
catalyzed addition reactions is not influenced by the different substituents on the amine substrate. 
This is of high synthetic significance, especially when compared to the Q73A-catalyzed ammonia 
addition to mesaconate (the natural reaction), which shows low diastereoselectivity (Table 1, entry 
1). Recently, a mechanism was proposed for MAL,
[8, 12, 13]
 in which the proton abstraction/addition 
steps are effected by K331 and H194 as the (S)- and (R)-specific general base/acid catalysts, 
respectively, which are juxtaposed on either side of the chiral C-3 carbon of the amino acid 
substrate. In view of this mechanism, the high diastereoselectivity of the Q73A-catalyzed amine 
addition reactions could be explained by assuming that the substituents on the amine substrate 
sterically hinder protonation of the C-3 carbon (numbering according to the amino acid product) of 
mesaconate by H194, thereby preventing the formation of erythro isomers. Structural analysis of 
the Q73A mutant showed that this mutant enzyme has an enlarged amine binding pocket, without 
changes in the orientation of active site residues, thus rationalizing its ability to convert the new 
amine substrates. 
Engineering of the alkyl binding pocket (Fig. 1b) yielded a mutant (L384A) that has a very 
broad electrophile scope and excellent regio- and enantioselectivity in the amination reaction, 
producing (S)-aspartic acid (4a) and its 3-substituted derivatives 4b-4n (Table 2). The structure of 
L384A showed that this mutant enzyme has an enlarged alkyl binding pocket, with an otherwise 
unchanged active site geometry, thus rationalizing its ability to convert fumarate derivatives with 
large substituents. In contrast to the Q73A-catalyzed amine additions, the L384A-catalyzed 
amination of the fumarate derivatives gives varying degrees of diastereoselectivity. This irregular 




Figure 4. Molecular docking of substrates in the active sites of wild-type MAL and the two MAL 
mutants. (a) Overlay of the most favorable docked conformations of threo-(2S,3S)-3-methylaspartic acid 
(threo-3a) and threo-(2S,3S)-2-(cyclohexylamino)-3-methylbutanedioic acid (3k) in the active sites of wild-
type MAL (grey) and the Gln73Ala mutant (green), respectively. Residue Gln73 in wild-type MAL is 
represented by a solvent accessible surface calculated with a probe radius of 1.4 Å. (b) Overlay of the most 
favorable docked conformations of threo-3a and threo-(2S,3S)-3-pentylaspartic acid (4f) in the active sites of 
wild-type MAL (grey) and the Leu384Ala mutant (orange), respectively. Residue Leu384 in wild-type MAL 
is represented by a solvent accessible surface calculated with a probe radius of 1.4 Å. In both figures, 
interactions between active site residues or the Mg
2+
 ion and substrate threo-3a in wild-type MAL are 
displayed as orange dashed lines. The distance between the substrate’s C-3 atom and the side chain of 
Lys331 is shown in Å (atoms connected by a solid line). The figures were prepared with Discovery Studio 
2.5. 
 
fumarate derivatives, like the natural substrate mesaconate, are optimally positioned to undergo 
protonation by both K331 and H194 from either face of the substrate, producing the undesired 
mixture of threo and erythro isomers, whereas others are bound in a position which does not favor 
protonation by H194, yielding only the desired threo-isomers. Nonetheless, the synthetic potential 
of the L384A mutant is convincingly demonstrated by its use as catalyst in the stereoselective 
synthesis (de values are >95%) of threo-3-benzyloxyaspartate (4j) and threo-3-benzylaspartate 





In summary, we provide evidence that a single amino acid substitution is sufficient to 
dramatically expand the nucleophile or electrophile spectrum of MAL. The results provide support 
for the notion that structure-guided saturation mutagenesis of sites lining the substrate binding 
pocket is a powerful strategy to create enzymes that can accommodate nonnative substrates and 
perform reactions not observed in Nature.
[22]
 The new designer enzymes catalyze attractive and 
straightforward asymmetric transformations in water, making use of readily available starting 
substrates, without the need for organic (co)solvents or the implementation of dynamic kinetic 
resolution strategies. These represent very desirable features in view of the quest for 
environmentally benign and atom efficient processes. The potential of the two engineered MALs for 
application in selective synthesis of new and valuable aspartic acid derivatives has been 
demonstrated, given that the product yields may be further improved by optimizing the reaction 
conditions and purification protocols. The Q73 and L384 residues represent good targets for future 
combinatorial mutagenesis experiments (see Supplementary Results & Discussion), potentially 
yielding new biocatalysts with an even larger substrate scope. 
 
METHODS 
Mutant library preparation and screening 
Site-saturation mutagenesis libraries were generated by overlap extension PCR
[33]
 using plasmid 
pBAD(MAL-His)
[8]
 as template and the primers listed in Supplementary Table 4. Detailed 
procedures for library preparation and screening are provided in the Supplementary Methods. 
 
Enzyme expression, purification and kinetic characterization 
Wild-type MAL and MAL mutants were overproduced in E. coli TOP10 cells and purified to 
homogeneity as described before.
[8]
 Procedures for the kinetic characterization of MAL (wild-type 




General procedure for monitoring the addition of various amines to mesaconate 
The ability of wild-type MAL and the Q73A mutant to add different amines (2a-2u) to mesaconate 
(1b) was examined by using 
1
H NMR spectroscopy. Reaction mixtures consisted of 500 µl of a 1 M 
stock solution of amine in water (pH 9.0, containing 20 mM MgCl2), 100 µl of 500 mM 1b in water 
(pH 9.0, containing 20 mM MgCl2), and 50 µl of D2O. In the case of amines 2f, 2g and 2m 500 µl 
of a 250 (2f) or 125 mM (2g and 2m) stock solution was added to the reaction mixtures to avoid 
protein precipitation. Reactions were started by the addition of 200 µg of freshly purified enzyme, 
and reaction mixtures were incubated at 22°C. 
1
H NMR spectra were recorded 3 h, 3 d, and 7 d 
after the addition of enzyme. Product amounts were estimated by integration of the respective 
product signals, if present. 
 
General procedure for monitoring the amination of various electrophiles 
The ability of wild-type MAL and the L384A mutant to add ammonia to different electrophiles (1a-
1n) was examined by using 
1
H NMR spectroscopy. Reaction mixtures consisted of 500 μl of a 1 M 
stock solution of NH4Cl in water (pH 9.0, containing 20 mM MgCl2), 50 µl D2O, and 200 µl of a 
250 mM stock solution (or 100 µl of a 500 mM stock solution) of electrophile in water (pH 9.0, 
containing 20 mM MgCl2). Reactions were started by the addition of 200 µg of freshly purified 
enzyme, and reaction mixtures were incubated at 22°C. 
1
H NMR spectra were recorded 3 h, 3 d, 
and 7 d after the addition of enzyme. Product amounts were estimated by integration of the 
respective product signals, if present. 
 
Starting substrates 
Amines 2a-2u and unsaturated acids 1a and 1b were purchased from Sigma-Aldrich Chemical Co 
(St. Louis, MO) or Merck (Darmstadt, Germany). Unsaturated acids 1c-1n were prepared according 




Identification of the amino acid products 
Procedures for the enzymatic synthesis and purification of amino acids 3n-3u and 4a-4n are 
described in the Supplementary Methods. The relative configuration of products 4b-4d, 4h, 4j, and 
4n was determined by comparison of their 
1
H NMR signals to those of commercially available or 
wild-type MAL-synthesized
[17]
 authentic standards with known configuration, and/or by referring to 
the literature.
[29-31]
 Compound threo-DL-4j was purchased from Tocris Bioscience (Missouri, USA). 
The procedures to establish the relative configuration of products 4k-4m are provided in the 
Supplementary Methods. The enantiomeric excess of products 4a and 4j was determined by chiral 
HPLC using a Chirex 3126-(D)-penicillamine column (250 mm x 4.6 mm, Phenomenex, USA) or a 
Nucleosil chiral-1 column (250 mm x 4 mm, Macherey-Nagel, Germany), respectively. Authentic 
standards L-4a and D-4a were purchased from Sigma-Aldrich Chemical Co. HPLC conditions and 
observed retention times are given in the Supplementary Methods. 
 
Identity and configuration of amino acid products 3a-3m 
The identity and relative configuration of products 3a-3m were determined by comparative 
1
H 
NMR analysis of the crude reaction mixtures and authentic compounds with known relative 
configuration. The experimental procedures for the synthesis of these authentic standards are 
provided in the Supplementary Methods. Products 3c-3e, 3h, 3i, and 3l were also purified from 
preparative scale (0.15 g 1b) reactions and their enantiomeric excess was determined by chiral 
HPLC. The HPLC conditions, procedures for the synthesis of the threo-DL standards, and the 
observed retention times are provided in the Supplementary Methods. 
 
Optimization of reaction conditions for amino acid synthesis 
By increasing both the amount of biocatalyst and the molar excess of amine over mesaconate, 
excellent conversions were achieved for several Q73A-catalyzed amine additions within short 
reaction times. The optimized reaction conditions were as follows. Reaction mixtures (30 ml) 
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consisted of 3 M amine (either 2b or 2o) and 26 mM 1b in 20 mM MgCl2 (final pH = 9). In the case 
of amine 2i, a lower concentration (2 M) was used to avoid protein precipitation. The reactions were 
started by the addition of freshly purified enzyme (0.05 mol%), and reaction mixtures were 
incubated at 25°C. Aliquots of each reaction mixture (5 ml) were withdrawn 5 min, 15 min, 45 min, 
90 min, 180 min, and 24 h after the addition of enzyme. For each sample, the reaction was stopped 
by incubating the reaction mixture at 100°C for 5 min. 
Optimized conditions for several L348A-catalyzed amination reactions were as follows. 
Reaction mixtures (6-12 ml) consisted of 5 M NH4Cl and 30 mM 1a, 1g or 1j in 20 mM MgCl2 
(final pH = 9). The reactions were started by the addition of freshly purified enzyme (0.05 mol%), 
and reaction mixtures were incubated at 25°C. Aliquots (1-2 ml) of the reaction mixtures were 
withdrawn 5 min, 15 min, 45 min, 90 min, 180 min, and 24 h after the addition of enzyme. For each 
sample, the reaction was stopped by incubating the reaction mixture at 100°C for 5 min. 
Each sample was dried in vacuo, followed by resuspending the resulting residue in ~10 ml 
of water for lyophilization. This process was repeated 5 to 10 times in order to remove the excess of 
amine/ammonia to enable analysis by 
1
H NMR spectroscopy. The final residue was dissolved in 
800 µl D2O. The conversion of substrate to product was estimated by integration of the respective 
substrate and product signals. 
 
Crystallization, structure determination and molecular docking 
The procedures used for crystallization, structure determination, and comparative docking 
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Mutant library preparation 
The plasmid pBAD(MAL-His)
[1]
 contains the wild-type MAL gene under the transcriptional control 
of the araBAD promoter. The libraries Q73NNS, Q172NNS, Q73NNS/Q172NNS, F170NNS, 
Y356NNS and L384NNS were generated by the overlap extension PCR method
[2]
 using plasmid 
pBAD(MAL-His) as the template and the primers listed in Supplementary Table 4. The final PCR 
products were gel purified, digested with NdeI and HindIII restriction enzymes, and ligated in frame 
with both the initiation ATG start codon and the sequence that codes for the polyhistidine region of 
the expression vector pBADN/Myc-His A.
[3]
 An aliquot of each ligation mixture was transformed 
into competent E. coli TOP10 cells. Transformants were selected at 37
o
C on Luria-Bertani (LB) 
agar plates containing 100 µg/ml ampicillin (Ap). For each library, plasmid DNA was isolated from 
several colonies chosen at random, and analyzed by restriction analysis for the presence of the 
insert. Plasmids containing the insert were sequenced to verify that the correct mutations had been 
introduced during the amplification of the MAL gene. Libraries were stored at -80°C as plasmid 
DNA isolated from at least 1000 (in the case of the single-site libraries) or 3000 (in the case of the 
double-site library) transformants. 
 
Mutant library screening 
Individual colonies from freshly transformed E. coli TOP 10 cells were placed into 2.2-ml 96-deep-
well plates containing (in each well) 1.5 ml of LB medium with 100 μg/ml Ap and 0.004% (w/v) 
arabinose as inducer. After cell growth at 22°C for 96 h with shaking at 800 rpm, a duplicate plate 
was made on solid LB-Ap medium. After cell growth overnight at 37°C, this duplicate plate was 
stored at 4°C. The remaining cells from the original plate were harvested by centrifugation at 4000 
rpm and 4°C for 20 min and the supernatants were discarded. Each cell pellet was resuspended in 
400 μl of Bug-Buster (Novagen) and incubated at 800 rpm and 30°C for 45 min. Cell debris was 
removed by centrifugation at 4000 rpm and 4°C for 50 min. The supernatants from each well were 
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transferred into a new plate and stored at 4°C (<24 h) until further use. For each library, small 
aliquots of several randomly chosen supernatants were analyzed by SDS-PAGE (on gels containing 
10% acrylamide) to confirm expression of the MAL protein. 
For libraries Q73NNS, Q172NNS and Q73NNS/Q172NNS, 50 µl of each cleared supernatant 
was transferred to a 0.3-ml 96-well plate. Then in each well, 150 µl of substrate solution (400 mM 
methylamine and 5 mM mesaconate in 0.5 M Tris-HCl buffer, pH 9.0, containing 20 mM MgCl2) 




) and 30°C for 120 min using a SpectroStar Omega UV-plate reader from Isogen Life Science 
(De Meern, The Netherlands). For libraries F170NNS, Y356NNS, and L384NNS, 50 µl of each 
cleared supernatant was mixed with 150 µl of a different substrate solution (5 mM 2-n-
hexylfumarate and 400 mM NH4Cl in 0.5 M Tris-HCl buffer, pH 9.0, containing 20 mM MgCl2) in 
a 0.3-ml 96-well plate. The reactions were monitored by following the depletion of 2-n-
hexylfumarate at 270 nm (ε = 742 M-1 cm-1) and 30°C for 120 min using the UV-plate reader. 
Active clones were collected from the corresponding duplicate plate. From each positive hit, 
plasmid DNA was extracted and the entire MAL gene sequenced to identify the mutation(s). 
 
Ammonia addition to mesaconate and product identification 
The products of the ammonia addition to mesaconate (1b) by wild-type MAL and the MAL mutants 
Q73A and L384A were identified by 
1
H NMR spectroscopy using a previously described 
procedure
[1]
 with the following modifications. In separate experiments, wild-type MAL, mutant 
Q73A, or mutant L384A was incubated with ammonium chloride and 1b, and the reactions were 
followed by 
1
H NMR spectroscopy. Reaction mixtures consisted of 500 μl of 1 M NH4Cl 
(containing 20 mM MgCl2, pH 9.0), 50 µl of D2O, and 100 µl of 500 mM 1b (pH 9.0, containing 20 
mM MgCl2). The reactions were started by the addition of 200 µg of freshly purified enzyme and 
reaction mixtures were incubated at 22°C. An additional amount (200 µg) of enzyme was added to 
the individual mixtures after 7 d. 
1
H NMR spectra were recorded 3 h, 7 d and 14 d after the first 
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addition of enzyme. Product amounts were estimated by integration of the signals corresponding to 
threo-(2S,3S)-3-methylaspartate (threo-3a) and erythro-(2S,3R)-3-methylasparate (erythro-3a). 
 
Kinetic characterization 
The wild-type MAL and the Q73A mutant catalyzed ammonia or methylamine addition to 
mesaconate was monitored by following the depletion of mesaconate at 270 nm in 500 mM Tris-
HCl buffer (pH 9.0) containing 20 mM MgCl2 and 5 mM mesaconate at 30°C. The concentrations 
of ammonia and methylamine used in the assay ranged from 10 to 500 mM and 0.1 to 2 M, 
respectively. The wild-type MAL and the L384A mutant catalyzed amination of substrates 1a-1g 
was monitored by following the depletion of substrate at 240 or 270 nm in 500 mM Tris-HCl buffer 
(pH 9.0) containing 20 mM MgCl2 and 400 mM NH4Cl at 30°C. The concentrations of substrate 
1a-1g used in the assay ranged from 0.1 to 60 mM. All substrate stock solutions were prepared in 
500 mM Tris-HCl buffer, and the pH was adjusted to 9.0. Molar absorption coefficients were 
determined in the same buffer (Supplementary Table 5). 
 
Crystallization and structure determination 
Prior to setting up crystallization screens, the isolated MAL mutants Q73A and L384A were further 
purified by gel filtration chromatography on a Superdex 200 column (GE Healthcare) using 50 mM 
Tris-HCl (pH 8.0), containing 2 mM MgCl2 and 0.1 mM KCl, as a running buffer. The proteins 
eluted as dimers with an apparent molecular weight of ~110 kDa. The purified proteins were 
concentrated to 10 mg/ml using an Amicon centrifugal filtration device with a 10 kDa molecular 
mass cut-off. A nanodrop crystallization robot (Mosquito, TTP Labtech) was employed for the 
initial screening of crystallization conditions using the sitting-drop vapour-diffusion method at 295 
K. Screens included PACT premier (Molecular Dimensions) and Cryo Screens I and II (Emerald 
Biosystems). Lead optimization was performed manually in a hanging drop setup using custom-





. The optimized crystallization solution contained 14-16% (w/v) PEG6000, 100 mM 
MES (pH 6.0), and 100 mM MgCl2. 
Diffraction data were measured from shock-cooled crystals that were cryo-protected by 
briefly soaking in 18% (w/v) PEG6000, 100 mM MES, pH 6.0, 100 mM MgCl2, containing 20% 
(v/v) glycerol. Data collection was performed using an in-house Bruker AXS rotating anode 
generator equipped with a DIP2030 image plate detector. Data were integrated and scaled with 
XDS
[4]
 and merged with SCALA.
[5]
 The crystals of mutants Q73A and L384A diffracted to 2.0 Å 
and 1.9 Å resolution, respectively, and had the same symmetry and unit cell dimensions as those 
reported previously for native C. tetanomorphum MAL.
[6]
 The structures of the MAL mutants were 
determined by the maximum-likelihood molecular replacement method, as implemented in the 
program PHASER,
[7]
 using the native C. tetanomorphum MAL structure (PDB code 1KCZ) as a 
search model. Inspection of 2Fo-Fc and Fo-Fc Fourier maps confirmed the single amino acid 
replacement in each mutant structure. In addition, residue C361 in monomers A and B of Q73A was 
oxidized and identified as an S-hydroxycysteine and cysteine sulfonic acid, respectively, like 
reported previously for native C. tetanomorphum MAL.
[6]
 In the asymmetric unit of the L384A 
crystal, however, residue C361 of monomers A and B had a different covalently attached adduct, 
most likely an amidopropyl (i.e., 3-amino-3-oxopropyl) moiety. Since the amidopropyl adduct was 
not present in the purified protein (as revealed by mass spectrometry), it must have been acquired 
during crystallization. Nonetheless, the modification leaves the overall active site architecture 





 The program MolProbity
[10]
 was used for structure validation. The 
crystallographic R-factors of the refined models are 0.198 (Rfree = 0.249) at 2.0 Å resolution and 






Comparative docking simulations were performed using Discovery Studio 2.5 (Accelrys, San 
Diego, CA, USA). Models for the enzymes were based on the newly determined structures of the 
Q73A (PDB code 3ZVH) and L384A (PDB code 3ZVI) mutants and that of the corresponding 
wild-type C. tetanomorphum MAL (PDB code 1KCZ).
[6]
 A comparison of the unliganded structure 
of C. tetanomorphum MAL
[6]
 with that of C. amalonaticus MAL in complex with the natural 
substrate threo-(2S,3S)-3-methylaspartic acid
[11]
 (PDB code 1KKR) revealed that the side chain of 
the catalytic active site residue K331 adopts a different conformation in the unliganded versus 
substrate-bound MAL structure. Consequently, we introduced distance restraints on K331 (based on 
the coordinates of the K331 in the substrate-bound C. amalonaticus MAL structure) in both wild-
type C. tetanomorphum MAL and the mutants Q73A and L384A. The three structures were then 
energy minimized using the CHARMm (Momany and Rone) forcefield.
[12, 13]
 Models of the 
substrates, threo-(2S,3S)-3-methylaspartate (3a), threo-(2S,3S)-2-(cyclohexylamino)-3-
methylbutanedioate (3k) and threo-(2S,3S)-3-pentylaspartate (4f), were constructed and the energy 
minimized using the CHARMm forcefield. Minimization was done by using a dielectric constant of 
1 and a nonbonded cutoff distance of 12 Å. The substrates were docked in the respective structure 
by using the grid-based approach CDOCKER,
[14, 15]
 a molecular dynamics simulated-annealing-
based algorithm. The enzyme active site was fixed, and the atoms of the substrate were allowed to 
move. Subsequently, the constraints on the amino acids forming the active site were removed and 
the ligand-docked structures were refined by energy minimization using CHARMm. A final 
minimization step was applied that consisted of 100 steps of steepest descent followed by 500 









Preparative scale enzymatic synthesis of a mixture of threo-(2S,3S)- and erythro-(2S,3R)-3-
methylaspartic acid 
 
Mesaconic acid (1.0 g, 7.69 mmol) was suspended in water (8.7 ml) and added to a solution of 
ammonium chloride (5.0 M, 15.4 ml) containing MgCl2 (20 mM). The pH of the mixture was 
adjusted to 9.0 by the addition of small aliquots of either an aqueous NaOH or HCl solution. Wild-
type MAL (7.5 mg in 0.5 ml of water) was added and the reaction mixture was incubated at 22°C. 
After 45 h, another portion of the enzyme (7.5 mg in 0.5 ml of water) was added. After a total 
incubation time of 116 h, the solvent was evaporated and the residue was redissolved in aqueous 
HCl (1 N, 10 ml). The mixture was loaded onto a column packed with ion-exchange resin (10.0 g of 
Dowex 50W X8, 50-100 mesh), which was pre-treated with 2 M aqueous ammonia (4 column 
volumes), 1 N HCl (2 column volumes) and distilled water (4 column volumes). The column was 
washed with distilled water (1 column volume) and the product was eluted with 2 M aqueous 
ammonia (2 column volumes). The ninhydrin-positive fractions were collected and lyophilized to 
yield 800 mg (71% isolated yield) of an ~1:1 mixture of threo-(2S,3S)- and erythro-(2S,3R)-3-
methylaspartic acid. This mixture of 3-methylaspartic acid isomers, with known absolute 
configuration,
[1]
 was used as starting material in the synthesis of isomeric mixtures of amino acids 




H NMR (400 MHz, D2O):  0.98 (d, 3H, 
3
J = 7.6 Hz, 
CH3CH), 2.79 (dq, 1H, 
3
J = 7.6 Hz, 
3
J = 3.2 Hz, CH3CH), 3.96 (d, 1H, 
3






H NMR (400 MHz, D2O):  1.12 (d, 3H, 
3
J = 7.6 Hz, 
CH3CH), 2.73 (dq, 1H, 
3
J = 7.6 Hz, 
3
J = 6.0 Hz, CH3CH), 3.50 (d, 1H, 
3
J = 6.0 Hz, CHNH2). 
 














In order to establish the identity and relative configuration of the amino acid products of the Q73A-
catalyzed amine (2c-2m) additions to mesaconate, we have synthesized the expected amino acid 
products 3c-3m both as threo-isomers and as a mixture of threo- and erythro-isomers via reductive 
amination. The general procedure is as follows. 3-Methylaspartic acid (1.00 mmol, 147 mg) was 
suspended in methanol (3 ml) at room temperature. Carbonyl compound (1.20 mmol) was added, 
followed by sodium cyanoborohydride (1.50 mmol, 95 mg), and the incubation mixture was stirred 
at room temperature. After 20 h, the undissolved substrate was filtered off and the solvent was 
evaporated. The residue was triturated with ethyl acetate (3 x 10 ml) and dried under vacuum. This 
reductive amination reaction was carried out both on commercially available threo-DL-3-
methylaspartic acid as well as on the mixture of threo-(2S,3S)- and erythro-(2S,3R)-3-
methylaspartic acid, which was synthesized by using wild-type MAL as described above. A 
comparison of the 
1
H NMR signals of these synthesized reference molecules to those obtained with 
the (lyophilized) crude enzyme reaction mixtures established the identity and relative configuration 




threo-DL-2-(ethylamino)-3-methylbutanedioic acid (3c) 
1
H NMR (400 MHz, D2O):  0.99 (d, 3H, 
3
J = 7.6 Hz, CH3CH), 1.16 (t, 3H, 
3
J 
= 7.2 Hz, CH3CH2), 2.75 (dq, 1H, 
3
J = 7.2 Hz,
 3
J = 3.2 Hz, CH3CH), 2.85-
3.10 (m, 2H, CH2NH), 3.71 (d, 1H, 
3
J = 3.2 Hz, CHNH); 
13
C NMR (125 
MHz, D2O): 10.9, 12.0, 41.0, 43.4, 63.6, 172.7, 181.6; HRMS (ESI+): calcd. for C7H13NO4Na, 
198.0737; found, 198.0720; HPLC (Chirex 3126-D-penicillamine, 2 mM aq. CuSO4:isopropanol 
90:10, flow 0.9 ml/min): Rt-1 = 11.0 min, Rt-2 = 18.4 min. The diastereomeric ratio (d.r.) can be 
determined by integration of the 
1
H NMR signals at 3.71 ppm (threo isomer) and 3.84 ppm (erythro 
isomer) corresponding to the CHNH proton.  
 
threo-DL-2-(propylamino)-3-methylbutanedioic acid (3d) 
1
H NMR (400 MHz, D2O):  0.84 (t, 3H, 
3
J = 7.2 Hz, CH3CH2), 0.98 (d, 3H, 
3
J = 7.2 Hz, CH3CH), 1.52-1.65 (m, 2H, CH3CH2), 2.73 (dq, 1H, 
3
J = 7.6 Hz, 
3
J = 3.2 Hz, CH3CH), 2.74-2.81 (m, 1H, CH2NH), 2.98-3.02 (m, 1H, 
CH2NH), 3.69 (d, 1H, 
3
J = 3.2 Hz, CHNH); 
13
C NMR (125 MHz, D2O): 10.4, 12.1, 19.4, 40.8, 
49.9, 64.0, 172.5, 181.8; HRMS (ESI+): calcd. for C8H16NO4, 190.1074; found, 190.1071; HPLC 
(Chirex 3126-D-penicillamine, 2 mM aq. CuSO4:isopropanol 90:10, flow 0.9 ml/min): Rt-1 = 15.9 
min, Rt-2 = 27.7 min. The d.r. can be determined by integration of the 
1
H NMR signals at 0.98 ppm 
(threo isomer) and 1.08 ppm (erythro isomer) corresponding to the CHCH3 protons. 
 
threo-DL-2-(butylamino)-3-methylbutanedioic acid (3e) 
1
H NMR (400 MHz, D2O):  0.78 (t, 3H, 
3
J = 7.2 Hz, CH3CH2), 0.98 (d, 3H, 
3
J = 7.6 Hz, CH3CH), 1.15-1.32 (m, 2H, CH3CH2), 1.47-1.62 (m, 2H, 
CH3CH2CH2), 2.73 (dq, 1H, 
3
J = 7.6 Hz, 
3
J = 3.2 Hz, CH3CH), 2.78-2.90 (m, 
1H, CH2NH), 2.98-3.05 (m, 1H, CH2NH), 3.69 (d, 1H, 
3
J = 3.2 Hz, CHNH); 
13
C NMR (125 MHz, 












204.1230; found, 204.1229; HPLC (Chirex 3126-D-penicillamine, 2 mM aq. CuSO4:isopropanol 
90:10, flow 0.9 ml/min): Rt-1 = 49.7 min, Rt-2 = 84.6 min. The d.r. can be determined by integration 
of the 
1
H NMR signals at 0.98 ppm (threo isomer) and 1.06 ppm (erythro isomer) corresponding to 
the CHCH3 protons. 
 
threo-DL-2-(pentylamino)-3-methylbutanedioic acid (3f) 
1
H NMR (400 MHz, D2O):  0.74 (t, 3H, 
3
J = 7.2 Hz, CH3CH2), 0.98 (d, 3H, 
3
J = 7.6 Hz, CH3CH), 1.15-1.26 (m, 4H, CH3CH2CH2), 1.50-1.62 (m, 2H, 
NHCH2CH2), 2.72 (dq, 1H, 
3
J = 7.6 Hz, 
3
J = 3.2 Hz, CH3CH), 2.77-2.89 (m, 
1H, CH2NH), 2.96-3.07 (m, 1H, CH2NH), 3.68 (d, 1H, 
3
J = 3.2 Hz, CHNH); 
13
C NMR (125 MHz, 
D2O): 12.2, 13.3, 21.6, 25.4, 28.0, 40.8, 48.2, 64.0, 172.6, 181.8; HRMS (ESI+): calcd. for 
C10H20NO4, 218.1395; found, 218.1393. The d.r. can be determined by integration of the 
1
H NMR 
signals at 3.68 ppm (threo isomer) and 3.71 ppm (erythro isomer) corresponding to the CHNH 
proton. 
 
threo-DL-2-(hexylamino)-3-methylbutanedioic acid (3g) 
1
H NMR (300 MHz, D2O):  0.75 (t, 3H, 
3
J = 6.6 Hz, CH3CH2), 0.96 (d, 3H, 
3
J = 7.5 Hz, CH3CH), 1.09-1.30 (m, 6H, CH3(CH2)3), 1.46-1.56 (m, 2H, 
NHCH2CH2), 2.52-2.82 (m, 3H, CH3CH, CH2NH), 3.54 (d, 1H, 
3
J = 3.3 Hz, 
CHNH); 
13
C NMR (125 MHz, D2O): 12.2, 13.4, 22.0, 25.8, 26.8, 30.8, 42.3, 
48.2, 64.7, 175.8, 182.4; HRMS (ESI+): calcd. for C11H22NO4, 232.1553; found, 232.1551. The d.r. 
can be determined by integration of the 
1
H NMR signals at 3.53 ppm (threo isomer) and 3.67 ppm 










threo-DL-2-(iso-propylamino)-3-methylbutanedioic acid (3h) 
1
H NMR (400 MHz, D2O):  0.91 (d, 3H, 
3
J = 7.2 Hz, CH3CHCOOH), 1.02 
(d, 3H, 
3
J = 6.8 Hz, CH3CH), 1.06 (d, 3H, 
3
J = 6.8 Hz, CH3CH), 2.61 (dq, 1H, 
3
J = 7.2 Hz, 
3
J = 4.0 Hz, CH3CH), 2.93 (app hept, 1H, 
3
J = 6.8 Hz, 
CH(CH3)2), 3.62 (d, 1H, 
3
J = 4.0 Hz, CHNH); 
13
C NMR (125 MHz, D2O): 12.2, 19.2, 20.6, 42.5, 
50.2, 62.6, 176.3, 182.1; HRMS (ESI+): calcd. for C8H16NO4, 190.1074; found, 190.1071; HPLC 
(Chirex 3126-D-penicillamine, 2 mM aq. CuSO4:isopropanol 90:10, flow 0.9 ml/min): Rt-1 = 9.2 
min, Rt-2 = 19.7 min. The d.r. can be determined by integration of the 
1
H NMR signals at 2.61 ppm 
(threo isomer) and 2.37 ppm (erythro isomer) corresponding to the CHCH3 protons. 
 
threo-DL-2-(cyclo-butylamino)-3-methylbutanedioic acid (3i) 
1
H NMR (400 MHz, D2O):  0.91 (d, 3H, 
3
J = 7.2 Hz, CH3CH), 1.45-2.10 (m, 
6H, c-butyl), 2.61 (dq, 1H, 
3
J = 7.2 Hz, 
3
J = 3.6 Hz, CH3CH), 3.30-3.42 (m, 
1H, c-butyl), 3.44 (d, 1H, 
3
J = 3.6 Hz, CHNH); 
13
C NMR (125 MHz, D2O): 
12.1, 14.4, 27.8, 28.2, 42.9, 52.2, 62.4, 177.0, 182.4; HRMS (ESI+): calcd. for C9H16NO4, 
202.1074; found, 202.1071; HPLC (Chirex 3126-D-penicillamine, 2 mM aq. CuSO4:isopropanol 
90:10, flow 0.9 ml/min): Rt-1 = 34.7 min, Rt-2 = 57.9 min. The d.r. can be determined by integration 
of the 
1
H NMR signals at 2.61 ppm (threo isomer) and 2.70 ppm (erythro isomer) corresponding to 
the CHCH3 protons. 
 
threo-DL-2-(cyclo-pentylamino)-3-methylbutanedioic acid (3j) 
1
H NMR (400 MHz, D2O):  0.95 (d, 3H, 
3
J = 7.6 Hz, CH3CH), 1.42-1.63 (m, 
6H, c-pent), 1.74-1.91 (m, 2H, c-pent), 2.70 (dq, 1H, 
3
J = 7.6 Hz, 
3
J = 3.2 Hz, 
CH3CH), 3.32-3.40 (m, 1H, CHNH, c-pentyl), 3.70 (d, 1H, 
3
J = 3.2 Hz, 
CHCHNH); 
13
C NMR (125 MHz, D2O): 12.2, 23.3, 23.4, 29.0, 30.5, 41.4, 60.0, 63.0, 173.8, 












determined by integration of the 
1
H NMR signals at 3.70 ppm (threo isomer) and 3.73 ppm (erythro 
isomer) corresponding to the CHNH proton. 
 
threo-DL-2-(cyclo-hexylamino)-3-methylbutanedioic acid (3k) 
1
H NMR (400 MHz, D2O):  0.98 (d, 3H, 
3
J = 7.6 Hz, CH3CH), 1.03-1.55 (m, 
6H, (CH2)3), 1.59-1.71 (m, 2H, (CH2)CHNH), 1.86-1.97 (m, 2H, 
(CH2)CHNH), 2.74 (dq, 1H, 
3
J = 7.6 Hz, 
3
J = 3.2 Hz, CH3CH), 2.88-2.97 (m, 
1H, CHNH, c-hexyl), 3.77 (d, 1H, 
3
J = 3.2 Hz, CHNH); 
13
C NMR (125 MHz, 
D2O): 12.3, 24.0, 24.1, 24.7, 29.0, 30.1, 40.9, 58.5, 61.6 172.9, 181.7; HRMS (ESI+): calcd. for 
C11H19NO4, 230.1387; found, 230.1385. The d.r. can be determined by integration of the 
1
H NMR 
signals at 3.77 ppm (threo isomer) and 3.80 ppm (erythro isomer) corresponding to the CHNH 
proton. 
 
threo-DL-2-(cyclo-propyl-methylamino)-3-methylbutanedioic acid (3l) 
1
H NMR (400 MHz, D2O):  0.21-0.28 (m, 2H, c-propyl), 0.50-0.65 (m, 2H, 
c-propyl), 0.91-1.09 (m, 1H, c-propyl), 1.01 (d, 3H, 
3
J = 7.6 Hz, CH3CH), 
2.71 (dd, 1H, 
2
J = 12.8 Hz, 
3
J = 4.8 Hz, CH2NH), 2.75 (dq, 1H, 
3
J = 7.2 Hz, 
3
J 
= 2.8 Hz, CH3CH), 2.97 (dd, 1H, 
2
J = 12.8 Hz, 
3
J = 7.2 Hz, CH2NH), 3.78 (d, 1H, 
3
J = 2.8 Hz, 
CHNH); 
13
C NMR (125 MHz, D2O): 3.7, 3.8, 7.1, 12.1, 40.8, 53.0, 63.4, 172.6, 181.8; HRMS 
(ESI+): calcd. for C9H16NO4, 202.1074; found, 202.1071; HPLC (Chirex 3126-D-penicillamine, 2 
mM aq. CuSO4:isopropanol 90:10, flow 0.9 ml/min): Rt-1 = 16.3 min, Rt-2 = 23.2 min. In this case, 
only the threo-isomer has been synthesized, the 
1
H NMR spectrum of which is consistent with that 










threo-DL-2-(benzylamino)-3-methylbutanedioic acid (3m) 
1
H NMR (400 MHz, D2O):  0.98 (d, 3H, 
3
J = 7.6 Hz, CH3CH), 2.72 (dq, 1H, 
3
J = 7.6 Hz, 
3
J = 3.2 Hz, CH3CH), 3.70 (d, 1H, 
3
J = 3.2 Hz, CHNH), 4.04 (d, 
1H, 
2
J = 12.8 Hz, PhCH2), 4.24 (d, 1H, 
2
J = 12.8 Hz, PhCH2), 7.20-7.40 (m, 
5H, ArH); 
13
C NMR (125 MHz, D2O): 12.2, 40.7, 51.3, 62.9, 129.4, 129.8, 130.2, 131.0, 172.3, 
181.7; HRMS (ESI+): calcd. for C12H16NO4, 238.1074; found, 238.1071. The d.r. can be 
determined by integration of the 
1
H NMR signals at 3.70 ppm (threo isomer) and 3.85 ppm (erythro 
isomer) corresponding to the CHNH proton. 
 
Preparative scale enzymatic synthesis of N-substituted 3-methylaspartic acids 3n-3u 
 
The N-substituted 3-methylaspartic acid derivatives 3n-3u were synthesized by using mutant Q73A 
as catalyst in the amine (2n-2u) additions to mesaconate (1b). A solution of mesaconic acid (0.40 g, 
3.1 mmol), amine (31 mmol) and MgCl2 (20 mM) was prepared in water (25 ml), and the pH was 
adjusted to 9.0 by the addition of small aliquots of either an aqueous NaOH or HCl solution. The 
reactions were started by the addition of 5 mg of freshly purified enzyme (i.e., the Q73A mutant), 
and the reaction mixtures were incubated at 22°C. An additional amount (5 mg) of enzyme was 
added to the individual mixtures after 4 d, because the enzyme loses about 50% of its original 





spectra were recorded 1 d and 7 d after the first addition of enzyme. All reactions 






after 14 d. The individual reaction mixtures were lyophilized, after which the amino acid product 
was purified using cation exchange chromatography (Dowex, 50W X8, 100-200 mesh size, Merck). 
A Dowex column (10.0 g resin per 1 g of mesaconic acid) was prepared by pre-treatment with a 
solution of aqueous NH3 (2 M, 4 column volumes), aqueous HCl (1 N, 2 column volumes) and 
distilled water (4 column volumes). The lyophilized reaction mixture was suspended in aqueous 
HCl (1 N, 20 ml) and loaded onto the column. The column was washed with distilled water (1 
column volume) and the product was eluted with aqueous NH3 (2 M, 2 column volumes). The 
ninhydrin-positive fractions were collected and concentrated under reduced pressure, followed by 
lyophilization to give the purified amino acid product. 
 
2-(cyclopropylamino)-3-methylbutanedioic acid (3n) 
Conversion 80% (
1
H NMR after 7 d). Yield 42%. Pale brown solid. 
1
H NMR 
(200 MHz, CD3OD): δ 0.60-0.95 (m, 4H, c-propyl), 1.04 (d, 3H, 
3
J = 7.6 Hz, 
CH3CH), 2.60-2.86 (m, 2H, CH3CH, CHCH2, c-propyl), 3.72 (d, 1H, 
3
J = 3.7 
Hz, CHNH); 
13
C NMR (50 MHz, CD3OD): δ 3.6, 5.2, 13.2, 31.3, 41.5, 66.5, 172.4, 181.6; HRMS 
(ESI+): calcd. for C8H14NO4, 188.0923; found, 188.0917. 
 
2-(ethoxyamino)-3-methylbutanedioic acid (3o)  
Conversion 100% (
1
H NMR after 7 d). Yield 38%. White solid. 
1
H NMR (500 
MHz, D2O): δ 0.87 (d, 3H, 
3
J = 7.3 Hz, CHCH3), 0.98 (t, 3H, 
3
J = 7.0 Hz, 
CH3CH2O), 2.56 (dq, 1H, 
3
J = 7.1 Hz, 
3
J = 4.8 Hz, CH3CH), 3.63 (q, 2H, 
3
J = 7.1 Hz, CH3CH2O), 
3.72 (d, 1H, 
3
J = 4.6 Hz, CHNH); 
13
C NMR (125 MHz, D2O): δ 12.2, 13.1, 42.1, 61.5, 67.1, 178.4, 











2-(2-hydroxyethyl-amino)-3-methylbutanedioic acid (3p) 
Conversion 32% (
1
H NMR after 14 d). Yield 9%. White solid. 
1
H NMR (500 
MHz, D2O): δ 1.26 (d, 3H, 
3
J = 7.5 Hz, CHCH3), 3.16-3.27 (m, 2H, 
NHCH2CH2), 3.32-3.36 (m, 1H, CH3CH), 3.89 (t, 2H, 
3
J = 5.1 Hz, 
CH2CH2OH), 4.06 (d, 1H, 
3
J = 3.0 Hz, NHCH); 
13
C NMR (125 MHz, D2O): δ 14.1, 42.2, 52.4, 
59.2, 65.8, 173.9, 180.4. HRMS (ESI+): calcd. for C7H14NO5, 192.0872; found, 192.0866. 
 
2-(3-hydroxypropyl-amino)-3-methylbutanedioic acid (3q)  
Conversion 57% (
1
H NMR after 7 d). Yield 45%. White solid. Signals 
corresponding to two diastereoisomers (d.r. = 90:10) were observed in the 
1
H NMR spectra. Major diastereoisomer: 
1
H NMR (200 MHz, D2O): δ 0.99 (d, 3H, 
3
J = 7.5 Hz, 
CHCH3), 1.75-1.90 (m, 2H, CH2CH2CH2), 2.75 (dq, 1H, 
3
J = 7.6 Hz, 
3
J = 3.1 Hz, CH3CH), 2.80-
3.25 (m, 2H, NHCH2CH2), 3.57 (t, 2H, 
3
J = 6.1 Hz, CH2CH2OH), 3.70 (d, 1H, J = 3.1 Hz, NHCH); 
13
C NMR (50 MHz, D2O): δ 11.9, 27.9, 38.8, 45.9, 59.0, 63.9, 172.1, 181.1; HRMS (ESI+): calcd. 
for C8H16NO5, 206.1029; found, 206.1023. 
 
2-(2-methoxyethyl-amino)-3-methylbutanedioic acid (3r)  
Conversion 57% (
1
H NMR after 7 d). The product was purified using two 
column chromatography steps, but still contained trace amounts of the starting 
substrate 2-methoxyethylamine (2r). Yield 45%. White solid. 
1
H NMR (200 
MHz, D2O): δ 1.01 (d, 3H, 
3
J = 7.5 Hz, CHCH3) 2.74 (dq, 1H, 
3
J = 7.6 Hz, 
3
J = 3.2 Hz, CH3CH), 
3.00-3.10 (m, 2H, CH2CH2NH), 3.26 (s, 3H, OCH3), 3.52-3.64 (m, 2H, CH2CH2O), 3.75 (d, 1H, 
3
J 
= 3.2 Hz, CHNH); 
13
C NMR (50 MHz, D2O): δ 11.9, 38.8, 40.4, 47.0, 58.1, 63.9, 172.0, 181.6; 















2-(N-(2-methylamino-ethyl)amino)-3-methylbutanedioic acid (3s)  
Conversion 94% (
1
H NMR after 7 d). Yield 66%. Pale brown solid. 
1
H NMR 
(200 MHz, D2O): δ 0.95 (d, 3H, 
3
J = 7.6 Hz, CH3CH), 2.64 (s, 3H, CH3NH), 
2.75 (dq, 1H, 
3
J = 7.5 Hz, 
3
J = 3.2 Hz, CHCH3), 3.11-3.26 (m, 4H, CH2CH2), 
3.70 (d, 1H, 
3
J = 3.2 Hz, CHNH); 
13
C NMR (50 MHz, D2O): δ 11.5, 32.9, 41.4, 43.3, 45.5, 64.3, 
174.0, 181.6; HRMS (ESI+): calcd. for C8H17N2O4, 205.1188; found, 205.1184. 
 
2-(N-(2-aminoethyl)amino)-3-methylbutanedioic acid (3t)  
Conversion 96% (
1
H NMR after 7 d). Yield 74%. Pale brown solid. 
1
H NMR 
(200 MHz, D2O): δ 1.00 (d, 3H, 
3
J = 7.6 Hz, CHCH3) 2.78 (dq, 1H, 
3
J = 7.5 
Hz, 
3
J = 3.2 Hz, CH3CH), 3.25-3.35 (m, 4H, CH2CH2), 3.80 (d, 1H, 
3
J = 3.0 Hz, CHNH); 
13
C 
NMR (50 MHz, D2O): δ 11.7, 35.8, 40.8, 44.6, 64.3, 172.4, 181.2; HRMS (ESI+): calcd. for 
C7H15N2O4, 191.1032; found, 191.1026. 
 
2-(3-aminopropyl-amino)-3-methylbutanedioic acid (3u)  
Conversion 80% (
1
H NMR after 7 d). Yield 10%. Pale brown solid. 
1
H 
NMR (200 MHz, D2O): δ 0.96 (d, 3H, 
3
J = 7.5 Hz, CHCH3), 1.84-1.98 (m, 
2H, CH2CH2CH2), 2.71 (dq, 1H, 
3
J = 7.6 Hz, 
3
J = 3.2 Hz, CH3CH), 2.86-3.04 (m, 4H, 
CH2CH2CH2), 3.68 (d, 1H, 
3
J = 3.0 Hz, CHNH); 
13
C NMR (50 MHz, D2O): δ 11.7, 24.2, 37.2, 
















Chemical synthesis of 2-substituted fumarates 
 
2-n-propylfumaric acid (1d) 
Sodium (10 mmol, 230 mg) was dissolved in ethanol (6.0 ml). Ethyl acetoacetate (9.0 mmol, 1.14 
ml) was added dropwise over 5 min at 5°C, followed by n-propyl iodide (12 mmol, 1.17 ml). The 
reaction was refluxed for 2 h and was then cooled to room temperature, poured on water (30 ml) 
and extracted with Et2O (3 x 25 ml). Organic fractions, containing a mixture of mono- and 
dialkylated product, were dried and concentrated to ~15 ml. Bromine (4.0 g) was added slowly at 
room temperature, and the reaction mixture was refluxed for 3 h. The volatiles were evaporated, 
and the residue was slowly added to a solution of KOH (4.0 g) in ethanol (15 ml). The resultant 
mixture was refluxed for 30 min, after which 20 ml of water was added and the refluxing continued 
for another 20 min. The reaction mixture was washed with EtOAc (2 x 40 ml). The aqueous phase 
was acidified with aqueous HCl (12 N) to pH < 1 and extracted with Et2O (4 x 50 ml). Collected 
organic fractions were dried, decolourized with activated carbon and the solvent was evaporated. 





H NMR (400 MHz, D2O + K2CO3): δ 0.70 (t, 3H, 
3
J = 7.6 Hz, CH3), 
1.19-1.25 (m, 2H, CH3CH2), 2.63 (t, 2H, 
3
J = 7.2 Hz, CH2C=C), 6.18 (s, 1H, vinyl H). 
1
H NMR is 






2-ethylfumaric acid (1c)  
Compound 1c was prepared according to the same procedure as that used for the synthesis of 1d, 





H NMR (400 MHz, D2O): δ 0.89 (t, 3H, 
3
J = 7.2 Hz, CH3), 2.49 (d, 2H, 
3
J = 7.2 Hz, CH2), 6.57 (s, 1H, vinyl H). 
1




2-n-butylfumaric acid (1e) 
Compound 1e was prepared according to the same procedure as that used for the synthesis of 1d. 




H NMR (400 MHz, D2O + 
K2CO3): δ 0.71 (t, 3H, 
3
J = 7.2 Hz, CH3), 1.06-1.24 (m, 4H, CH3CH2CH2), 2.31 (t, 2H, 
3
J = 7.2 Hz, 
CH2C=C), 6.17 (s, 1H, vinyl H). 
1




2-n-pentylfumaric acid (1f) 
Compound 1f was prepared according to the same procedure as that used for the synthesis of 1d, 
starting with commercially available ethyl 2-n-pentylacetoacetate. Yield: 40%. Yellow crystals; mp: 
160-162°C; 
1
H NMR (400 MHz, DMSO-d6):  0.83 (t, 3H, 
3
J = 6.8 Hz, CH3), 1.18-1.42 (m, 6H, 
CH3(CH2)3), 2.62 (t, 2H, 
3
J = 7.6 Hz, CH2C), 6.55 (s, 1H, vinyl H); 
13
C NMR (75 MHz, CDCl3): 
14.5, 22.4, 27.7, 28.9, 31.8, 127.5, 147.8, 167.4, 168.7; HRMS (ESI-): calcd. for C9H13O4, 
185.0808; found, 185.0804. 
 
2-n-hexylfumaric acid (1g) 
Compound 1g was prepared according to the same procedure as that used for the synthesis of 1d, 





H NMR (400 MHz, DMSO-d6):  0.83 (t, 3H, 
3
J = 6.8 Hz, CH3), 
1.19-1.38 (m, 8H, CH3(CH2)4), 2.62 (t, 2H, 
3
J = 7.6 Hz, CH2C) 6.55 (s, 1H, vinyl H). 
1
H NMR is 





2-benzylfumaric acid (1n) 
Compound 1n was prepared according to the same procedure as that used for the synthesis of 1d, 
starting with commercially available ethyl 2-benzylacetoacetate. Yield: 10%. Yellow crystals; mp: 
209-211°C; 
1
H NMR (300 MHz, CDCl3): δ 4.05 (s, 2H, CH2C=C), 6.73 (s, 1H, vinyl H), 7.13-7.22 
(m, 3H, ArH), 7.22-7.31 (m, 2H, ArH); 
13
C NMR (75 MHz, CDCl3): δ 32.3, 126.1, 127.6, 128.3, 
128.4, 128.7, 128.9, 138.4, 144.7, 166.8, 167.6; HRMS (ESI+): calcd. for C11H11O4, 207.0651; 
found, 207.0652. 
 
2-(benzyloxy)-fumaric acid (1j) 
 
Dimethyl 2-(benzyloxy)-fumarate (1.12 mmol, 280 mg), prepared according to a published 
procedure.
[18]
 was dissolved in tetrahydrofuran (3.0 ml). Aqueous NaOH (1 M, 3.0 ml) was added 
and the resultant mixture was stirred for 10 min at room temperature. The reaction mixture was 
poured on aqueous HCl (1 N, 20 mL) and extracted with ethyl acetate (3 x 20 ml). Collected 
organic phases were dried (MgSO4) and the solvent was evaporated. The residue was dissolved in 
ethyl ether and the product was precipitated with pentane to give a white powder (240 mg, 97%). 
Mp: 132-133°C (decomp.); 
1
H NMR (400 MHz, DMSO-d6):  5.09 (s, 2H, PhCH2), 6.06 (s, 1H, 
vinyl H), 7.30-7.41 (m, 5H, ArH); 
13
C NMR (75 MHz, CDCl3): 74.3, 111.0, 128.5, 128.7, 129.0, 




Dimethyl 2-phenylthiofumarate (5) 
 
A solution of dimethyl acetylenedicarboxylate (5.0 mmol, 710 mg) and thiophenol (5.0 mmol, 510 
l) in methanol (15 ml) was heated to reflux for 2 h. TLC indicated full conversion of the starting 
compound. The solvent was evaporated and the product was purified by flash chromatography 
(Silicagel, 40-63 m, Pentane/Et2O, 95:5, v/v). Yield: 34%. Yellow oil; TLC (Pentane/Et2O, 7:3 
v/v): Rf = 0.48; 
1
H NMR (400 MHz, CDCl3):  3.35 (s, 3H, CH3O), 3.79 (s, 3H, CH3O), 6.38 (s, 
1H, vinyl H), 7.31-7.46 (m, 5H, ArH); 
1




General procedure for the hydrolysis of 2-substituted fumarate esters 
 
To a 0.5 M solution of R'-substituted fumarate ester in ethanol was added an equivolumous amount 
of 2 M aqueous NaOH. The resultant solution was stirred at reflux for 2 h. After cooling down to 
room temperature, the reaction mixture was washed with ethyl acetate and acidified to pH 1 with 
30% aqueous HCl. The product was extracted with ethyl acetate. Collected organic phases were 





2-ethoxyfumaric acid (1h) 
Compound 1h was prepared from the respective diethyl ester, synthesized according to a previously 
reported protocol,
[20]
 by the general hydrolysis procedure, and further purified by precipitation from 




H NMR (400 MHz, 
acetone-d6):  1.31 (t, 3H, 
3
J = 7.2 Hz, CH3), 4.21 (q, 2H, 
3
J = 7.2 Hz, CH2), 6.18 (s, 1H, vinyl H). 
1
H NMR is in agreement with the literature data.
[20] 
 
2-phenoxyfumaric acid (1i) 
Compound 1i was prepared from the respective dimethyl ester, synthesized according to a 
previously reported protocol,
[21]
 by the general hydrolysis procedure. Yield: 83%. White powder. 
Mp: 236-237°C; 
1
H NMR (300 MHz, DMSO-d6):  6.52 (s, 1H, vinyl H), 6.89 (d, 2H, 
3
J = 8.1 Hz, 
o-PhH), 7.04 (t, 1H, 
3
J = 7.5 Hz, p-PhH), 7.31 (app t, 2H, 
3
J = 8.0 Hz, m-PhH); 
13
C NMR (75 MHz, 
DMSO-d6): 116.4, 117.3, 123.4, 130.3, 149.4, 157.3, 163.7, 165.2; HRMS (ESI-): calcd. for 
C10H7O5, 207.0288; found, 207.0298. 
 
2-ethylthiofumaric acid (1k)  
Compound 1k was prepared from the respective dimethyl ester, synthesized according to a 
previously reported protocol,
[22]
 by the general hydrolysis procedure. Yield: 85%. Yellow powder. 
Mp: 133-134°C; 
1
H NMR (400 MHz, D2O + K2CO3):  1.03 (t, 3H, 
3
J = 7.2 Hz, CH3), 2.55 (q, 2H, 
3
J = 7.2 Hz, CH2), 5.90 (s, 1H, vinyl H); 
13
C NMR (75 MHz, D2O + K2CO3): 14.7, 26.5, 122.6, 
147.1, 173.4, 175.1; HRMS (ESI-): calcd. for C6H7O4S, 175.0060; found, 175.0071. 
 
2-phenylthiofumaric acid (1l)  
Compound 1l was prepared from the respective dimethyl ester 5 by the general hydrolysis 
procedure. Yield: 80%. Yellow powder. Mp: 158-159°C; 
1
H NMR (400 MHz, DMSO-d6):  6.39 
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(s, 1H, vinyl H), 7.34-7.40 (m, 5H, ArH); 
13
C NMR (75 MHz, DMSO-d6): 121.7, 129.1, 129.8, 
133.0, 148.4, 165.7, 166.7; HRMS (ESI-): calcd. for C10H7O4S, 223.0060; found, 223.0070. 
 
2-benzylthiofumaric acid (1m) 
Compound 1m was prepared from the respective dimethyl ester, which was synthesized according 
to a previously reported protocol,
[22]
 by the general hydrolysis procedure. Yield: 80%. Yellow 




H NMR (400 MHz, DMSO-d6):  4.10 (s, 2H, 
PhCH2), 6.23 (s, 1H, vinyl H), 7.23-7.34 (m, 5H, ArH). 
1





Preparative scale enzymatic synthesis of (substituted) aspartic acids 4a-4n 
 
L-Aspartic acid (4a) and its 3-substituted derivatives 4b-4n were synthesized using the L384A 
mutant as catalyst in the ammonia addition to the unsaturated acids 1a-1n. A solution of unsaturated 
acid (3.1 mmol), ammonium chloride (1.7 g, 31 mmol) and MgCl2 (20 mM) was prepared in water 
(25 ml). The pH was adjusted to 9.0 by the addition of small aliquots of an aqueous NaOH (1 N) 
solution. The reactions were started by the addition of freshly purified enzyme (5 mg), and reaction 
mixtures were incubated at 22°C. An additional amount (5 mg) of enzyme was added to the 
individual mixtures after 2 d. 
1
H NMR spectra were recorded 1 d, 3 d and 7 d after the first addition 
of enzyme. All reactions were terminated after 7 d. Subsequently, each reaction mixture was 
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lyophilized and crude product was dissolved in aqueous HCl (1 N, 20 mL). The amino acid 
products were purified by cation exchange chromatography using a Dowex column (15.0 g of 
Dowex 50W X8, 100-200 mesh), as described above for the synthesis of the N-substituted 3-
methylaspartic acids 3n-3u. 
 
(S)-aspartic acid (4a) 
Conversion 99% (
1
H NMR after 7 d). Yield 80%. White solid. 
1
H NMR (500 
MHz, D2O): δ 2.68 (dd, 1H, 
2
J = 17.5 Hz, 
3
J = 8.1 Hz, CHCH2), 2.78 (dd, 1H, 
2
J = 17.5 Hz, 
3
J = 3.8 Hz, CHCH2), 3.88 (dd, 1H, 
3
J = 8.0 Hz,
 3
J = 3.9 Hz, CHNH2); 
13
C NMR (125 
MHz, D2O): δ 39.1, 54.7, 176.9, 180.1; HRMS (ESI+): calcd. for C4H8NO4, 134.0447; found, 
134.0449; HPLC (Chirex 3126-D-penicillamine, 2 mM aq. CuSO4:isopropanol 90:10, flow 0.9 
ml/min): (S)-aspartate, 8.2 min; (R)-aspartate, 9.9 min. The 
1
H NMR signals for the enzymatically 
generated (S)-aspartic acid are in agreement with those found with an authentic standard. 
 
3-methylaspartic acid (4b) 
Conversion 73% (
1
H NMR after 7 d). Yield 60%. White solid. Signals 





H NMR (500 MHz, D2O):  1.13 (d, 3H, 
3
J = 7.5 Hz, CH3CH), 1.27 (d, 3H, 
3
J = 
7.5 Hz, CH3CH), 2.86-2.94 (m, 2H, CH3CH, CH3CH), 3.67 (d, 1H, 
3
J = 5.4 Hz, CHNH2), 3.99 (d, 
1H, 
3
J = 3.2 Hz, CHNH2); 
13
C NMR (125 MHz, D2O): 14.1, 17.8, 43.3, 44.2, 59.0, 60.0, 176.0, 
176.4, 183.6, 183.9. HRMS (ESI+):
 
calcd. for C5H10NO4, 148.0604; found, 148.0605. The 
1
H NMR 












3-ethylaspartic acid (4c) 
Conversion 73% (
1
H NMR after 7 d). Yield 45%. White solid. 
1
H NMR (500 
MHz, D2O):  0.90 (t, 3H, 
3
J = 7.3 Hz, CH3CH2), 1.32-1.40 (m, 1H, CH2CH3), 
1.46-1.55 (m, 1H, CH2CH3), 2.68 (app dt, 1H, 
3
J = 10.4 Hz, 
3
J = 3.5 Hz, 
CHCH2), 3.89 (d, 1H, 
3
J = 3.0 Hz, CHNH2); 
13
C NMR (125 MHz, D2O): 14.4, 22.8, 51.1, 58.4, 
175.7, 183.3 HRMS (ESI+): calcd. for C6H12NO4, 162.0760; found, 162.0762. The 
1
H NMR 




3-propylaspartic acid (4d) 
Conversion 66% (
1
H NMR after 7 d). Yield 46%. White solid. 
1
H NMR (500 
MHz, D2O):  0.77 (t, 3H, 
3
J = 7.2 Hz, CH3CH2), 1.14-1.30 (m, 3H, 
CH2CH2CH3), 1.38-1.46 (m, 1H, CH2CH2CH3), 2.69-2.72 (m, 1H, CH2CH), 
3.80 (d, 1H, 
3
J = 3.2 Hz, CHNH2); 
13
C NMR (50 MHz, D2O): 15.7, 23.1, 31.5, 49.0, 58.5, 175.6, 
183.4; HRMS (ESI+): calcd. for C7H14NO4, 176.0923; found, 176.0917. The 
1
H NMR spectrum is 




3-butylaspartic acid (4e) 
Conversion 57% (
1
H NMR after 7 d). Yield 36%. White solid. Signals 





H NMR (500 MHz, D2O):  0.83-0.91 (m, 3H + 3H, 
CH3CH2CH2), 1.24-1.38 (m, 4H + 4H, CH2CH2CH2CH3), 1.52-1.59 (m, 1H + 1H, CHCH2CH2), 
1.64-1.72 (m, 1H + 1H, CHCH2CH2), 2.78-2.85 (m, 1H + 1H, CHCH2CH2), 3.75 (d, 1H, 
3
J = 4.6 
Hz, CHNH2), 4.91 (d, 1H, 
3
J = 3.2 Hz, CHNH2); 
13
C NMR (50 MHz, D2O): 13.0, 13.1, 21.6, 
21.7, 26.2, 28.7, 29.2, 29.4, 46.5, 47.0, 55.6, 55.8, 172.9, 173.7, 180.0, 180.7; HRMS (ESI+): calcd. 













3-pentylaspartic acid (4f) 
Conversion 52% (
1
H NMR after 7 d). Yield 23%. White solid. 
1
H NMR (200 
MHz, DMSO-d6):  0.85 (t, 3H, 
3
J = 6.7 Hz, CH3CH2), 1.16-1.32 (m, 7H, 
CHCH2(CH2)3CH3), 1.40-1.50 (m, 1H, CHCH2CH2), 2.53-2.57 (m, 1H, 
CHCH2), 3.41 (d, 1H, 
3
J = 3.2 Hz, CHNH2); 
13
C NMR (50 MHz, DMSO-d6): 14.4, 22.5, 27.6, 
31.9, 40.2 46.9, 55.9, 170.7, 177.3 HRMS (ESI+): calcd. for C9H18NO4, 204.1236; found, 
204.1229. 
 
3-hexylaspartic acid (4g) 
Conversion 53% (
1
H NMR after 7 d). Yield 48%. White solid. 
1
H NMR 
(200 MHz, DMSO-d6):  0.86 (t, 3H, 
3
J = 6.6 Hz, CH3CH2), 1.18-1.33 (m, 
9H, CHCH2(CH2)4CH3), 1.47-1.53 (m, 1H, CHCH2), 2.60-2.65 (m, 1H, 
CHCH2), 3.44 (d, 1H, 
3
J = 4.4 Hz, CHNH2); 
13
C NMR (50 MHz, DMSO-d6): 14.4, 22.5, 27.7, 
29.2, 31.6, 40.2, 46.3, 55.5, 170.3, 176.4; HRMS (ESI+): calcd. for C10H20NO4, 218.1392; found, 
218.1386. 
 
3-ethoxyaspartic acid (4h) 
Conversion 45% (
1
H NMR after 7 d). Yield 24%. White solid. Signals 
corresponding to two diastereoisomers (d.r. = 85:15) were observed in the 
1
H 
NMR spectrum. Major diastereoisomer: 
1
H NMR (500 MHz, D2O):  1.04 (t, 
3H, 
3
J = 7.0 Hz, CH3CH2O), 3.33-3.40 (m, 1H, OCH2CH3), 3.51-3.60 (m, 1H, OCH2CH3), 3.87 (d, 
1H, 
3
J = 2.4 Hz, CHNH2), 4.15 (d, 1H, 
3
J = 2.4, CHOCH2); 
13
C NMR (50 MHz, D2O): 14.1, 56.5, 














3-phenoxyaspartic acid (4i) 
Conversion 46% (
1
H NMR after 7 d). Yield 20%. White solid. 
1
H NMR (200 
MHz, D2O):  4.03 (d, 1H, 
3
J = 1.3 Hz, CHNH2), 4.90 (br d, 1H, CHO), 6.78-
7.29 (m, 5H, ArH); 
13
C NMR (50 MHz, D2O): 56.5, 76.9, 114.9, 121.9, 
129.8, 157.1, 171.9, 174.7; HRMS (ESI+): calcd. for C10H12NO5, 226.0715; found, 226.0710. 
 
3-benzyloxyaspartic acid (4j) 
Conversion 65% (
1
H NMR after 7 d). Yield 50%. White solid. 
1
H NMR (200 
MHz, DMSO-d6):  3.75 (d, 1H, 
3
J = 7.1 Hz, CHNH2), 4.17 (d, 1H, 
3
J = 7.2, 
CHO), 4.46 (d, 1H, 
2
J = 11.2 Hz, CH2Ar), 4.76 (d, 1H, 
2
J = 11.2 Hz, CH2Ar), 7.25-7.42 (m, 5H, 
ArH); 
13
C NMR (50 MHz, DMSO-d6): 54.3, 72.6, 76.3, 127.8, 128.3, 128.4, 138.5, 169.0, 171.7; 
HRMS (ESI+): calcd. for C11H14NO5, 240.0872; found, 240.0868; HPLC (Nucleosil chiral-1, 2 mM 
aq. CuSO4:methanol 90:10, flow 1.0 ml/min): threo-DL-4j, Rt-1 = 5.0 min; Rt-2 = 6.9 min. 
 
3-(ethylthio)aspartic acid (4k) 
Conversion 81% (
1
H NMR after 7 d). Yield 22%. White solid. Signals 





H NMR (500 MHz, D2O):  1.12 (t, 3H, 
3
J = 7.4 Hz, 
CH3CH2), 1.17 (t, 3H, 
3
J = 7.4, CH3CH2), 2.49-2.61 (m, 2H + 2H, CH2CH3), 3.78 (d, 1H, 
3
J = 3.0 
Hz, SCHCH), 3.80 (d, 1H, 
3
J = 3.9 Hz, SCHCH), 3.84 (d, 1H, 
3
J = 3.9 Hz, CHNH2), 4.05 (d, 1H, 
3
J 
= 3.0, CHNH2); 
13
C NMR (50 MHz, D2O): 13.6, 13.8, 25.6, 26.5, 48.0, 48.3, 55.4, 55.7, 171.7, 

















3-(phenylthio)aspartic acid (4l) 
Conversion 45% (
1
H NMR after 7 d). Yield 13%. White solid. Signals 
corresponding to two diastereoisomers (d.r. = 65:35) were observed in the 
1
H 
NMR spectrum. Major diastereoisomer: 
1
H NMR (500 MHz, D2O):  3.60 (br 
d, 1H, SCHCH), 4.23 (br d, 1H, CHNH2), 7.26-7.49 (m, 5H, ArH); 
13
C NMR (50 MHz, D2O): 
41.6, 53.5, 128.5, 129.6, 131.8, 132.4, 172.3, 174.6; HRMS (ESI+): calcd. for C10H12NO4S, 
242.0487; found, 242.0482. 
 
3-(benzylthio)aspartic acid (4m) 
Conversion 55% (
1
H NMR after 7 d). Yield 30%. White solid. Signals 





H NMR (500 MHz, DMSO-d6):  3.47-3.90 (m, 4H + 4H, 
CH2Ar, SCHCH, CHNH2), 7.18-7.36 (m, 5H + 5H, ArH); 
13
C NMR (50 MHz, DMSO-d6): 35.7, 
35.9, 48.7, 49.2, 54.6, 55.2. 127.0, 127.2, 128.6, 128.7, 129.5, 129.6, 138.6, 139.1, 169.1, 170.2, 
172.6, 173.2; HRMS (ESI+): calcd. for C11H13NO4S, 256.0644; found, 256.0638. 
 
3-benzylaspartic acid (4n) 
Conversion 90% (
1
H NMR after 7 d). Yield 55%. White solid. 
1
H NMR (500 
MHz, D2O):  2.74 (dd, 1H, 
2
J = 13.3 Hz, 
3
J = 4.3 Hz, ArCH2CH), 2.83 (dd, 
1H, 
2
J = 13.1 Hz, 
3
J = 11.4 Hz, ArCH2CH), 3.06 (ddd, 1H, 
3





J = 3.3 Hz, CH2CHCH), 3.97 (d, 1H, 
3
J = 3.1 Hz, CHNH2), 7.22-7.35 (m, 5H, ArH); 
13
C 
NMR (125 MHz, D2O): , 51.9, 58.4, 129.2, 131.3, 131.4, 141.5, 175.5, 182.3. HRMS (ESI+): 
calcd. for C11H14NO4, 224.0917; found: 224.0919. 
1
















Chemical synthesis of sulphur substituted aspartic acid derivatives 
 
In order to determine the relative configuration of the products (4k-4m) of the L384A-catalyzed 
amination of 2-ethylthiofumarate (1k), 2-phenylthiofumarate (1l) and 2-benzylthiofumarate (1m), 
we have synthesized the reference molecules, erythro-10, erythro-11 and erythro-12. The synthesis 
was mainly based on literature procedures.
[24-26]
 Briefly, L-diethyl tartrate (L-DET) was converted to 
the cyclic sulphite 6. Ring-opening of 6 was achieved with sodium azide in DMF to provide the 
azido alcohol 7. Triphenyl phosphine was used to form the corresponding aziridinium 8, which was 
subsequently protected as the acetyl derivative 9. BF3
.
(OEt)2 was used as Lewis acid to facilitate the 
nucleophilic attack on the aziridinium by either ethyl mercaptan, thiophenol, or benzyl mercaptan to 
provide the corresponding N-protected sulphur substituted aspartic acid analogues, erythro-10, 
erythro-11 and erythro-12. 
 
Diethyl (2R,3R)-2,3-O-sulfinyl-tartrate (6) 
L-DET (7.36 ml, 43 mmol) was dissolved in dichloromethane (20 ml) and cooled 
to 0°C. SOCl2 (3.62 ml, 52 mmol) was added to the solution drop-wise followed 
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by the addition of 10 drops of DMF. The reaction mixture was allowed to warm to room 
temperature and then heated at 50°C for 30 min. A fine stream of N2 (g) was used to remove excess 
SOCl2 and evolved HCl (g). Residual SOCl2 was then removed in vacuo (50°C, 25 mbar) to give 6 
as light yellow oil (10.6 g, 98%). TLC (EtOAc:Hexane, 1:1 v/v): Rf = 0.41; [α]D
20
 = +161 (0.025 M 
in DCM); 
1
H NMR (400 MHz, CDCl3): δ 1.34 (app t, 7.1 Hz, 6H, CH2CH3), 4.28-4.37 (m, 4H, 
CH2CH3), 5.24 (d, J = 4.3 Hz, 1H, CHO), 5.71 (d, J = 4.3 Hz, 1H, CHO); 
13
C NMR (75 MHz, 
CDCl3): δ 14.2, 63.3, 79.4, 80.0, 166.6; HRMS (ESI+): calcd. for C8H13O7S, 253.0374; found, 




Diethyl (2R,3S)-3-azido-3-deoxy-tartrate (7) 
NaN3 (7.37 g, 113.4 mmol) was added to a solution of 6 (10.57 g, 42 mmol) in 
DMF (24 ml) and stirred at room temperature until all the starting material was 
consumed (22 h, TLC, EtOAc:Hex 1:1 v/v). DCM (60 ml) and H2O (36 ml) were added to the 
reaction mixture and the mixture was stirred for 2 h. The layers were separated and the aqueous 
layer was extracted with DCM (3 x 35 ml). The combined organic layers were washed with H2O (5 
x 100 ml) and brine (100 ml), dried (Na2SO4), filtered and the solvent was removed in vacuo. The 
crude oil was purified by flash column chromatography (silica gel, EtOAc:Hex 1:4 v/v) to give 7 as 
a colourless oil (6.2 g, 64%). TLC (EtOA:Hexane, 1:4 v/v): Rf = 0.16; [α]D
20
 = +34.1 (7.2 mM in 
EtOH); 
1
H NMR (400 MHz, CDCl3): δ 1.30 (t, J = 7.1 Hz, 3H, CH2CH3), 1.31 (t, J = 7.1 Hz, 3H, 
CH2CH3), 3.28 (d, J = 5.4 Hz, 1H, CHN3), 4.22-4.35 (m, 4H, CH2CH3), 4.63 (dd, J = 5.4 Hz, J = 
2.7 Hz, 1H, CHOH); 
13
C NMR (75 MHz, CDCl3): δ 14.2, 62.5, 62.9, 64.6, 72.2, 167.1, 170.9; 







Diethyl (2S,3S)-aziridine-2,3-dicarboxylate (8) 
Triphenyl phosphine (12.20 g, 46.51 mmol) was slowly added over 30 min to 
a solution of 7 in DMF at 0°C. The ice bath was removed and the reaction 
mixture was stirred at room temperature for 90 min followed by another 270 min at 80°C. The 
solvent was removed in vacuo (77°C, 20 mbar), and the crude product was purified by flash column 
chromatography (silica gel, EtOAc:Hexane 1:3 v/v) to give 8 as a colourless oil (3.50 g, 72%). TLC 
(EtOAc:Hexane, 1:3 v/v): Rf = 0.25; [α]D
20
 = +147.3 (9.2 mM in CHCl3), 
1
H NMR (400 MHz, 
CDCl3): δ 1.30 (t, J = 7.1 Hz, 6H, CH2CH3), 2.86 (s, 2H, CHNH), 4.24 (q, J = 7.0 Hz, 4H, 
CH2CH3); 
13
C NMR (75 MHz, CDCl3): δ 14.3, 35.9, 62.2, 169.6; HRMS (ESI+): calcd. for 




Diethyl (2S,3S)-N-(acetyl)-aziridine-2,3-dicarboxylate (9) 
Pyridine (1.51 ml, 18.64 mmol) was added to 8 (3.49 g, 18.64 mmol) at room 
temperature and the mixture was stirred for 5 min. Acetic anhydride (2.64 ml, 
27.96 mmol) was added drop wise to the reaction mixture and the mixture was 
heated at 60°C for 1 h. The reaction mixture was allowed to cool to room temperature and diluted 
with DCM (50 ml). The mixture was washed with H2O (4 x 30 ml) and brine (30 ml), dried 
(Na2SO4), filtered and the solvent was removed in vacuo. The crude product was purified by flash 
column chromatography (silica gel, DCM: Et2O, 8:2 v/v) to give 9 as a light yellow oil (3.19 g, 
75%). TLC (DCM:Et2O, 8:2 v/v): Rf = 0.66; [α]D
20
 = +56.8 (0.025 M in CHCl3); 
1
H NMR (400 
MHz, CDCl3): δ 1.31 (app t, J = 7.1 Hz, 6H, CH2CH3), 2.13 (s, 3H, COCH3), 3.42 (s, 2H, 
CHNCO), 4.20-4.30 (m, 4H, CH2CH3); 
13
C NMR (75 MHz, CDCl3): δ 14.2, 24.0, 40.3, 62.6, 




Diethyl erythro-(2R,3R)-2-acetamido-3-(ethylthio)succinate (10) 
Ethanethiol (353 µl, 4.62 mmol) was added to a solution of 9 (530 mg, 2.31 
mmol) in anhydrous CHCl3 (20 ml). While stirring at room temperature, 
BF3
.
(OEt)2 (477 µl, 2.31 mmol) was slowly added to the reaction mixture, 
which was then heated to 37°C for 3 h. The reaction was quenched with 
saturated aqueous NaHCO3 (25 ml). The layers were separated and the organic layer was washed 
with saturated aqueous NaHCO3 (20 ml). The organic layer was dried (MgSO4) and the solvent was 
removed in vacuo to give 10 as a yellow oil (613 mg, 91%). TLC (DCM:Et2O, 8:2 v/v): Rf = 0.47; 
[α]D
20
 = +43.1 (0.034 M in EtOH); 
1
H NMR (300 MHz, CDCl3): δ 1.21-1.35 (m, 9H, CH2CH3), 
2.08 (s, 3H, COCH3), 2.68-2.82 (m, 2H, CH2S), 3.95 (d, J = 4.5 Hz, 1H, CHS), 4.13-4.27 (m, 4H, 
CH2CH3), 5.14 (dd, J = 9.7 Hz; J = 4.5 Hz, 1H, CHNH), 6.63 (d, J = 9.4 Hz, 1H, CHNH); 
13
C 
NMR (75.5 MHz, CDCl3): δ 14.2, 14.4, 23.2, 27.0, 47.6, 53.0, 62.0, 62.1, 169.8, 170.5, 171.9; 
HRMS (ESI+): calcd. for C12H22O5NS, 292.1213; found, 292.1212. 
 
Diethyl erythro-(2R,3R)-2-acetamido-3-(phenylthio)-succinate (11) 
Thiophenol (450 µl, 4.36 mmol) was added to a solution of 9 (500 mg, 2.18 
mmol) in anhydrous CHCl3 (18.70 ml). While stirring at room temperature, 
BF3
.
(OEt)2 (450 µl, 2.18 mmol) was slowly added to the reaction mixture, 
which was then heated at 37°C for 3 h. The reaction was quenched with 
saturated aqueous NaHCO3 (20 ml). The layers were separated and the organic layer was washed 
with saturated aqueous NaHCO3 (15 ml). The organic layer was dried (MgSO4), the solvent was 
removed in vacuo and the crude oil was purified with flash column chromatography (silica gel, 
DCM: Et2O, 8:2 v/v) to give 11 as a thick colourless oil (638 mg, 86%). TLC (DCM:Et2O, 8:2 v/v): 
Rf = 0.40; [α]D
20
 = +132.8 (3.9 mM in CHCl3); 
1
H NMR (400 MHz, CDCl3): δ 1.18-1.25 (m, 6H, 
CH2CH3), 2.02 (s, 3H, COCH3), 4.11-4.21 (m, 4H, CH2CH3), 4.28 (d, J = 4.2 Hz, 1H, CHS), 5.20 
(dd, J = 9.4 Hz, J = 4.2 Hz, 1H, CHNH), 6.63 (d, J = 9.4 Hz, 1H, CHNH), 7.29-7.34 (m, 3H, ArH), 
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7.50-7.55 (m, 2H, ArH); 
13
C NMR (75 MHz, CDCl3): δ 14.1, 14.2, 23.2, 52.5, 53.6, 62.1, 62.2, 
128.7, 129.3, 133.0, 133.6, 169.6, 170.4, 171.0; HRMS (ESI+): calcd. for C16H22O5NS, 340.1212; 
found, 340.1213. 
 
Diethyl erythro-(2R,3R)-2-acetamido-3-(benzylthio)-succinate (12) 
Benzyl mercaptan (512 µl, 4.36 mmol) was added to a solution of 9 (500 mg, 
2.18 mmol) in anhydrous CHCl3 (18.70 ml). While stirring at room 
temperature, BF3
.
(OEt)2 (450 µl, 2.18 mmol) was slowly added to the reaction 
mixture, which was then heated at 37°C for 3 h. The reaction was quenched 
with saturated aqueous NaHCO3 (20 ml). The layers were separated and the 
organic layer was washed with saturated aqueous NaHCO3 (15 ml). The organic layer was dried 
(MgSO4), the solvent was removed in vacuo and the crude oil was purified with flash column 
chromatography (silica gel, DCM:Et2O, 8:2 v/v) to give 12 as a white solid (614 mg, 80%). Mp: 77-
78°C; TLC (DCM:Et2O, 8:2 v/v): Rf = 0.51; [α]D
20
 = +29.4 (1.9 mM in CHCl3); 
1
H NMR (400 
MHz, CDCl3): δ 1.10 (t, J = 7.0 Hz, 3H, CH2CH3), 1.30 (t, J = 7.1 Hz, 3H, CH2CH3), 2.04 (s, 3H, 
COCH3), 3.80 (d, J = 4.4 Hz, 1H, CHS), 3.91 (iso(AB), J = 13.2 Hz, J = 4.5 Hz, 2H, CH2Ar), 4.09-
4.24 (m, 4H, CH2CH3), 5.06 (dd, J = 9.7 Hz, J = 4.4 Hz, 1H, CHNH), 6.53 (d, J = 9.6 Hz, 1H, 
CHNH), 7.82-7.36 (m, 5H, ArH); 
13
C NMR (75 MHz, CDCl3): δ 14.2, 14.3, 23.3, 36.9, 46.9, 52.7, 
61.1, 127.7, 128.8, 129.3, 136.7, 169.7, 170.4, 171.8; HRMS (ESI+): calcd. for C17H24O5NS, 




Procedure for determining the relative configuration of enzymatic products 4k-4m 
 
To determine the relative configuration of amino acid products 4k-4m, synthesized using mutant 
L384A, these products were first esterified and acetylated (in separate reactions). Then, their 
1
H 
NMR spectra were compared to those obtained with the respective reference molecules 10-12, 
which suggested the relative configuration of 4k-4m. The general procedure for the esterification 
and acetylation is as follows. Absolute ethanol (200 µl) was cooled in an ice-bath. Acetyl chloride 
(0.432 mmol) was added drop wise to generate HCl in situ and the mixture was stirred for 30 min. 
The acidic ethanol solution was added to either 4k, 4l or 4m (0.108 mmol). The reaction mixture 
was heated to reflux for 4 h. The reaction mixture was allowed to cool down to room temperature 
and the solvent removed in vacuo to give an oily residue. The residue was dissolved in toluene (750 
µl), pyridine (0.150 mmol) was added, and the solution was cooled to 0°C. Acetic anhydride (1.39 
mmol) was added and the solution was stirred overnight. The reaction mixture was poured onto ice-
diluted HCl (5 ml). The layers were separated and the organic layer was washed with H2O (5 ml) 
and then dried over MgSO4. After filtration and solvent removal under reduced pressure, the 
resulting residue was purified with flash column chromatography (silica gel, DCM: Et2O, 8:2 v/v) 
to give the modified product. 
 
Diethyl (threo/erythro)-2-acetamido-3-(ethylthio)-succinate 
Yellow oil (15 mg, 22%). Isolated as a mixture of diastereoisomers (d.r. = 58:42, threo:erythro). 
The d.r. has changed compared to that of the unmodified enzymatic product (d.r. = 68:32), which 
suggests that some epimerization had occurred during the chemical esterification and acetylation 
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procedure. Threo isomer: 
1
H NMR (300 MHz, CDCl3): δ 1.20–1.32 (m, 9H, CH2CH3), 2.03 (s, 3H, 
COCH3), 2.59-2.68 (m, 2H, CH2S), 3.86 (d, J = 5.3 Hz, 1H, CHS), 4.10-4.25 (m, 4H, CH2CH3), 
4.97 (dd, J = 7.9 Hz, J = 5.3 Hz, 1H, CHNH), 6.32 (d, J = 7.6 Hz, 1H, CHNH). Erythro-isomer: 
1
H 
NMR signals are listed above. 
 
Diethyl (threo/erythro)-2-acetamido-3-(phenylthio)-succinate  
Yellow oil (35 mg, 23%). Isolated as a mixture of diastereoisomers (d.r. = 64:36, threo:erythro). 
The diastereomeric ratio is nearly identical to that of the unmodified enzymatic product (d.r. = 
65:35), which suggests that no epimerization had occurred during the chemical esterification and 
acetylation procedure. Threo isomer: 
1
H NMR (300 MHz, CDCl3): δ 1.14–1.28 (m, 6H, CH2CH3), 
2.04 (s, 3H, COCH3), 4.08-4.22 (m, 4H, CH2CH3), 4.29 (d, J = 4.4 Hz, 1H, CHS), 5.12 (dd, J = 8.2 
Hz, J = 4.5 Hz, 1H, CHNH), 6.38 (d, J = 8.1 Hz, 1H, CHNH), 7.28–7.36 (m, 5H, ArH). Erythro-
isomer: 
1
H NMR signals are listed above. 
 
Diethyl (threo/erythro)-2-acetamido-3-(benzylthio)-succinate 
Yellow oil (2 mg, 25%). Isolated as a mixture of diastereoisomers (d.r. = 59:41, threo:erythro). The 
diastereomeric ratio is nearly identical to that of the unmodified enzymatic product (d.r. = 60:40), 
which suggests that no epimerization had occurred during the chemical esterification and 
acetylation procedure. Threo isomer: 
1
H NMR (300 MHz, CDCl3): δ 1.18–1.34 (m, 6H, CH2CH3), 
1.99 (s, 3H, COCH3), 3.75 (d, J = 5.4 Hz, 1H, CHS), 3.82-3.86 (m, 2H, CH2Ar), 4.09–4.25 (m, 4H, 
CH2CH3), 4.96 (dd, J = 8.1 Hz, J = 5.4 Hz, 1H, CHNH), 6.04 (d, J = 8.3 Hz, 1H, CHNH), 7.28–
7.36 (m, 5H, ArH). Erythro-isomer: 
1




SUPPLEMENTARY RESULTS & DISCUSSION 
Engineering of the amine binding pocket 
Engineering of the amine binding pocket through saturation mutagenesis at position 172 did not 
result in MAL variants with the ability to catalyze methylamine addition to mesaconate. A closer 
inspection of the crystal structure of MAL complexed with its natural substrate threo-(2S,3S)-3-
methylaspartate
[11]
 provides a likely explanation for this finding. Residue Q172 not only forms a 
hydrogen bond with the amino group of the substrate but also with its C-1 carboxylate group. 
Hence, the replacement of Q172 with other residues will eliminate this critical interaction with the 
substrate’s carboxylate group, thereby preventing the productive binding of mesaconate. 
 
Additional mutagenesis experiments 
The results may suggest that combining the Q73A and L384A mutations into one enzyme could 
yield a biocatalyst with the ability to process many different combinations of substituted amines and 
fumarates. However, the MAL double mutant (Q73A/L384A) is almost completely inactive (data 
not shown), which may be the result of a changed active site geometry, and thus not suitable for 
biocatalytic application. In future work, we therefore aim to construct a focused library by 
saturation mutagenesis at positions 73 and 384, screening of which may yield various active 
biocatalysts optimized for unique combinations of nucleophile and electrophile. The finding that at 
least six different substitutions at position 73 are allowed to give pronounced activity for 
methylamine addition to mesaconate argues in favor of this approach. It is important to note that not 
all nucleophile-electrophile combinations are likely to be productive as very bulky substituents on 
both the amine and fumarate substrates may sterically hinder the Michael-type addition. We also 
aim to develop MAL variants that lack specificity for the C-1 carboxylate group of the amino acid 
substrate, which, in contrast to the C-4 carboxylate group, appears not to play an essential role in 
the reaction mechanism.
[6,11]
 If successful, these engineering efforts may further extent the substrate 
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scope of MAL to include not only various N,3-disubstituted aspartic acid analogs, but also β-amino 









Supplementary Fig. 1. UV spectra monitoring the ammonia (2a, 400 mM) or methylamine (2b, 400 mM) 
additions to mesaconate (1b, 5 mM) catalyzed by wild-type MAL (WT) and the MAL mutants Q73A, Q73G, 
Q73N, Q73P, Q73S, and Q73T. (a) UV spectra monitoring the addition of 2a to 1b catalyzed by wild-type 
(15 µg/ml) or mutant (150 µg/ml) MAL. (b) UV spectra monitoring the addition of 2b to 1b catalyzed by 
wild-type (150 µg/ml) or mutant (150 µg/ml) MAL. The reactions were monitored by following the 


















Supplementary Fig. 2. 
 1
H NMR spectroscopic analysis of the products of the ammonia and methylamine 
additions to mesaconate catalyzed by wild-type MAL and the Q73A mutant. (a) 
1
H NMR spectrum 
monitoring the ammonia addition to mesaconate catalyzed by wild-type MAL. (b) 
1
H NMR spectrum 
monitoring the ammonia addition to mesaconate catalyzed by mutant Q73A. (c) 
1
H NMR spectrum 
monitoring the methylamine addition to mesaconate catalyzed by wild-type MAL. (d) 
1
H NMR spectrum 
monitoring the methylamine addition to mesaconate catalyzed by mutant Q73A. The spectra were taken after 
14 days of incubation at 22°C. In Figures 2a and 2b, the signals corresponding to mesaconate, threo-3-
methylasparate and erythro-3-methylaspartate are labeled 1b, t-3a and e-3a, respectively. In figures 2c and 
2d, the signals corresponding to mesaconate, methylamine, and threo-N,3-dimethylaspartate are labelled 1b, 





Supplementary Fig. 3. Identification of the relative configuration of the product, 2-(cyclo-pentylamino)-3-
methylbutanedioic acid (3j), of the Q73A-catalyzed cyclopentylamine (2j) addition to mesaconate (1b) by 
using 
1
H NMR spectroscopy and authentic standards. Spectrum 1: partial 
1
H NMR spectrum of 
enzymatically synthesized 3j. Spectrum 2: partial 
1
H NMR spectrum of chemically synthesized threo-3j. 
Spectrum 3: partial 
1
H NMR spectrum of a chemically synthesized mixture of threo- and erythro-3j. This 
analysis showed that the Q73A-catalyzed addition of 2j to 1b yields exclusively the threo isomer of 3j (de 
>95%). Similar analyses were performed to determine the relative configuration of the other Q73A-










Supplementary Fig. 4. Determination of the ee value of the product, threo-2-(propylamino)-3-
methylbutanedioic acid (3d), of the Q73A-catalyzed propylamine (2d) addition to mesaconate (1b) by using 
chiral HPLC. (a) Chromatogram of chemically synthesized threo-DL-3d. (b) Chromatogram of 
enzymatically prepared 3d. This analysis showed that the Q73A-catalyzed addition of 2d to 1b is highly 
enantioselective, yielding 3d with >99% ee. Similar analyses were performed to determine the ee value of 










Supplementary Fig. 5. UV spectra monitoring the ammonia (2a, 400 mM) addition to mesaconate (1b, 5 
mM) or 2-hexylfumarate (1g, 3 mM) catalyzed by wild-type MAL and the MAL mutants L384G and L384A. 
(a) UV spectra monitoring the addition of 2a to 1g catalyzed by wild-type (150 µg/ml) or mutant (150 
µg/ml) MAL. (b) UV spectra monitoring the addition of 2a to 1b catalyzed by wild-type (15 µg/ml) or 
mutant (150 µg/ml) MAL. The amination reactions were monitored by following the depletion of the 





Supplementary Table 1. Apparent kinetic parameters for wild-type MAL and the Q73A mutant 
using ammonia (2a) or methylamine (2b) as nucleophiles in the addition to mesaconate
a
. 




















50 ± 4 
0.6 ± 0.1 
- 
0.8 ± 0.1 
46 ± 5 
270 ± 40 
- 








The steady state kinetic parameters were determined at 30 C in 500 mM Tris buffer, pH 9.0, containing 20 




Supplementary Table 2. Apparent kinetic parameters for the wild-type MAL- and L384A-
catalyzed amination of fumarate (1a), mesaconate (1b), 2-ethylfumarate (1c), 2-n-propylfumarate 







































104 ± 5 
61 ± 1
b 





9.4 ± 1.6 
0.7 ± 0.02
b 




















36 ± 4 
32 ± 3 
21 ± 1 




25 ± 3 
11 ± 1 
2.0 ± 0.4 




















The steady state kinetic parameters were determined at 30 C in 500 mM Tris buffer, pH 9.0, containing 20 
mM MgCl2 and 400 mM NH4Cl. Errors are standard deviations from each fit. 
b
These kinetic parameters 





Supplementary Table 3. Data collection and refinement statistics. 
 Q73A L384A 
Data collection   
Space group P212121 P212121 
Cell dimensions a, b, c (Å) 66.8, 109.7, 110.1 66.6, 109.8, 110.8 
Resolution (Å)  38.9 – 2.00 (2.11 – 2.00)* 39.0 – 1.90 (2.00 – 1.90) 
No. of observations 216949 (23742) 280019 (32561) 
No. of unique reflections 54091 (7596) 61377 (8172) 
Rmerge (%) 15.6 (57.7) 14.4 (64.2) 
Rpim (%) 8.4 (36.6) 7.4 (35.3) 
Completeness (%) 98.0 (95.4) 94.2 (87.2) 
Mean I/σ (I) 6.9 (2.1) 9.8 (2.3) 
   
Refinement   
R/Rfree (%) 19.8 / 24.9 16.2 / 21.0 
No. of atoms in asymmetric unit   
Protein (chain A, B) 3218, 3220 3223, 3223 
Water  535 796 
Magnesium ions  2 2 
Chloride ions  1 1 
Glycerol 30 30 
Propanamide -  10 
B-factors    
Protein (chain A, B) 15.2, 13.9 13.6, 13.0 
Ligands / ions 21.5 / 13.3 21.8 / 13.3 
Water 14.1 16.2 
Geometry   
 RMSD bond lengths (Å) 0.011 0.010 
 RMSD bond angles (
o
) 1.3 1.3 
 Ramachadran favored (%) 95.5 97.1 
 Ramachandran outliers (%) 0 0 
 Molprobity score 1.85 1.52 
Protein Data Bank code 3ZVH 3ZVI 
*Values in parentheses are for highest-resolution shell. 
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Supplementary Table 4. The primers used for library construction. 
Primer Nucleotide sequence (from 5' to 3') 
Fwd-Q73X GGAGATTGTGCTGCAGTTNNSTACTCAGGAGCAGGCGGA  
Rev-Q73X  CCGCCTGCTCCTGAGTASNNAACTGCAGCACAATCTCC  
Fwd-Q172X CCTGTATTTGCTNNSTCAGGTGATGATAGATACG  
Rev-Q172X CGTATCTATCATCACCTGASNNAGCAAATACAGG  
Fwd-F170X  CAATGCAGTTCCTGTANNSGCTCAGTCAGGTGATGATAGATAC 
Rev-F170X  GTATCTATCATCACCTGACTGAGCSNNTACAGGAACTGCATTG 
Fwd-Y356X  GCTAACGGAATGGGAGCTNNSTGTGGAGGAACTTGTAACG 
Rev-Y356X  CGTTACAAGTTCCTCCACASNNAGCTCCCATTCCGTTAGC 
Fwd-L384X  GGAGCTAGACAGGTTNNSGCTAAACCAGGTATGGG 





Supplementary Table 5. Molar absorption coefficients of (2-substituted) fumaric acids at 240 and 
270 nm. The extinction coefficients were measured in 500 mM Tris-HCl buffer, pH 9.0, at 30°C. 
Substrate 
ε (M -1 cm-1) 
240 nm 




















 4.31 x 10
2
 
2-n-propylfumarate 3.73 x 10
3
 4.63 x 10
2
 
2-n-butylfumarate 3.66 x 10
3
 6.60 x 10
2
 
2-n-pentylfumarate 3.94 x 10
3
 7.29 x 10
2
 
2-n-hexylfumarate 3.22 x 10
3
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We report the synthesis of a large variety of N-substituted aspartic acids by the addition of structurally 
diverse amines to fumaric acid, catalyzed by a previously engineered variant of methylaspartate ammonia 
lyase. The enzyme-catalyzed additions are highly enantioselective, only yielding the L-enantiomers of the 






N-substituted aspartic acids are important building blocks for pharmaceuticals, artificial sweeteners, 
synthetic enzymes, and peptidomimetics.
[1-4]
 In such applications the optical purity of the 
compounds is paramount. The most common synthetic route to N-substituted aspartic acids is via 
the direct Michael-type addition of amines to maleic acid, maleic anhydride, or the ester or amide 
derivatives of maleic acid.
[5-8]
 Recently, a novel one-step method for the preparation of N-
substituted aspartic acids from maleic anhydride and amines via the monolithium salt of maleic acid 
was reported.
[9]
 However, the products of all these reactions are racemic mixtures and further 
separation steps are needed to get an optically pure amino acid. A general method for the synthesis 
of enantiomerically pure N-substituted aspartic acids is the reductive amination of carbonyl 
compounds with enantiopure aspartic acid.
[10, 11]
 However, this method is limited by the availability 
of the corresponding carbonyl compounds and the formation of multiple undesired side-products. In 
addition to these chemical synthesis routes, two classes of ammonia lyases, aspartate ammonia 
lyases (E.C 4.3.1.1) and 3-methylaspartate ammonia lyases (EC 4.3.1.2),
[12]
 have recently been 




Scheme 1. Biocatalytic synthesis of a few N-substituted-L-aspartic acids. 
 
 Aspartate ammonia lyases play a key role in microbial nitrogen metabolism by catalyzing the 
reversible amination of fumaric acid to produce L-aspartic acid.
[12, 15, 16]
 These enzymes are highly 
enantioselective and have been used in industry for the production of L-aspartic acid, which in turn 
is an ingredient in the synthesis of the artificial sweetener aspartame.
[17, 18]
 The aspartate ammonia 
lyase from Bacillus species YM55-1 (AspB) is highly active, thermostable and lacks allosteric 
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regulation by substrate or metal ions.
[19-21]
 AspB processes different amines in the addition reaction 
and has been used to synthesize N-substituted-L-aspartic acids with high enantiomeric excess 
(>97% ee).
[14]
 However, the enzyme only accepts a few small amines such as hydroxylamine, 
hydrazine, methylamine and methoxylamine in the addition reaction, yielding a limited number of 
aspartic acid derivatives (Scheme 1). To overcome this limitation, we have attempted to broaden the 
amine scope of AspB by rational design and structure-guided saturation mutagenesis. However, we 
were unsuccessful in these engineering attempts, which may have to do with complex loop 
movement upon substrate binding,
[22, 23]
 making protein engineering of AspB (and other aspartate 
ammonia lyases) a formidable challenge. 
 
Scheme 2. Biocatalytic synthesis of a large variety of N-substituted aspartic acids by MAL-Q73A catalyzed 
addition of various amines to fumaric acid. 
 
 3-Methylaspartate ammonia lyases catalyze the reversible addition of ammonia to 
mesaconic acid (2-methylfumaric acid) to give threo-(2S,3S)-3-methylaspartic acid and erythro-
(2S,3R)-3-methylaspartic acid as products.
[12, 24-28]
 These enzymes are part of glutamate catabolic 




 ions for full activity. The 
methylaspartate ammonia lyase from Clostridium tetanomorphum (MAL) accepts fumaric acid as 
well as a range of 2-substituted fumaric acids (ethyl-, propyl-, isopropyl- and halo-derivatives) in 
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the ammonia addition reaction.
[29, 30]
 MAL also accepts hydrazine, hydroxylamine, methylamine, 
methoxylamine and ethylamine in the addition reaction. The MAL-catalyzed additions of these 
amines to fumaric acid were highly enantioselective and yielded the corresponding N-substituted-L-
aspartic acids as the only product (Scheme 1).
[13]
 Unfortunately, like AspB, MAL has a very narrow 
amine scope and only accepts these small amines as substrates. Interestingly, previous protein 
engineering work on MAL, which involved structure-guided saturation mutagenesis and activity 
screening, has resulted in the MAL variant Q73A, which accepts many structurally distinct amines 
in the addition to mesaconic acid.
[31]
 In the present study, we have exploited the synthetic potential 
of this engineered MAL variant for the preparation of a large variety of N-substituted aspartic acids 
by the addition of structurally diverse amines to fumaric acid. The enzyme-catalyzed additions are 
highly enantioselective, only yielding the L-enantiomers of the amino acid products (>99% ee).  
 To test MAL-Q73A as catalyst in amine additions to fumaric acid (Scheme 2), the enzyme was 
incubated with fumaric acid (1, 86 mM) and various amines (2a-2n, 0.5 to 5 M) in separate reaction 
mixtures (15 mL final volume; pH 9.0) at 22°C. The reactions were started by the addition of a 
freshly purified MAL-Q73A enzyme (32 mg, 0.05 mol%) and the progress of the reactions was 
monitored by UV-Vis and 
1
H NMR spectroscopy. Interestingly, the MAL-Q73A enzyme was found 
to efficiently catalyze the addition of amines 2a-2n to fumaric acid (Table 1). With only 0.05 mol% 
of biocatalyst, excellent (91-100%) conversions were achieved within 0.5-48 h at 22°C. The single 









Table 1. Conversions and yields of isolated products determined for MAL-Q73A catalyzed 














Molar concentration of amine used; 
b
Hours of incubation; 
c
Isolated product yield; 
d
The enantiomeric excess 
of the isolated product was determined by chiral HPLC using authentic standards with known L- or D-
configuration; 
e
n.d. = not determined. 
 
 
Scheme 3. Reductive amination using D- or L-aspartic acid to obtain enantiopure N-substituted aspartic acids 
with D or L configuration. 
Entry Amine (M)
a







a 2a (5) 3a 100 (0.5) 79 >99 
b 2b (3) 3b 100 (2.5) 96 >99 
c 2c (3) 3c 100 (24) 75 >99 
d 2d (3) 3d 99 (3) 53 >99 
e 2e (2) 3e 97 (24) 33 >99 
f 2f (0.5) 3f 91 (48) 14 >99 
g 2g (2) 3g 99 (13) 74 >99 
h 2h (3) 3h 96 (24) 28 >99 
i 2i (2) 3i 100 (48) 48 n.d.
e
 
j 2j (3) 3j 99 (2.5) 67 n.d. 
k 2k (3) 3k 100 (9) 61 n.d. 
l 2l (3) 3l 99 (13) 57 n.d. 
m 2m (3) 3m 100 (0.5) 61 n.d. 
n 2n (3) 3n 100 (9) 53 n.d. 
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 For eight selected products (3a-3h), the absolute configuration and enantiomeric excess were 
determined by high-performance liquid chromatography (HPLC) on a chiral stationary phase using 
authentic standards with known L or D configuration. Whereas the L- and D-enantiomers of 3a and 
3b are commercially available, those for 3c-3h were chemically synthesised using pure L- and D-
aspartic acid in reductive amination of the corresponding carbonyl compounds (Scheme 3).
[10, 11]
 
Chiral HPLC analysis revealed that in all cases (entries a-h, Table 1) the absolute configuration of 
the enzymatically prepared amino acid product is L, whereas no D-enantiomers were observed. This 
demonstrates that the high enantioselectivity (ee values are >99%) of the MAL-Q73A catalyzed 
addition reactions is not influenced by the different substituents on the amine substrate. The 
absolute configuration of products 3i-3n has not been determined by comparison to enantiopure 
authentic standards with L or D configuration, but we assume the absolute configuration to be L for 
all amino acid products 3a-3n. 
 In conclusion, we have demonstrated the potential of the MAL-Q73A enzyme for application 
in the asymmetric synthesis of a large variety of valuable N-substituted L-aspartic acids, given that 
the product yields may be further improved by optimizing isolation procedures. This attractive 
biocatalytic methodology for the enantioselective synthesis of a wide range of N-substituted L-
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Materials and general methods  
All reagents were purchased from Sigma-Aldrich Chemical Co. (St. Louis, MO) or Merck 
(Darmstadt, Germany) and used without further purification. L-aspartic acid, D-aspartic acid, N-
methyl-DL-aspartic acid and N-methyl-D-aspartic acid were purchased from Sigma-Aldrich. Flash 
chromatography was carried out on Silicagel (300-400 nm) using CH2Cl2/MeOH: 40/60 (v/v) as 
solvent. NMR spectra were recorded on either a Varian 500 (500 MHz) or on a Varian 200 (200 
MHz) spectrometer. High resolution mass spectrometry (HRMS) measurements were performed on 
a LTQ-Orbitrap XL mass spectrometer (Thermo Fisher Scientific, Bremen,
 
Germany). HPLC 
analysis was performed using a Shimadzu VP HPLC system. The MAL-Q73A enzyme was 
overproduced and purified to homogeneity by following a previously described protocol.
[1] 
 
General procedure for biocatalytic synthesis of N-substituted aspartic acids using MAL-
Q73A  
N-substituted aspartic acids were synthesized using the MAL-Q73A enzyme. For each substrate 
pair, a solution (15 mL) of fumaric acid (0.15 g, 86mM), amine (0.5-5 M) and MgCl2 (20 mM) was 
prepared. The pH was adjusted to 9.0 by addition of aqueous HCl or NaOH. The reactions were 
started by the addition of freshly purified MAL-Q73A enzyme (32 mg, 0.05 mol%) and reaction 
mixtures were incubated at 22°C. The progress of each reaction was monitored by UV-Vis and 
1
H 
NMR (500 MHz) spectroscopy. The reaction was stopped by incubating the reaction mixture at 
100°C for 10 min. The excess of amine was removed from the reaction mixture by purification 
using anion-exchange chromatography. A Dowex column (50 g anion-exchange resin, Dowex 1X8 
chloride, 50-100 mesh) was prepared by pre-treatment with a solution of aqueous HCl (2 N, 4 
column volumes), aqueous NaOH (1 M, 2 column volumes) and distilled water (4 column 
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volumes). The reaction mixture was basified (with ~10 mL of 1 M NaOH) and loaded onto the 
column, the column was washed with distilled water to remove unbound amine (2 column 
volumes), and the product was eluted with aqueous HCl (2 N, 2 column volumes). The ninhydrine 
positive fractions were pooled and concentrated under reduced pressure, followed by lyophilization. 
The crude product was re-dissolved in water (20 mL) and further purified by cation-exchange 
chromatography to remove the unreacted fumaric acid, if present. A Dowex column (50 g cation-
exchange resin, Dowex 50W X8, 100-200 mesh) was prepared by pre-treatment with aqueous NH3 
(2 M, 4 column volumes), aqueous HCl (1 N, 2 column volumes) and distilled water (4 column 
volumes). The crude product solution was loaded onto the column, the column was washed with 
water (2 column volumes) and the product was eluted with aqueous NH3 (2 M, 2 column volumes). 
The ninhydrine positive fractions were pooled and concentrated under reduced pressure, followed 





C NMR and HRMS.  
 
L-aspartic acid (L-3a) 
Conversion 100% (after 0.5 h). Yield 79%. White solid. 
1
H NMR (500 MHz, D2O): δ 2.68 (dd, 1H, 
J = 17.5 Hz, 8.6 Hz, CHCH2), 2.80 (dd, 1H, J = 17.5 Hz, 3.8 Hz, CHCH2), 3.89 (dd, 1H, J = 8.6 
Hz, 3.8 Hz, CHCH2); 
13
C NMR (125 MHz, D2O): δ 39.1, 54.7, 176.8, 180.0; HRMS: m/z calc. for 
C4H8NO4, 134.0453 [M+H]
 +
; found: 134.0448. 
 
N-methyl-L-aspartic acid (L-3b) 
Conversion 100% (after 2.5 h). Yield 96%. White solid. 
1
H NMR (500 MHz, D2O): δ 2.70-2.75 (m, 
4H CHCH2NHCH3), 2.82 (dd, 1H, J = 17.6 Hz, 4.1 Hz, CHCH2), 3.73 (dd, 1H, J = 7.7 Hz,
 
 4.1 Hz, 
CHCH2); 
13
C NMR (125 MHz, D2O): δ 34.3, 37.8, 63.2, 175.9, 179.8; HRMS: m/z calc. for 
C5H10NO4, 148.0610 [M+H]
+




N-ethyl-L-aspartic acid (L-3c) 
Conversion 100% (after 24 h). Yield 75%. White solid. 
1
H NMR (500 MHz, D2O): δ 1.30 (t, 3H, J 
= 7.3 Hz, CH3CH2), 2.71 (dd, 1H, J = 17.5 Hz, 8.0 Hz, CHCH2), 2.82 (dd, 1H, J = 17.5 Hz, 3.4 Hz, 
CHCH2), 3.09-3.16 (m, 2H, CH3CH2), 3.81 (dd, 1H, J = 7.6 Hz,
 
3.8 Hz, CHCH2); 
13
C NMR (125 
MHz, D2O): δ 13.4, 38.2, 44.5, 61.4, 176.0, 179.5; HRMS: m/z calc. for C6H12NO4, 162.0766 
[M+H]
+
; found: 162.0761. 
 
N-propyl-L-aspartic acid (L-3d) 
Conversion 99% (after 3 h). Yield 53%. White solid. 
1
H NMR (500 MHz, D2O): δ 0.97 (t, 3H, J = 
7.5 Hz, CH2CH2CH3), 1.68-1.76 (m, 2H, CH2CH2CH3), 2.69 (dd, 1H, J = 17.6 Hz, 8.5 Hz, 
CHCH2), 2.82 (dd, 1H, J = 17.5 Hz, 4.0 Hz, CHCH2), 2.98-3.06 (m, 2H, NHCH2CH2), 3.79 (dd, 
1H, J = 8.4 Hz, 4.0 Hz, CHCH2); 
13
C NMR (125 MHz, D2O): δ 12.8, 21.9, 38.0, 50.8, 61.8, 175.9, 
179.7; HRMS: m/z calc. for C7H14NO4, 176.0923 [M+H]
+
; found: 176.0917. 
 
N-butyl-L-aspartic acid (L-3e) 
Conversion 97% (after 24 h). Yield 33%. White solid. 
1
H NMR (500 MHz, D2O): δ 0.93 (t, 3H, J = 
7.4 Hz, CH2CH2CH3), 1.38-1.43 (m, 2H, CH2CH2CH3), 1.66-1.72 (m, 2H, CH2CH2CH3), 2.69 (dd, 
1H, J = 17.5 Hz, 8.5 Hz, CHCH2), 2.81 (dd, 1H, J = 17.5 Hz, 4.0 Hz, CHCH2), 3.04-3.11 (m, 2H, 
NHCH2CH2), 3.80 (dd, 1H, J = 8.4 Hz, 4.0 Hz, CHCH2); 
13
C NMR (125 MHz, D2O): δ 15.3, 21.7, 





N-pentyl-L-aspartic acid (L-3f) 
Conversion 91% (after 48 h). Yield 14%. White solid. 
1
H NMR (500 MHz, D2O): δ 0.89 (t, 3H, J = 
7.0 Hz, CH2CH2CH3), 1.31-1.39 (m, 4H, CH2CH2CH2CH3), 1.69-1.75 (m, 2H, CH2CH2CH2CH3), 
2.69 (dd, 1H, J = 17.5 Hz, 8.1 Hz, CHCH2), 2.82 (dd, 1H, J = 17.5 Hz, 4.4 Hz, CHCH2), 3.03-3.12 
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(m, 2H, NHCH2CH2), 3.77 (dd, 1H, J = 8.1 Hz, 4.4 Hz, CHCH2); 
13
C NMR (125 MHz, D2O): δ 
13.0, 21.3, 25.2, 27.7, 35.4, 46.5, 59.2, 173.2, 177.1; HRMS: m/z calc. for C9H18NO4, 204.1236 
[M+H]
+
; found: 204.1230. 
 
N-cyclobutyl-L-aspartic acid (L-3g) 
Conversion 99% (after 13 h). Yield 74%. White solid. 
1
H NMR (500 MHz, D2O): δ 1.81-1.92 (m, 
2H, CH2CH2CH2), 2.18–2.31 (m, 4H, CH2CH2CH2), 2.68 (dd, 1H, J = 17.5 Hz, 7.5 Hz, CHCH2), 
2.78 (dd, 1H, J = 17.6 Hz, 4.6 Hz, CHCH2), 3.71 (dd, 1H, J = 7.5 Hz, 4.5 Hz, CHCH2COOH), 3.82 
(p, 1H, J = 8.2 Hz, NHCH(CH2)2); 
13
C NMR (50 MHz, D2O): δ 12.2, 24.1, 33.5, 48.7, 55.2, 171.2, 
174.8; HRMS: m/z calc. for C8H14NO4, 188.0923 [M+H]
+
; found: 188.0918. 
 
N-(cyclopropyl)methyl-L-aspartic acid (L-3h) 
Conversion 96% ( after 24 h). Yield 28%. White solid. 
1
H NMR (500 MHz, D2O): δ 0.31-0.41 (m, 
2H, CH2CH2), 0.65-0.70 (m, 2H, CH2CH2) 1.07-1.15 (m, 1H, CH2CH(CH2)2), 2.67 (dd, 1H, J = 
17.5 Hz, 8.8 Hz, CHCH2), 2.80 (dd, 1H, J = 17.5 Hz, 4.0 Hz, CHCH2), 2.93 (dd, 1H, J = 12.9 Hz, 
7.4 Hz, NHCH2), 3.01 (dd, 1H, J = 12.9 Hz, 7.4 Hz, NHCH2), 3.86 (dd, 1H, J = 8.8 Hz, 4.0 Hz, 
CHCH2); 
13
C NMR (125 MHz, D2O): δ 6.0, 6.2, 9.6, 38.3, 54.1, 61.4, 175.9, 179.9; HRMS: m/z 
calc. for C8H14NO4, 188.0923 [M+H]
+
; found: 188.0917. 
 
N-cyclopropylaspartic acid (3i) 
Conversion 100% (after 48 h). Yield 48%. White solid. 
1
H NMR (500 MHz, D2O): δ 0.85-0.97 (m, 
4H, CH2CH2), 2.66-2.82 (m, 2H, CH2CHCH2, CHCH2), 2.89 (dd, 1H, J = 17.6 Hz, 4.2 Hz, 
CHCH2), 3.96 (dd, 1H, J = 8.1 Hz, 4.4 Hz, CHCH2); 
13
C NMR (125 MHz, D2O): δ 3.0, 3.2, 29.0, 
35.3, 60.5, 173.4, 177.2; HRMS: m/z calc. for C7H12NO4, 174.0766 [M+H]
 +




N-(2-aminoethyl)aspartic acid (3j) 
Conversion 99% (after 2.5 h). Yield 67%. White solid. 
1
H NMR (500 MHz, D2O): δ 2.53 (dd, 1H, J 
= 16.9 Hz, 8.8 Hz, CHCH2), 2.70 (dd, 1H, J = 16.9 Hz, 3.9 Hz, CHCH2), 3.17-3.25 (m, 4H, 
NHCH2CH2NH2), 3.66 (dd, 1H, J = 8.8 Hz, 3.9 Hz, CHCH2); 
13
C NMR (125 MHz, D2O): δ 39.4, 





N-(3-aminopropyl)aspartic acid (3k) 
Conversion 100% (after 9 h). Yield 61%. White solid. 
1
H NMR (500 MHz, D2O): δ 2.08–2.14 (m, 
2H, CH2CH2CH2NH2), 2.65 (dd, 1H, J = 17.5 Hz, 8.7 Hz, CHCH2), 2.79 (dd, 1H, J = 17.5 Hz, 3.9 
Hz, CHCH2), 3.10 (t, 2H, J = 7.7 Hz, CH2CH2CH2NH2), 3.13–3.22 (m, 2H, NHCH2CH2CH2), 3.81 
(dd, 1H, J = 8.7 Hz, 3.9 Hz, CHCH2); 
13
C NMR (125 MHz, D2O): δ 26.5, 38.3, 39.2, 46.1, 62.1, 
175.7, 179.9; HRMS: m/z calc. for C7H15N2O4, 191.1032 [M+H]
+
; found: 191.1026. 
 
N-(3-hydroxypropyl)aspartic acid (3l) 
Conversion 99% (after 13 h). Yield 57%. White solid. 
1
H NMR (200 MHz, D2O): δ 1.90-2.03 (m, 
2H, CH2CH2CH2OH), 2.69 (dd, 1H, J = 17.5 Hz, 7.9 Hz, CHCH2), 2.83 (dd, 1H, J = 17.5 Hz, 4.3 
Hz, CHCH2), 3.12-3.31 (m, 2H, NHCH2CH2CH2), 3.71-3.84 (m, 3H, NHCH2CH2CH2, CHCH2); 
13
C NMR (50 MHz, D2O): δ 25.8, 33.3, 42.5, 57.0, 57.3, 171.0, 175.0; HRMS: m/z calc. for 
C7H14NO5, 191.0872 [M+H]
+
; found: 191.0867. 
 
N-ethoxyaspartic acid (3m) 
Conversion 100% (after 0.5 h). Yield 61%. White solid. 
1
H NMR (500 MHz, D2O): δ 1.05 (t, 3H, J 
= 7.0, CH3CH2O), 2.26 (dd, 1H, J = 15.7 Hz, 8.7 Hz, CHCH2), 2.49 (dd, 1H, J = 15.7 Hz, 5.0 Hz, 
CHCH2), 3.68-3.76 (m, 3H, CH3CH2O, CHCH2); 
13
C NMR (125 MHz, D2O): δ 15.8, 39.9, 65.4, 
71.9, 181.2, 181.3; HRMS: m/z calc. for C6H12NO5, 178.0715 [M+H]
+
; found: 178.0712. 
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N-(2-methoxy)ethylaspartic acid (3n) 
Conversion 100% (after 9 h). Yield 53%. White solid. 
1
H NMR (500 MHz, D2O): δ 2.69 (dd, 1H, J 
= 18.0 Hz, 7.3 Hz, CHCH2), 2.82 (dd, 1H, J = 18.0 Hz, 4.9 Hz, CHCH2), 3.17-3.29 (m, 2H, 
NHCH2CH2), 3.40 (s, 3H, CH2OCH3), 3.67 (t, 2H, J = 5.0 Hz, CH2CH2OCH3), 3.79 (dd, 1H, J = 
7.2 Hz, J = 4.8 Hz, CHCH2); 
13
C NMR (50 MHz, D2O): δ 34.3, 46.0, 58.1, 58.4, 66.8, 172.2, 175.1; 
HRMS: m/z calc. for C7H14NO5, 192.0872 [M+H]
+
; found: 192.0867. 
 
Chemical synthesis of enantiopure N-substituted aspartic acids  
N-substituted aspartic acids were prepared by the method of Ohfune et al.
[2]
 The preparation of N-
pentyl-L-aspartic acid is given here as an example. To a suspension of L-aspartic acid (666 mg, 5 
mmol) and NaBH3CN (471 mg, 7.5 mmol) in MeOH (15 mL) was added pentaldehyde (0.64 ml, 6 
mmol). The reaction mixture was stirred for 18 h at room temperature. The mixture was then 
filtered and the filtrate was evaporated. Subsequently, the residue was washed with ethyl acetate (3 
x 10 mL) and dried under vacuum. A white precipitate was formed, which was dissolved in 1-2 mL 
of 1 N HCl. The solution was triturated with acetone and the white precipitate formed was filtered 
and dried to obtain the product N-pentyl-L-aspartic acid. For products 3c, 3g and 3h silica 
chromatography (CH2Cl2/MeOH: 40/60, v/v) was used to further purify the product. For analysis by 
NMR spectroscopy, the amino acid products were dissolved in 0.2 M NaOH in D2O. In similar 
manner, the L- and D- enantiomers of 3c-3h were successfully synthesized and purified. All 
chemically synthesized compounds were characterized by 
1
H NMR and 
13
C NMR spectroscopy and 
HRMS analysis. 
 
N-ethyl-L-aspartic acid (L-3c) 
Yield 5%. White solid. 
1
H NMR (200 MHz, D2O): δ 1.06 (t, 3H, J = 7.3 Hz, CH3CH2), 2.30 (dd, 
1H, J = 11.1 Hz, 4.8 Hz, CHCH2), 2.44-2.59 (m, 3H, CH3CH2, CHCH2), 3.40 (dd, 1H, J = 8.2 Hz, 
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5.6 Hz, CHCH2); 
13
C NMR (50 MHz, D2O): δ 13.7, 41.5, 41.5, 61.2, 179.8, 181.7; HRMS: m/z 
calc. for C6H12NO4, 162.0766 [M+H]
+
; found: 162.0762. 
 
N-ethyl-D-aspartic acid (D-3c) 
Yield 5%. White solid. 
1
H NMR (200 MHz, D2O): δ 1.02 (t, 3H, J = 7.2 Hz, CH3CH2), 2.27 (dd, 
1H, J = 15.0 Hz, 8.2 Hz, CHCH2), 2.41–2.59 (m, 3H, CH3CH2, CHCH2), 3.36 (dd, 1H, J = 8.2 Hz, 
5.7 Hz, CHCH2); 
13
C NMR (50 MHz, D2O): δ 13.7, 41.5, 41.6, 61.2, 179.8, 181.8; HRMS: m/z 
calc. for C6H12NO4, 162.0766 [M+H]
+
; found: 162.0762. 
 
N-propyl-L-aspartic acid (L-3d) 
Yield 43%. White solid. 
1
H NMR (200 MHz, D2O): δ 1.02 (t, 3H, J = 7.4 Hz, CH2CH2CH3), 1.68-
1.87 (m, 2H, CH2CH2CH3), 2.92–2.98 (m, 2H, CHCH2), 3.04-3.15 (m, 2H, NHCH2CH2), 3.94 (dd, 
1H, J = 6.8 Hz, 4.9 Hz, CHCH2); 
13
C NMR (50 MHz, D2O): δ 10.1, 19.2, 34.5, 48.5, 58.3, 172.6, 
175.3; HRMS: m/z calc. for C7H14NO4, 176.0923 [M+H]
+
; found: 176.0918. 
 
N-propyl-D-aspartic acid (D-3d) 
Yield 34%. White solid. 
1
H NMR (200 MHz, D2O): δ 1.02 (t, 3H, J = 7.4 Hz, CH2CH2CH3), 1.68-
1.88 (m, 2H, CH2CH2CH3), 3.04-3.09 (m, 2H, CHCH2), 3.12-3.17 (m, 2H, NHCH2CH2), 4.03 (dd, 
1H, J = 6.8 Hz, 4.9 Hz, CHCH2); 
13
C NMR (50 MHz, D2O): δ 10.1, 19.1, 34.0, 48.7, 57.7, 172.1, 
174.1; HRMS: m/z calc. for C7H14NO4, 176.0923 [M+H]
+
, found: 176.0918. 
 
N-butyl-L-aspartic acid (L-3e) 
Yield 14%. White solid. 
1
H NMR (200 MHz, D2O): δ 0.98 (t, 3H, J = 7.3 Hz, CH2CH2CH3), 1.36-
1.55 (m, 2H, CH2CH2CH3), 1.68-1.83 (m, 2H, CH2CH2CH3), 2.73 (dd, 1H, J = 17.5 Hz, 8.0 Hz, 
CHCH2), 2.88 (dd, 1H, J = 17.5 Hz, 4.4 Hz, CHCH2), 3.10-3.18 (m, 2H, NHCH2CH2), 3.85 (dd, 
1H, J = 8.0 Hz, 4.4 Hz, CHCH2); 
13
C NMR (50 MHz, D2O): δ 13.2, 19.8, 30.8, 41.6, 46.9, 61.4, 
179.9, 181.9; HRMS: m/z calc. for C8H16NO4, 190.1079 [M+H]
+
; found: 190.1074. 
173 
 
N-butyl-D-aspartic acid (D-3e) 
Yield 18%. White solid. 
1
H NMR (200 MHz, D2O): δ 0.97 (t, 3H, J = 7.3 Hz, CH2CH2CH3), 1.36-
1.55 (m, 2H, CH2CH2CH3), 1.67-1.83 (m, 2H, CH2CH2CH3), 2.71 (dd, 1H, J = 17.5 Hz, 8.2 Hz, 
CHCH2), 2.86 (dd, 1H, J = 17.5 Hz, 4.4 Hz, CHCH2), 3.06-3.19 (m, 2H, NHCH2CH2), 3.84 (dd, 
1H, J = 8.1 Hz, 4.3 Hz, CHCH2); 
13
C NMR (50 MHz, D2O): δ 13.2, 19.8, 30.8, 41.6, 46.9, 61.4, 
179.9, 181.8; HRMS: m/z calc. for C8H16NO4, 190.1079 [M+H]
+
; found: 190.1074. 
 
N-pentyl-L-aspartic acid (L-3f) 
Yield 25%. White solid. 
1
H NMR (200 MHz, D2O): δ 0.92 (t, 3H, J = 7.0 Hz, CH2CH2CH3), 1.33-
1.43 (m, 4H, CH2CH2CH2CH3), 1.68-1.79 (m, 2H, CH2CH2CH2CH3), 2.78 (dd, 1H, J = 17.6 Hz, 
7.7 Hz, CHCH2), 2.91 (dd, 1H, J = 17.6 Hz, 4.6 Hz, CHCH2), 3.07-3.16 (m, 2H, NHCH2CH2), 3.86 
(dd, 1H, J = 7.6 Hz, 4.6 Hz, CHCH2); 
13
C NMR (50 MHz, D2O): δ 13.0, 21.4, 25.2, 27.7, 35.0, 
46.7, 58.9, 173.0, 176.4; HRMS: m/z calc. for C9H18NO4, 204.1236 [M+H]
+
; found: 204.1229. 
 
N-pentyl-D-aspartic acid (D-3f) 
Yield 20%. White solid. 
1
H NMR (200 MHz, D2O): δ 0.92 (t, 3H, J = 7.1 Hz, CH2CH2CH3), 1.33-
1.44 (m, 4H, CH2CH2CH2CH3), 1.68-1.79 (m, 2H, CH2CH2CH2CH3), 2.77 (dd, 1H, J = 17.6 Hz, 
7.7 Hz, CHCH2), 2.91 (dd, 1H, J = 17.6 Hz, 4.6 Hz, CHCH2), 3.08-3.16 (m, 2H, NHCH2CH2), 3.86 
(dd, 1H, J = 7.7 Hz, 4.6 Hz, CHCH2); 
13
C NMR (50 MHz, D2O): δ 13.0, 21.4, 25.2, 27.7, 35.1, 
46.7, 58.9, 173.1, 176.5; HRMS: m/z calc. for C9H18NO4, 204.1236 [M+H]
+
; found: 204.1229. 
 
N-cyclobutyl-L-aspartic acid (L-3g) 
Yield 5%. White solid. 
1
H NMR (200 MHz, D2O): δ 1.50-1.85 (m, 4H, CH2CH2CH2), 2.07-2.19 
(m, 2H, CH2CH2CH2), 2.26 (dd, 1H, J = 15.1 Hz, 8.3 Hz, CHCH2), 2.45 (dd, 1H, J = 15.0 Hz, 5.6 





(50 MHz, D2O): δ 14.3, 29.8, 29.9, 41.7, 52.0, 59.3, 179.8, 182.1; HRMS: m/z calc. for C8H14NO4, 
188.0923 [M+H]
+
; found: 188.0918. 
 
N-cyclobutyl-D-aspartic acid (D-3g) 
Yield 5%. White solid. 
1
H NMR (200 MHz, D2O): δ 1.49-1.84 (m, 4H, CH2CH2CH2), 2.07-2.17 
(m, 2H, CH2CH2CH2), 2.26 (dd, 1H, J = 15.1 Hz, 8.3 Hz, CHCH2), 2.45 (dd, 1H, J = 15.1 Hz, 5.6 
Hz, CHCH2), 3.19 (m, 1H, NHCH(CH2)2), 3.34 (dd, 1H, J = 8.2 Hz, 5.6 Hz, CHCH2); 
13
C NMR 
(50 MHz, D2O): δ 14.3, 29.8, 29.9, 41.7, 52.0, 59.3, 179.8, 182.1; HRMS: m/z calc. for C8H14NO4, 
188.0923 [M+H]
+
; found: 188.0918. 
 
N-(cyclopropyl)methyl-L-aspartic acid (L-3h) 
Yield 5%. White solid. 
1
H NMR (200 MHz, D2O): δ 0.03-0.14 (m, 2H, CH2CH2), 0.33-0.53 (m, 
2H, CH2CH2) 0.78-0.99 (m, 1H, CH2CH(CH2)2), 2.19-2.52 (m, 4H, CHCH2, NHCH2), 3.40 (dd, 
1H, J = 8.4 Hz, 5.5 Hz, CHCH2); 
13
C NMR (50 MHz, D2O): δ 0.0, 0.6, 7.5, 39.2, 49.9, 58.7, 177.4, 
179.3; HRMS: m/z calc. for C8H14NO4, 188.0923 [M+H]
+
; found: 188.0920. 
 
N-(cyclopropyl)methyl-D-aspartic acid (D-3h) 
Yield 5%. White solid. 
1
H NMR (200 MHz, D2O): δ 0.04-0.18 (m, 2H, CH2CH2), 0.36-0.48 (m, 
2H, CH2CH2) 0.78-1.00 (m, 1H, CH2CH(CH2)2), 2.20-2.53 (m, 4H, CHCH2, NHCH2), 3.41 (dd, 
1H, J = 8.4 Hz, 5.5 Hz, CHCH2); 
13
C NMR (50 MHz, D2O): δ 0.0, 0.6, 7.5, 39.2, 49.9, 58.7, 177.4, 
179.3; HRMS: m/z calc. for C8H14NO4, 188.0923 [M+H]
+
; found: 188.0920. 
 
Chiral HPLC analysis of the purified amino acid products 
Chiral HPLC was performed using a Chirex 3126-D-penicillamine column (250 mm x 4.6 mm, 
Phenomenex, USA) with 2 mM CuSO4 solution:isopropanol (90:10, v/v) as eluent at 25°C at a flow 
rate of 0.9 mL min
-1
. First, racemic mixtures of N-substituted aspartic acids were prepared by 
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mixing the D- and L-enantiomers in equimolar amounts. These mixtures were then separated by 
chiral HPLC. The peak assignments were carried out by chiral HPLC analysis of the pure 
enantiomers. Finally, samples of the enzymatically prepared amino acids were injected on the chiral 
stationary phase to determine their absolute configuration and enantiomeric excess. 
 
Table S1. Retention times of racemic mixtures of N-substituted aspartic acids as determined by 














r.t., retention time. 
  








A 3a 8.2 9.9 
B 3b 15.1 12.2 
C 3c 20.4 10.7 
D 3d 35.5 17.9 
E 3e 82.6 42.5 
F 3f 253.0 133.5 
G 3g 55.9 30.2 




1. Raj, H., Szymański, W., de Villiers, J., Rozeboom, H. J., Puthan Veetil, V., Reis, C. R., de 
Villiers, M., Dekker, F. J., de Wildeman, S., Quax, W. J., Thunnissen, A. M. W. H., Feringa, 
B. L., Janssen, D. B., and Poelarends G. J. (2012) Engineering methylaspartate ammonia lyase 
for the asymmetric synthesis of unnatural amino acids. Nat. Chem. 4, 478-484.  
2. Ohfune, Y., Kurokawa, N., Higuchi, N., Saito, M., Hashimoto, M., and Tanaka, T. (1984) An 

















Kinetic resolutions and stereoselective synthesis of  
3-substituted aspartic acids using engineered 
methylaspartate ammonia lyases 
Hans Raj,a Wiktor Szymanski,b Jandré de Villiers,a Vinod Puthan Veetil,a Wim J. Quax,a 
Keiko Shimamoto,c Dick B. Janssen,d Ben L. Feringa,b and Gerrit J. Poelarendsa 
a 
Department of Pharmaceutical Biology, Groningen Research Institute of Pharmacy, University of 
Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands. 
b 
Center for Systems Chemistry, Stratingh Institute for Chemistry, University of Groningen, 
Nijenborgh 4, 9747 AG Groningen, The Netherlands 
c
 Suntory Foundation for Life Sciences, Wakayamadai, Shimamotocho, Mishima-gun,  
Osaka 618-8503, Japan. 
d 
Department of Biochemistry, Groningen Biomolecular Sciences and Biotechnology Institute, 
University of Groningen, Nijenborgh 4, 9747 AG Groningen, The Netherlands. 






We describe kinetic resolutions and asymmetric synthesis of various valuable 3-substituted aspartic 
acids, which were obtained in fair to good yields with dr values of up to >98:2 and ee values of up 
to >99%, using engineered methylaspartate ammonia lyases. These biocatalytic methodologies for 







Optically pure aspartic acid derivatives are highly valuable as tools for biological research and as 
chiral building blocks for pharmaceuticals, nutraceuticals, and peptidomimetics.
[1, 2]
 The preparation 
of these amino acids remains a difficult and laborious task with conventional organic synthesis, and 
the use of a biocatalytic methodology can be an important and highly competitive alternative 
option.
[3-7]
 In recent years, the enzyme 3-methylaspartate ammonia lyase (MAL) has gained a lot of 
interest because of its potential for application in the asymmetric synthesis of substituted aspartic 
acids.
[7]
 MAL catalyzes the reversible addition of ammonia to mesaconate (1a) to give L-threo-
(2S,3S)-3-methylaspartate (L-threo-2a) and L-erythro-(2S,3R)-3-methylaspartate (L-erythro-2a) as 
products (Scheme 1).
[8]
 In addition to mesaconate, MAL also accepts fumarate as well as a few 2-
substituted fumarates (ethyl-, ethoxy-, ethylthio-, propyl-, isopropyl- and halo-derivatives) in the 
ammonia addition reaction.
[9-11]
 However, the enzyme has a narrow electrophile scope, and only 
displays amination activity towards fumarate derivatives with a small substituent at the C2 position. 
Interestingly, recent protein engineering work on MAL, which involved structure-guided saturation 
mutagenesis and activity screening, has resulted in the MAL variant L384A, which has a very broad 
electrophile scope in the ammonia addition reaction, including fumarate derivatives with large 
alkyl, aryl, alkoxy, aryloxy, alkylthio and arylthio substituents at the C2 position.
[11]
 The synthetic 
potential of both wild-type MAL and the L384A mutant has been demonstrated by their use as 
biocatalyst in the asymmetric synthesis of various 3-substituted aspartic acids. Unfortunately, 
however, the MAL- and L384A-catalyzed amination of fumarate derivatives gives varying degrees 
of diastereoselectivity, with several amination reactions yielding an undesired mixture of threo and 
erythro isomers of the corresponding 3-substituted aspartic acids.
[11]
 Obviously, this irregular 







Scheme 1. MAL-catalyzed amination of mesaconate (1a) to yield L-threo-(2S,3S)-3-methylaspartate (L-
threo-2a) and L-erythro-(2S,3R)-3-methylaspartate (L-erythro-2a). 
 
In previous work, we have shown that an alanine substitution at position His-194 in MAL 
resulted in a mutant enzyme with strongly enhanced diastereoselectivity in the amination of 
mesaconate.
[12]
 In the present study, we have exploited the high diastereo- and enantioselectivity of 
the H194A mutant in kinetic resolutions and asymmetric synthesis of various 3-substituted aspartic 
acids. In addition, we have combined the high stereoselectivity of the H194A mutant with the broad 
electrophile scope of the L384A mutant by generating the double mutant H194A/L384A, which has 
the unique ability to catalyze the diastereoselective amination of 2-butylfumarate to give 
exclusively threo-3-butylaspartic acid. 
To demonstrate the synthetic usefulness of the H194A mutant, a preparative-scale reaction 
using 0.05 mol% biocatalyst, ammonia (5 M) and mesaconate (1.0 g, 7.7 mmol, 77 mM) was 
performed (Scheme 2). Under these optimized conditions, the reaction was complete within 30 min 
at 25°C, achieving a final conversion of >95% (Table 1, entry 1). The amino acid product was 
purified (90% isolated yield) and identified as the threo isomer of 3-methylaspartic acid (d.r. >98:2) 
by comparison of its 
1
H NMR signals to those of authentic standards with known threo or erythro 
configuration. No other regio- or diastereoisomer was observed. The absolute configuration of the 
product was determined by high-performance liquid chromatography (HPLC) on a chiral stationary 
phase using authentic standards with known L-threo or D-threo configuration (Figure 1). This 
analysis revealed that the product has the L-threo configuration (Figure 1C) and is present as a 




application in the diastereo- and enantioselective synthesis of L-threo-(2S,3S)-3-methylaspartic acid 
(L-threo-2a, Scheme 2). 
 
Scheme 2. H194A- or H194A/L384A-catalyzed amination of fumarate derivatives 1a-1d to yield the 3-
substituted aspartic acids 2a-2d. 
 
Table 1. Preparative-scale synthesis of 3-substituted aspartic acids using MAL wild-type or 









The relative configuration of the isolated product was assigned by 
1
H NMR 
spectroscopy using reference compounds with known threo or erythro configuration. 
e
The purified product 
could be tentatively assigned the threo configuration on the basis of analogy. 
f
The enantiomeric excess of the 
isolated product was determined by chiral HPLC using authentic standards with known absolute 
configuration. 
g
Both the threo and erythro isomers have the L-configuration. ND, not determined.  














































Having established that the H194A mutant is highly diastereoselective, we have exploited this 
biocatalyst for the kinetic resolution of a mixture of L-threo and L-erythro isomers of 3-
methylaspartic acid (L-threo-2a and L-erythro-2a, respectively, in Scheme 3). As these two 
diastereoisomers are not commercially available, they were first synthesized using wild-type MAL 
as catalyst (Scheme 1). The preparative-scale reaction mixture contained 0.05 mol% biocatalyst, 
ammonia (5 M) and mesaconate (1.0 g, 7.7 mmol, 77 mM). The reaction was stopped after 24 h, 
resulting in a final conversion of >95% (Table 1, entry 2). The two amino acid products were 
purified (87% isolated yield), giving an ~1:1 mixture of L-threo-2a and L-erythro-2a (Figure 1B). 
Subsequently, this mixture of diastereoisomers was incubated with the H194A mutant to achieve 
selective deamination of L-threo-2a (Scheme 3). After 2 h of incubation, ~15% of the starting 
amount of L-threo-2a was still present. To achieve better conversion of L-threo-2a, the amino acid 
mixture was purified (to remove ammonia and mesaconate) and then incubated again with the 
H194A enzyme. After 2 h, the reaction was stopped, resulting in a final conversion of the starting 
material of >45% (Table 2, entry 1). The remaining amino acid product was purified (44% isolated 
yield) and its identity verified by 
1
H NMR spectroscopy and chiral HPLC (Figure 1D) as L-erythro-
(2S,3R)-3-methylaspartic acid (d.r. = 95:5). 
Next, the high enantioselectivity of the H194A mutant was exploited for the kinetic resolution 
of a racemic mixture of DL-threo-3-methylaspartic acid (165 mg, 1.12 mmol, 112 mM). With 0.05 
mol% of biocatalyst, the reaction (Scheme 4) was complete within 60 min, achieving >45% 
conversion of the starting material (Table 2, entry 2). The remaining amino acid product was 
purified (44% isolated yield) and its identity verified by 
1
H NMR spectroscopy and chiral HPLC as 
D-threo-(2R,3R)-3-methylaspartic acid (D-threo-2a, e.e. >99%). Taken together, the results 
demonstrate the usefulness of the H194A mutant for the preparation of various stereoisomers of the 






Scheme 3. Kinetic resolution of a mixture of L-threo-3-methylaspartate (L-threo-2a) and L-erythro-3-
methylaspartate (L-erythro-2a) using the H194A mutant as biocatalyst.  
 
 
Scheme 4. Kinetic resolution of a racemic mixture of DL-threo-3-methylaspartate using the H194A mutant 
as biocatalyst. 
 
Table 2. Kinetic resolutions of stereoisomeric mixtures of amino acids 2a and 2c using the MAL-









The relative configuration of the isolated product was assigned by 
1
H NMR 
spectroscopy using reference compounds with known threo or erythro configuration. 
e
The enantiomeric 
excess of the isolated product was determined by chiral HPLC using authentic standards with known 
absolute configuration. ND, not determined. 
  
















































Figure 1. Separation of stereoisomers of 3-methylaspartic acid by HPLC on a chiral stationary phase. (a) 
Chromatogram of a commercially available racemic mixture of L-threo-3-methylaspartic acid (L-threo-2a) 
and D-threo-3-methylaspartic acid (D-threo-2a). (b) Chromatogram of a ~1:1 mixture of L-threo-3-
methylaspartic acid (L-threo-2a) and L-erythro-3-methylaspartic acid (L-erythro-2a), which was prepared 
with wild-type MAL as biocatalyst. (c) Chromatogram of L-threo-3-methylaspartic acid (L-threo-2a), which 
was prepared with the H194A mutant as biocatalyst. (d) Chromatogram of L-erythro-3-methylaspartic acid 






To investigate the potential of the H194A mutant for the stereoselective synthesis of valuable 
unnatural amino acids, the amination of 2-methoxyfumarate (1b in Scheme 2) was selected as a 
model reaction for three reasons. First, substrate 1b shows close structural resemblance to 
mesaconate (1a), the natural substrate of MAL. Second, the presumed product of the amination 
reaction is 3-methoxyaspartic acid (2b in Scheme 2), which is an important inhibitor of the 
excitatory amino-acid transporters EAAT1-5.
[2a]
 Third, the selective chemical preparation of L-
threo-3-methoxyaspartic acid, the 2b isomer with the most potent inhibitory properties, is a highly 
challenging multiple-step synthesis procedure.
[13]
 To test whether H194A is able to catalyze the 
selective amination of 1b, a preparative-scale reaction using 0.05 mol% biocatalyst, ammonia (5 M) 
and 2-methoxyfumarate (100 mg, 0.685 mmol, 68.5 mM) was performed. The reaction was stopped 
after 7 d at 25°C, achieving a final conversion of 82% (Table 1, entry 3). The single amino acid 
product was purified (41% isolated yield) and identified as the desired threo isomer of 3-
methoxyaspartic acid (d.r. >98:2) by comparison of the 
1
H NMR signals (Figure 1A, 
Supplementary Information) to those of chemically synthesized L-threo-3-methoxyaspartic acid.
[13]
 
In contrast to the excellent diastereoselectivity of the H194A mutant, the wild-type MAL-catalyzed 
amination of 1b (using the same preparative-scale reaction conditions) yielded an undesired mixture 
of threo and erythro isomers of 2b (Figure 1B, Supplementary Information). 
To further explore the electrophile scope of the H194A mutant, its ability to catalyze the 
amination of 2-ethylthiofumarate (1c) and 2-butylfumarate (1d) was tested (Scheme 2). Whereas 1c 
is a known substrate for both wild-type MAL and the L384A mutant, the larger compound 1d is 
only accepted as substrate by the L384A mutant.
[11]
 Like wild-type MAL, the H194A mutant only 
shows activity with 1c, indicating that its substrate scope is also limited to fumarate derivatives with 
a small substituent at the C2 position (1a-1c in Scheme 2). A preparative-scale reaction [using 0.05 
mol% biocatalyst, 5 M ammonia and 57 mM 1c (100 mg, 0.57 mmol)] was stopped after 24 h, 
yielding a final conversion of 80% (Table 1, entry 4). The single amino acid product was purified 




>98:2) by comparison of the 
1
H NMR signals to those of chemically synthesized authentic 
standards with known threo or erythro configuration.
[11]
 Thus, unlike wild-type MAL and the 
L384A mutant which both catalyze the amination of 1c to yield an undesired mixture of 
diastereoisomers of 2c, the H194A mutant has exciting potential for the diastereoselective synthesis 
of threo-2c. 
Next, the high diastereoselectivity of the H194A mutant was exploited for the kinetic 
resolution of a mixture of threo- and erythro-2c. Because these two diastereoisomers are not 
commercially available, they were first synthesized using the L384A mutant as catalyst (0.05 
mol%) in a preparative-scale reaction, using ammonia (5 M) and 1c (100 mg, 0.57 mmol, 57 mM). 
The reaction was stopped after 72 h, resulting in a final conversion of 85% (Table 1, entry 5). The 
two amino acid products were purified (43% isolated yield), giving an ~1:1 mixture of threo-2c and 
erythro-2c. Subsequently, this mixture of diastereoisomers was incubated with the H194A mutant 
to achieve selective deamination of threo-2c. The reaction was complete in 3 h, resulting in >45% 
conversion of the starting material (Table 2, entry 3). The product was purified (40% isolated yield) 
and its identity verified by 
1
H NMR spectroscopy as erythro-3-(ethylthio)aspartic acid (d.r. = 95:5). 
The preceding results suggest that combining the high stereoselectivity of the H194A mutant 
with the broad electrophile scope of the L384A mutant could yield a new biocatalyst with the 
unique ability to catalyze the diastereoselective amination of 2-butylfumarate (1d, Scheme 2) and 
other fumarate derivatives with a large substituent at the C2 position. Accordingly, we have 
constructed the double mutant H194A/L384A and tested its synthetic usefulness in a preparative-
scale reaction, using 0.05 mol% biocatalyst, ammonia (5 M) and 2-butylfumarate (125 mg, 0.87 
mmol, 58.2 mM). The reaction was stopped after 24 h, resulting in 68% conversion (Table 1, entry 
6). The amino acid product was purified (40% isolated yield), identified as a single diastereoisomer 
(d.r. >98:2) of 3-butylaspartic acid by 
1
H NMR spectroscopy (2d, Scheme 2), and could be 






catalyzed amination of 1d yields an undesired mixture of diastereoisomers of 2d,
[11]
 the 
H194A/L384A mutant has striking potential for application in the diastereoselective synthesis of 
threo-3-butylaspartic acid. 
We have also tested 2-phenylthio- and 2-benzylthiofumarate, which are both aminated by the 
L384A mutant with poor diastereoselectivity,
[11]
 as potential substrates for the H194A/L384A 
mutant. Unfortunately, the double mutant showed very low-level amination activity with these 
fumarate derivatives, preventing the enzymatic synthesis of the corresponding amino acids. We 
have therefore initiated studies to enhance the catalytic activity of the H194A/L384A mutant by 
directed evolution. If these studies are successful, they may lead to a new biocatalytic methodology 
that provides simple and environmentally friendly access to a broad range of 3-substituted aspartic 
acids with a very high diastereomeric excess. 
In summary, we have demonstrated the potential of the H194A and H194A/L384A mutants 
for application in stereo- and regioselective amination reactions as well as kinetic resolutions of 
stereoisomeric mixtures to prepare a variety of 3-substituted aspartic acids with a very high 
diastereo- and enantiomeric excess. These attractive biocatalytic methodologies for the selective 
preparation of 3-substituted aspartic acids appear to be simple, environmentally friendly alternatives 
for existing chemical methods. This is best illustrated by the H194A-catalyzed synthesis of threo-3-
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Materials and general methods  
Mesaconic acid (1a), DL-threo-3-methylaspartic acid (DL-threo-2a), and other chemicals were 
purchased from Sigma-Aldrich unless stated otherwise. The fumaric acid derivatives 1b-1d and L-
threo-3-methoxyaspartic acid (L-threo-2b) were prepared according to previously described 
experimental procedures.
[1, 2]
 The sources for the biochemicals, buffers, solvents, components of 
Luria-Bertani (LB) media as well as the materials, enzymes, and reagents used in the molecular 
biology procedures are reported elsewhere.
[3, 4]
 Oligonucleotides for DNA amplification were 
synthesized by Operon Biotechnologies (Cologne, Germany). Escherichia coli strain XL1-Blue 
(Stratagene, La Jolla, CA) was used for cloning and isolation of plasmids. E. coli strain TOP10 
(Invitrogen) and the pBAD/Myc-His A expression vector (Invitrogen) were used for recombinant 
protein production. DNA sequencing was performed by Macrogen (Seoul, Korea). Protein was 
analyzed by polyacrylamide gel electrophoresis (PAGE) using sodium dodecyl sulfate (SDS) gels 
containing polyacrylamide (10%). The gels were stained with Coomassie brilliant blue. Protein 




Construction, expression and purification of MAL wild-type and mutants 
The construction of the H194A and L384A mutants has been reported elsewhere.
[1, 3]
 The double 
mutant H194A/L384A was constructed by the overlap extension PCR method
[6]
 using plasmid 
pBAD(MAL-His), which contains the wild-type MAL gene under the transcriptional control of the 
araBAD promoter, as the template and the primers that have previously been used for the 
construction of the individual mutants.
[1, 3]
 The final PCR products were gel-purified, digested with 
NdeI and HindIII restriction enzymes, and cloned in frame with both the initiation ATG start codon 
and the sequence that codes for the polyhistidine region of the expression vector pBADN/Myc-His 
A.
[3]




intended mutations had been introduced. Wild-type MAL and the mutant enzymes were 
overproduced in E. coli TOP10 cells harboring the appropriate expression vector and purified to 




Preparative-scale enzymatic synthesis of aspartic acid derivatives 
The 3-substituted aspartic acids (2a-2d) were synthesized using wild-type MAL or MAL mutants as 
catalyst in the ammonia additions to unsaturated acids 1a-1d. The general procedure is as follows. 
A solution of NH4Cl (5 M), unsaturated acid (0.57-7.7 mmol, 57-77 mM), and MgCl2 (20 mM) was 
prepared in water (10-100 mL), and the pH was adjusted to 9.0 by the addition of small aliquots of 
an aq. NaOH solution. The reactions were started by the addition of freshly purified enzyme (0.05 
mol%), and the reaction mixtures were incubated at 25°C. The progress of each reaction was 
monitored by UV-Vis and 
1
H NMR spectroscopy. The reactions were stopped (reaction times are 
given in the main text) by incubating the reaction mixture at 100°C for 10 min, and the enzyme was 
removed by filtration. The individual reaction mixtures were lyophilized, after which the amino 
acid product was purified using cation exchange chromatography (Dowex, 50W X8, 100-200 mesh 
size, Merck) by following a previously described protocol.
[1, 4]
 The ninhydrin-positive fractions 
were collected and concentrated under reduced pressure, followed by lyophilization to give the 
purified amino acid product as diammonium salt. 
 
L-threo-(2S,3S)-3-methylaspartic acid (L-threo-2a) 
Product L-threo-2a was synthesized using the H194A mutant as catalyst in the ammonia addition to 
mesaconate (1a). Conversion >95%. Yield 90% (1.25 g). White solid. 
1
H NMR (300 MHz, D2O): δ 
1.15 (d, 3H, 
3
J = 7.5 Hz, CHCH3), 2.97 (dq, 1H, 
3
J = 3.3 Hz, 
3
J = 7.6 Hz, CHCH3), 4.01 (d, 1H, 
3
J 
= 3.0 Hz, CHNH); 
13
C NMR (75 MHz, D2O): δ 11.7, 41.0, 56.5, 173.5, 181.3. HRMS (ESI+) m/z 
calc. for C5H10NO4: 148.0610 [M+H]
+
, found: 148.0604. HPLC (Chirex 3126-D-penicillamine, 




threo-3-methoxyaspartic acid (threo-2b) 
Product threo-2b was synthesized using the H194A mutant as catalyst in the ammonia addition to 
2-methoxyfumarate (1b). Conversion 82%. Yield 41% (55 mg). White solid. 
1
H NMR (500 MHz, 
D2O): δ 3.38 (s, 3H, OCH3), 4.00 (d, 1H, 
3
J = 2.4 Hz, CHNH2), 4.18 (d, 1H, 
3
J = 2.4 Hz, 
CHOCH3); 
13
C NMR (75 MHz, D2O): δ 56.4, 58.3, 80.0, 171.8, 175.8. HRMS (ESI+) m/z calc. for 
C5H10NO5: 164.0599 [M+H]
+
, found: 164.0553. 
 
threo-3-(ethylthio)aspartic acid (threo-2c) 
Product threo-2c was synthesized using the H194A mutant as catalyst in the ammonia addition to 2-
ethylthiofumarate (1c). Conversion 80%. Yield 26% (35 mg). Yellow solid. 
1
H NMR (500 MHz, 
D2O): δ 1.24 (t, 3H, 
3
J = 7.4 Hz, CH2CH3), 2.60-2.73 (m, 2H, SCH2CH3), 3.92 (d, 1H, 
3
J = 3.0 Hz, 
CH2SCH), 4.18 (d, 1H,
 3
J = 3.0 Hz, CHNH2); 
13
C NMR (125 MHz, D2O): δ 13.8, 26.5, 48.3, 55.3, 
171.7, 176.5. HRMS (ESI+) m/z calc. for C6H12NO4S: 194.0487 [M+H]
+
, found: 194.0481. 
 
threo-3-butylaspartic acid (threo-2d)  
Product threo-2d was synthesized using the H194A/L384A mutant as catalyst in the ammonia 
addition to 2-butylfumarate (1d). Conversion 68%. Yield 40% (78 mg). Pale brown solid. 
1
H NMR 
(500 MHz, D2O): δ 0.85 (t, 3H, 
3
J = 6.7 Hz, CH2CH3), 1.25-1.37 (m, 5H, CH(CH2)2CH3), 1.52-
1.59 (m, 1H, CHCH2CH2), 2.80-2.83 (m, 1H,
 
CHCHCH2), 3.92 (d, 1H, 
3
J = 3.1 Hz, CHNH2); 
13
C 
NMR (125 MHz, D2O): δ 15.7, 24.3, 28.9, 31.9, 49.2, 58.5, 175.6, 183.2. HRMS (ESI+) m/z calc. 
for C8H16NO4: 190.1079 [M+H]
+





Kinetic resolutions of isomeric mixtures of aspartic acid derivatives 
L-erythro-(2S,3R)-3-methylaspartic acid (L-erythro-2a)  
Product L-erythro-2a was prepared using the H194A mutant in the kinetic resolution of a mixture of 
L-threo- and L-erythro-2a. First, a mixture of L-threo- and L-erythro-2a was synthesized using 
wild-type MAL as catalyst in the ammonia addition to mesaconate (1a). This was done according to 
the general preparative-scale enzymatic synthesis procedure described above, and yielded ~1.2 g 
(87% yield) of ~1:1 mixture of L-threo- and L-erythro-2a. This stereoisomeric mixture was 
dissolved in water (30 mL), containing 1 mM KCl and 20 mM MgCl2 (final pH of 9.0). The 
reaction was started by the addition of freshly purified H194A enzyme (0.05 mol%), and the 
reaction mixture was incubated at 25°C. The progress of the reaction was monitored by UV-Vis and 
1
H NMR spectroscopy. After 2 h, the reaction was stopped and the product of the reaction was 
purified using cation exchange chromatography (Dowex, 50W X8, 100-200 mesh size, Merck) by 
following a previously reported protocol.
[1] 1
H NMR analysis revealed that the purified product 
consisted of about 15% L-threo-2a and 85% L-erythro-2a. To achieve better resolution, the product 
was incubated for a second time with the H194A enzyme. The reaction was stopped after 2 h 
(>45% conversion of the starting material), and the amino acid product was purified using the same 
cation-exchange protocol, giving an overall yield of 44% (530 mg). The final purified product was 
obtained as a white solid in the form of a diammonium salt, and contained <5% of L-threo-2a. The 
analytical data for L-erythro-2a are as follows. 
1
H NMR (500 MHz, D2O): δ 1.26 (d, 3H, 
3
J = 7.5, 
CHCH3), 2.84-2.95 (m, 1H, CHCH3), 3.66 (d, 1H, 
3
J = 5.3 Hz, CHNH); 
13
C NMR (125 MHz, 
D2O): δ 15.1, 41.5, 57.3, 173.8, 181.0. HRMS (ESI+) m/z calc. for C5H10NO4: 148.0610 [M+H]
+
, 
found: 148.0604. HPLC (Chirex 3126-D-pencillamine, 2 mM aq. CuSO4:iso-propanol; 90:10, flow 





Erythro-3-(ethylthio)aspartic acid (erythro-2c) 
Product erythro-2c was prepared using the H194A mutant in the kinetic resolution of a mixture of 
threo- and erythro-2c. First, a mixture of threo- and erythro-2c was synthesized using the L384A 
mutant as catalyst in the ammonia addition to 2-ethylthiofumarate (1c). This was done according to 
the general preparative-scale enzymatic synthesis procedure described above, and yielded 55 mg 
(43% yield) of ~1:1 mixture of threo- and erythro-2c. This stereoisomeric mixture was dissolved in 
water (10 mL), containing 1 mM KCl and 20 mM MgCl2 (final pH of 9.0). The reaction was started 
by the addition of freshly purified H194A enzyme (0.05 mol%), and the reaction mixture was 
incubated at 25°C. The progress of the reaction was monitored by UV-Vis and 
1
H NMR 
spectroscopy. After 3 h (>45% conversion of the starting material), the reaction was stopped and 
the product of the reaction was purified using cation exchange chromatography (40% yield, 20 mg). 
The final purified product was obtained as a yellow solid in the form of a diammonium salt, and 
contained only a trace amount of threo-2c. The analytical data for erythro-2c are as follows. 
1
H 
NMR (500 MHz, D2O): δ 1.23 (t, 3H, 
3
J = 7.3 Hz, SCHCH3), 2.54-2.64 (m, 2H, SCH2CH3), 3.29 
(d, 1H, 
3
J = 9.9 Hz, CHNH), 3.37 (d, 1H, 
3
J = 9.9 Hz, CHNH); 
13
C NMR (125 MHz, D2O): δ 13.9, 





D-threo-(2R,3R)-3-methylaspartic acid (D-threo-2a) 
Product D-threo-2a was prepared using the H194A mutant in the kinetic resolution of a racemic 
mixture of L-threo- and D-threo-2a. The racemic mixture of DL-threo-2a (165 mg, 1.12 mmol) was 
dissolved in water (10 mL), containing MgCl2 (20 mM) and KCl (1 mM). The pH of the solution 
was adjusted to 9.0 using aq. NaOH. The reaction was started by the addition of freshly purified 
H194A enzyme (0.05 mol%) and the reaction mixture was incubated at 25°C. After 1 h, the 
reaction was stopped by incubating at 100°C for 10 min and the product was purified using cation 




product was obtained as a white solid in the form of a diammonium salt. 
1
H NMR (500 MHz, D2O): 
δ 1.14 (d, 3H, 3J = 7.5 Hz, CHCH3), 2.96 (dq, 1H, 
3
J = 3.2 Hz, 
3
J = 7.5 Hz, CHCH3), 4.01 (d, 1H, 
3
J = 3.1 Hz, CHNH); 
13
C NMR (125 MHz, D2O): δ 11.8, 41.4, 56.5, 173.8, 181.6. HRMS (ESI+) 
m/z calc. for C5H10NO4: 148.0610 [M+H]
+
, found: 148.0604. HPLC (Chirex 3126-D-penicillamine, 









Supporting Figure 1. (a) 
1
H NMR spectrum of purified threo-3-methoxyaspartic acid, which was prepared 
using H194A as biocatalyst. (b) 
1
H NMR spectrum of purified 3-methoxyaspartic acid (a mixture of 
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Methylaspartate ammonia lyase (MAL) catalyzes the reversible addition of ammonia to mesaconate 
to yield L-threo-(2S,3S)-3-methylaspartate and L-erythro-(2S,3R)-3-methylaspartate as products. In 
the proposed minimal mechanism for MAL, Lys-331 acts as the (S)-specific base catalyst and 
abstracts the 3S-proton from L-threo-3-methylaspartate, resulting in an enolate anion intermediate. 
This enolic intermediate is stabilized by coordination to the essential active site Mg
2+
 ion and 
hydrogen bonding to the Gln-329 residue. Collapse of this intermediate results in the release of 
ammonia and the formation of mesaconate. His-194 likely acts as the (R)-specific base catalyst and 
abstracts the 3R-proton from the L-erythro isomer of 3-methylaspartate, yielding the enolic 
intermediate. In the present study, we have investigated the importance of the residues Gln-73, Phe-
170, Gln-172, Tyr-356, Thr-360, Cys-361 and Leu-384 for the catalytic activity of MAL. These 
residues, which are part of the enzyme surface lining the substrate binding pocket, were subjected to 
site-directed mutagenesis and the mutant enzymes were characterized for their structural integrity, 
ability to catalyze the amination of mesaconate, and regio- and diastereoselectivity. Based on the 
observed properties of the mutant enzymes, combined with previous structural studies and protein 
engineering work, we propose a detailed catalytic mechanism for the MAL-catalyzed reaction, in 
which the side chains of Gln-73, Gln-172, Tyr-356, Thr-360, and Leu-384 provide favorable 
interactions with the substrate, which are important for substrate binding and activation. This 






The enzyme methylaspartate ammonia lyase (MAL) catalyzes the reversible addition of ammonia to 
mesaconate (1) to yield L-threo-(2S,3S)-3-methylaspartate (2) and L-erythro-(2S,3R)-3-
methylaspartate (3) as products (Scheme 1).
[1, 2]
 MAL is used by the bacterium Clostridium 
tetanomorphum H1 as part of a catabolic pathway that converts L-glutamate, via 2, to yield acetyl-
CoA.
[1-3]
 In recent years, MAL has gained a lot of interest because of its potential for application in 
the asymmetric synthesis of a wide variety of aspartic acid derivatives.
[4-8]
 These non-proteinogenic 





Scheme 1. MAL catalyzed reversible amination of mesaconate (1) to yield L-threo-(2S,3S)-3-
methylaspartate (2) and L-erythro-(2S,3R)-3-methylaspartate (3). 
 
The structure of MAL and that of the isozyme from Citrobactor amalonaticus have been 
solved by X-ray crystallography.
[15, 16]
 On the basis of these structural studies,
[15-17]
 combined with 
kinetic isotope measurements
[18, 19]
 and mutagenesis experiments,
[20]
 a minimal mechanism has 
emerged for the MAL-catalyzed reaction. In this proposed mechanism, an (S)-specific (Lys-331) or 
(R)-specific (His-194) catalytic base abstracts the C3 proton of the respective stereoisomer of 3-
methylaspartate to generate an enolate anion intermediate that is stabilized by a hydrogen bond 




 Collapse of the 
enolic intermediate results in the elimination of ammonia and yields 1. This mechanism, however, 
is far from complete and the importance of other residues for the catalytic activity of MAL has not 




Figure 1. Crystal structure of MAL in complex with the natural substrate L-threo-(2S,3S)-3-
methylaspartate.
[16]
 (a) Close-up of the active site showing the hydrogen-bond interactions between the 
substrate’s carboxylate groups (C1 and C4) and the side chains of His-194, Gln-329, Gln-172 and Thr-360, 
or the main chain NH of Cys-361. The carbon atoms of the active site residues are shown in green, and those 
of the substrate in cyan. Hydrogen bonds are represented as dashed lines. The distance (in Ångstroms) 
between the C3 atom of the substrate and side chain of Lys-331 is shown (atoms connected by a solid line). 
The magnesium ion is shown as a magenta sphere. (b) Close-up of the active site showing the hydrogen-
bond interactions between the substrate’s amino group and the side chains of Gln-73 (via a water molecule) 
and Gln-172, as well as the observed distances (in Ångstroms, atoms connected by solid lines) between the 
substrate’s methyl group and the side chains of Leu-384, Phe-170 and Tyr-356. The magnesium ion and 
water molecule are shown as magenta and yellow spheres, respectively. Colour scheme as in (a). The figures 




The crystal structure of MAL complexed with its natural substrate 2 shows that the surface of 
the enzyme lining the substrate binding pocket is provided, in part, by residues Gln-73, Phe-170, 
Gln-172, Tyr-356, Thr-360, Cys-361 and Leu-384 (Figure 1).
[16]
 In the present study, we performed 
site-directed mutagenesis experiments on all these residues to provide insight into their roles in the 
catalytic mechanism for the MAL-catalyzed reaction. The mutant enzymes were characterized for 
their structural integrity, ability to catalyze the amination of mesaconate, and regio- and 
diastereoselectivity. Based on the observed properties of the mutant enzymes, combined with 




mechanism for the MAL-catalyzed reaction, with important roles for Gln-73, Gln-172, Tyr-356, 
Thr-360, and Leu-384 in substrate binding and activation. 
 
RESULTS  
Production, purification and characterization of the MAL mutants 
The surface of the protein lining the substrate binding site is provided by the residues shown in 
Figure 1.
[16]
 In a previous study, the roles of residues His-194, Gln-329 and Lys-331 in the catalytic 
mechanism of the MAL-catalyzed reaction have been investigated by site-directed mutagenesis.
[20] 
The residues selected for mutagenesis in the present study were Gln-73, Phe-170, Gln-172, Tyr-
356, Thr-360, Cys-361 and Leu-384 (Figure 1). Similar to wild-type MAL, all mutant proteins were 
constructed as His6-tagged fusion proteins, produced in E. coli TOP10 cells, and purified to >95% 
homogeneity (as assessed by SDS-PAGE) using a one-step Ni-based immobilized metal affinity 
chromatography procedure.
[20]
 This yielded about 20-30 mg of homogenous protein per liter of cell 
culture. 
Each MAL mutant was analyzed by non-denaturing PAGE (data not shown). The mutant 
enzymes were found to migrate comparably with the wild-type enzyme, which suggests that the 
homodimeric association of the mutants was still intact. The structural integrity of each mutant was 
also assessed by circular dichroism (CD) spectroscopy. The CD spectra of the mutants were 
comparable to that of wild-type MAL, suggesting that the mutations did not result in any major 
conformational changes (data not shown). 
 
Residues that interact with the substrate’s 1-carboxylate group 
The crystal structure of MAL in complex with 2 shows that the 1-carboxylate group of the substrate 
has hydrogen-bonding interactions with the main chain NH of Cys-361, the oxygen atom (Oγ) of 
Thr-360, and the nitrogen atom (Nε2) of Gln-172 (Figure 1a).[16] Residue Gln-172 also interacts, via 
hydrogen-bonding, with the 2-amino group of the substrate (Figure 1b).
[16]
 To investigate the 
 210 
 
importance of these residues for the catalytic activity and regio- and diastereoselectivity of MAL, 
six single site-directed mutants were constructed in which Thr-360 was replaced with either an 
alanine or a serine (T360A and T360S), Cys361 with either an alanine or a lysine (C361A and 
C361K), and Gln-172 with either an alanine or an asparagine (Q172A and Q172N). The amination 
activities of the mutants were assayed using 1 as the substrate.  
The mutation of Thr-360 to an alanine has a large effect on the catalytic efficiency of MAL. 
For the T360A mutant, a ~100-fold decrease in kcat and a ~22-fold increase in Km was observed, 
which results in a ~2200-fold decrease in kcat/Km (Table 1). Hence, the major effect of this mutation 
is on the value of kcat. The mutation of Thr-360 to another residue with an aliphatic hydroxyl group 
(serine), however, has a less drastic effect on the catalytic efficiency. For the T360S mutant, the 
kcat/Km is reduced only approximately 3.5-fold (Table 1).  
Obviously, mutations at position 361 cannot eliminate the main chain NH interaction with the 
substrate. As might therefore be expected, the removal of the side chain at this position, by the 
substitution of Cys-361 with an alanine, has hardly any effect on the catalytic efficiency of MAL. 
For the C361A mutant, there is a ~2.2-fold decrease in kcat and an approximately 4.2-fold increase 
in Km. As a result, the kcat/Km is reduced only ~9-fold (Table 1). However, the introduction of a new 
side chain at position 361, by mutation of Cys-361 to a lysine, essentially abolished enzymatic 



















 61 ± 1 0.7 ± 0.02 8.7 x 10
4
 
T360A 0.6 ± 0.1 15 ± 2.5 40 
T360S 35 ± 1 1.4 ± 0.3 2.5 x 10
4
 
C361A 27.5 ± 2.5 2.9 ± 0.5 9.5 x 10
3
 
C361K ND ND <0.1 
Q172A > 20 > 60 3.4 x 10
2
 
Q172N ND ND <0.1 
Q73A 0.7 ± 0.1 0.2 ± 0.02 3.5 x 103 
Q73N ND ND <0.1 
F170A 10 ± 1 0.9 ± 0.1 1.1 x 10
4
 
Y356A > 0.7 > 60 12 
L384A >16 > 60 2.7 x 10
2
 
[a] The steady state kinetic parameters were determined in 500 mM Tris-HCl buffer (pH 9.0) containing 20 
mM MgCl2 and 400 mM NH4Cl at 30ºC. Errors are standard deviations from each fit. ND, not determined. 




The mutation of Gln-172 to an alanine (i.e., removal of the functional side chain) has a large 
effect on the values of Km and kcat/Km. For the Q172A mutant, a plot of various concentrations of 1 
versus the initial rates measured at each concentration remained linear up to 60 mM. Hence, the 
Q172A mutant could not be saturated. Accordingly, only the kcat/Km was determined, and this 
parameter is reduced ~255-fold compared to that of wild-type MAL (Table 1). Because the increase 
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in Km for the Q172A mutant is >85-fold, the kcat must be >20 s
-1
. Surprisingly, the mutation of Gln-
172 to an asparagine, which has a side chain with a similar functional group, essentially abolished 
enzymatic activity (Table 1). 
The amination of 1 catalyzed by wild-type MAL and the mutants was also monitored by 
1
H 
NMR spectroscopy to identify the products of the reaction. This spectroscopic analysis showed that 
the ammonia additions to 1 catalyzed by the MAL mutants lead to the same amino acid product 
(i.e., 3-methylaspartate) as the corresponding wild-type MAL-catalyzed reaction. This demonstrates 
that the mutations at positions 172, 360 and 361 do not affect the regioselectivity of MAL. 
However, varying diastereomeric product ratios were observed. Consistent with the fact that MAL 
catalyzes the fast anti-addition and the much slower syn-addition of ammonia to 1,
[20]
 leading to the 
threo and erythro isomers of 3-methylaspartate, respectively, the 
1
H NMR spectra recorded after 2 
h predominantly showed the formation of 2, whereas the signals corresponding to 3 mainly 
appeared in later spectra (Table 2). After 7 days of incubation, the Q172A, T360A, T360S, and 
C361A mutant-catalyzed amination reactions resulted in 74%, 82%, 85%, and 78% conversion of 1 
into the amino acid product with a diastereomeric ratio (d.r.) of 89:11, 54:46, 51:49, and 53:47, 
respectively (Table 2). The reactions catalyzed by the Q172N and C361K mutants, which have low-
level amination activities, resulted in ~70% conversion of 1 into 3-methylaspartate with a d.r. of 




Table 2. Conversions and diastereomeric product ratios for the ammonia additions to mesaconate 
catalyzed by wild-type and mutant MAL
[a]
 




after 2 h 





after 7 d 
MAL 73 89:11 81 51:49 
T360A 38 93:7 82 54:46 
T360S 76 86:14 85 51:49 
C361A 47 >95:5 78 53:47 
C361K 10 >95:5 70 >95:5 
Q172A 16 >95:5 74 89:11 
Q172N 6 >95:5 68 >95:5 
Q73A 37 91:9 71 69:31 
Q73N 18 >95:5 74 >95:5 
F170A 63 >95:5 83  55:45 
Y356A 24 >95:5 74  80:20 
L384A 61  >95:5 75  86:14 
[a] Reactions were monitored by 
1
H NMR spectroscopy. [b] The d.r. [defined as threo-3-methylaspartate 
(2):erythro-3-methylaspartate (3)] of the amino acid product was determined by comparison of its 
1
H NMR 
signals in the crude reaction mixture to those of authentic standards of 2 and 3. 
 
Residues that interact with the substrate’s 2-amino group  
The crystal structure of MAL in complex with 2 shows that the 2-amino group of the substrate has 
hydrogen-bonding interactions with the oxygen atom (Oε1) of Gln-172 and, via a water molecule, 
with the nitrogen atom (Nε2) of Gln-73 (Fig. 1b).[16] The importance of Gln-172 for the catalytic 
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activity of MAL is described above. To investigate the importance of the Gln-73 residue for the 
catalytic activity and regio- and diastereoselectivity of MAL, this residue was mutated to either an 
alanine or an asparagine. These mutations are expected to completely remove the functional side 
chain (Q73A) or to replace the side chain with another one that has a similar functional group 
(Q73N). The replacement of Gln-73 with an alanine resulted in an active enzyme with a 87-fold 
reduction in kcat and a 3.5-fold decrease in Km, resulting in a ~25-fold lower kcat/Km compared to 
wild-type MAL (Table 1). Hence, the major effect of this mutation is on the value of kcat. 
Surprisingly, the Q73N mutant showed very low-level amination activity, preventing the 
measurement of kinetic parameters (Table 1). 
The ammonia additions to 1 catalyzed by the Q73A and Q73N mutants were also monitored 
by 
1
H NMR spectroscopy to identify the amino acid products of these reactions. After a 7 days 
incubation period, the Q73A- and Q73N-catalyzed amination reactions resulted in 71% and 74% 
conversion of 1 into 3-methylaspartate with d.r. values of 69:31 and >95:5, respectively (Table 2). 
No other amino acid products were observed, indicating that the regioselectivity of the enzyme is 
not influenced by the mutations at position 73. 
 
Residues lining the binding site for the substrate’s 3-methyl group 
The crystal structure of MAL in complex with 2 suggests that the side chains of Phe-170, Tyr-356 
and Leu-384 are involved in the formation of the binding pocket for the 3-methyl group of the 
substrate (Figure 1b).
[16]
 To study the importance of these residues for the catalytic activity and 
regio- and diastereoselectivity of MAL, each residue was replaced with an alanine. The mutation of 
Phe-170 to an alanine resulted in a mutant enzyme with a ~6-fold decrease in kcat and a ~1.3-fold 
higher Km, which results in an approximately 8-fold decrease in kcat/Km (Table 1). The substitutions 
of Tyr-356 and Leu-384 to an alanine, however, have a larger effect on the catalytic efficiencies of 
MAL (Table 1). For both the Y356A and L384A mutants, saturation by substrate 1 (up to 60 mM) 
could not be achieved and therefore only the kcat/Km was determined. A 7250- and 320-fold 
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reduction in kcat/Km was observed for the Y356A and L384A mutants, respectively. Hence, it is 
clear that the mutations at positions Tyr-356 and Leu-384 largely influence the Km for 1 (Table 1). 
The amination reactions catalyzed by the F170A, Y356A and L384A mutants were also 
followed by 
1
H NMR spectroscopy. After an incubation period of 7 days, the F170A-, Y356A- and 
L384A-catalyzed reactions resulted in about 83%, 74% and 75% conversion of 1 into 3-
methylaspartate with d.r. values of 55:45, 80:20 and 86:14, respectively (Table 2). No other amino 
acid products were observed, which indicates that the regioselectivity of the enzyme is also not 
influenced by the mutations at positions 170, 356 and 384. 
 
DISCUSSION 







 a minimal mechanism has emerged for the MAL-catalyzed reaction. In 
this proposed mechanism, Lys-331 acts as the (S)-specific base catalyst and abstracts the 3S-proton 
from L-threo-3-methylaspartate (2), resulting in an enolate anion intermediate (4 in Scheme 2). This 





His-194 and Gln-329 are thought to assist the Mg
2+
 ion in binding the substrate’s 4-carboxylate 
group and stabilizing the enolate intermediate. Collapse of this intermediate results in the release of 
ammonia and the formation of mesaconate (1). In addition to its proposed role in binding the 4-
carboxylate group of the substrate, His-194 is believed to also act as the (R)-specific base catalyst 
and abstracts the 3R-proton from the L-erythro isomer of 3-methylaspartate, yielding the enolic 
intermediate 4. The strongest support for this catalytic role of His-194 comes from the observation 
that the H194A mutant of MAL is highly diastereoselective and can be used as biocatalyst in the 
synthesis of exclusively the threo isomers of various 3-substituted aspartic acids.
[20, 22]
 In the 
present study, guided by the crystal structure of MAL complexed with the natural substrate 2, we 
have selected seven other active site residues for site-directed mutagenesis to provide further insight 
into the catalytic mechanism of MAL. The obtained results allow us to present of a full catalytic 
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mechanism for the MAL-catalyzed reaction, detailed knowledge of which can serve as an important 
guide for future protein engineering experiments. 
The crystal structure of MAL in complex with 2 shows that the 1-carboxylate group of the 
substrate has hydrogen-bond interactions with the main chain NH of Cys-361, Oγ of Thr-360, and 
Nε2 of Gln-172 (Figure 1a).[16] To examine the role of Gln-172 and Thr-360 in the mechanism of 
the MAL-catalyzed reaction, we have mutated these two residues. Complete removal of the 
functionality at position Thr-360 by replacement with an alanine leads to a ~2200-fold decrease in 
kcat/Km with a ~22-fold increase in the Km for 1. The same substitution at position Gln-172 also 
results in a reduced catalytic efficiency with a large increase (>85-fold) in the Km for 1. These 
observations, combined with the increase in activity and decrease in Km observed with a serine 
mutation at position Thr-360, support a role for the side chains of Thr-360 and Gln-172 in assisting 
the main chain NH of Cys-361 to bind and position the substrate (1, 2 or 3) through hydrogen-bond 
interactions with its 1-carboxylate group. 
The crystal structure of MAL in complex with 2 shows that the 2-amino group of the substrate 
has hydrogen-bond interactions with Oε1 of Gln-172 and, via a water molecule, with Nε2 of Gln-73 
(Figure 1b).
[16]
 This suggests roles for the functional groups of these residues in binding the amino 
group of 2 (or 3) in the deamination reaction or ammonia in the reverse addition to 1. Examination 
of the kinetic properties of the amination reaction catalyzed by the Q73A mutant, which is the only 
mutation at this position that resulted in an enzyme with significant activity, shows that there is only 
a minor effect on the value of Km for 1 (Table 1), suggesting that Gln-73 indeed does not play a role 
in binding this substrate. One potential explanation for the loss in activity (i.e., reduced kcat value) 
of the Q73A mutant is that Gln-73 could bind and position ammonia in a favorable orientation for 
amination of 1. Support for this view is provided by a recent study in which engineering of the 
amine binding pocket (i.e., saturation mutagenesis at positions Gln-73 and Gln-172), followed by 





 Interestingly, the Q73A mutation moved the specificity of MAL away from ammonia and 
towards alkylamines. For example, a comparison of kcat/Km values shows that wild-type MAL is 
~500-fold more efficient in ammonia addition to 1 than the Q73A mutant, whereas the Q73A 
mutant is at least 140-fold more efficient in the addition of methylamine to 1. These observations 
clearly indicate that Gln-73 is one of the residues that influences the amine specificity of MAL, 
strongly supporting the proposed role for Gln-73 in binding the amino group of 2 (or 3) in the 
deamination reaction or ammonia in the reverse addition to 1. 
The crystal structure of MAL complexed with 2 suggests that the enzyme surface lining the 
binding site for the 3-methyl group of the substrate is composed almost entirely of side chains, 
including those of Phe-170, Tyr-356 and Leu-384 (Figure 1b).
[16]
 To assess their role in catalysis, 
we have mutated these residues to an alanine. Examination of the kinetic properties for the Y356A 
and L384A mutants shows that there is a significant reduction in catalytic efficiency and a large 
increase (>85-fold) in the Km for 1, suggesting that these residues play a major role in binding the 
methyl group of the substrate. By contrast to these observations, examination of the kinetic 
properties for the F170A mutant shows that there is only a small effect of replacing Phe-170 to an 
alanine on the values of Km and kcat/Km, suggesting that Phe-170 is not directly involved in binding 
the methyl group of the substrate. Consistent with the observed distances between the substrate’s 
methyl group and the side chains of Leu-384, Phe-170 and Tyr-356 (Figure 1b),
[16]
 our results 
suggest that additional stabilization of the substrate in the active site is provided by favorable van 
der Waals packing interactions between the substrate’s methyl group and the side chains of Tyr-356 
and Leu-384, while the side chain of Phe-170 is likely too far away to provide a stabilizing 
interaction. Strong support for the interaction between Leu-384 and the methyl group of the 
substrate also comes from a recent protein engineering study, in which position Leu-384 was 
randomized, followed by screening of mutants for amination activity towards 2-hexylfumarate.
[23]
 
This approach yielded mutants L384G and L384A, and both mutations moved the specificity of 
MAL away from mesaconate and towards the unnatural substrate 2-hexylfumarate. Intriguingly, the 
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L384A mutant was shown to exhibit a broad substrate scope, including fumarate derivatives with 
alkyl, aryl, alkoxy, aryloxy, alkylthio and arylthio substituents at the C2 position. These 
observations indicate that Leu-384 is one of the residues that influences the substrate (i.e., fumarate) 
specificity of MAL, supporting a role for Leu-384 in assisting Tyr-356 to bind and position the 
substrate through van der Waals interactions with its methyl group. 
 Notably, all mutants described in this study retained the high regioselectivity of the wild-type 
enzyme, producing 3-methylaspartate as single amino acid product in the amination reaction. 
Hence, altering the regioselectivity of MAL probably requires the synergistic effects encountered 
by multiple simultaneous mutations. However, although all mutants exclusively produce 3-
methylaspartate, varying diastereomeric ratios (i.e., mixtures of L-threo and L-erythro isomers of 3-
methylasparate) were observed. Whereas the amination reactions catalyzed by most mutants 
provided a mixture of threo and erythro isomers, the amination reactions catalyzed by the C361K, 
Q172N, and Q73N mutants provided a single diastereoisomer having the threo configuration (Table 
2). It is important to emphasize that the latter mutants have very low-level amination activities. 
Given that for wild-type MAL the rate of anti-addition is approximately 100-fold higher than the 
rate for syn-addition,
[20, 24-26]
 and assuming that for these mutants both rates are equally reduced by 
the mutation, the amount of syn-addition product (i.e., the erythro isomer) formed in the reaction 
mixture might be too low to detect by 
1
H NMR spectroscopy. Hence, these mutant enzymes do not 




Scheme 2. A schematic representation of the proposed catalytic mechanism of the MAL-catalyzed reaction. 
 
On the basis of the results described in this study, the previously proposed minimal 
mechanism for the MAL-catalyzed deamination reaction can now be extended (Scheme 2). As 
described above, residues Lys-331, His-194 and Gln-329 and the Mg
2+
 ion play important roles in 
formation and stabilization of the enolate anion intermediate 4. In the next step, this enolic 
intermediate collapses and eliminates ammonia to form the mesaconate (1) product. Residues Gln-
73 (via a water molecule) and Gln-172 could position and ‘lock’ the amino group in a favorable 
orientation for deamination, whereas Thr-360 and Cys-361, assisted by Gln-172, play important 
roles in binding the substrate’s 1-carboxylate group. In addition, residues Tyr-356 and Leu-384 
provide stabilizing interactions with the substrate’s 3-methyl group. Together, these interactions are 
important for the optimal positioning and activation of the substrate, and are important determinants 
of the substrate specificity of MAL. This detailed understanding of the catalytic mechanism of 
MAL can serve as an important guide for future engineering experiments that aim to further expand 
the substrate scope of this fascinating enzyme. 
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MATERIALS AND METHODS  
Materials  
Mesaconic acid and other chemicals were purchased from Sigma-Aldrich Chemical Co. (St Louis, 
MO, USA), unless stated otherwise. The sources for the media components, buffers, solvents, pre-
packed PD-10 Sephadex G-25 columns, and molecular biology reagents, including PCR 
purification, gel extraction, and Miniprep kits, are reported elsewhere.
[20, 23, 26]
 Oligonucleotides for 
DNA amplification were synthesized by Operon Biotechnologies (Cologne, Germany). 
 
Bacterial strains, plasmids and growth conditions 
Escherichia coli strain XL1-Blue (Stratagene, La Jolla, CA) was used for cloning and isolation of 
plasmids. E. coli strain TOP10 (Invitrogen) was used in combination with the pBAD/Myc-His A 
vector (Invitrogen) for recombinant protein production. E. coli cells were grown in Luria-Bertani 
(LB) medium. When required, Difco agar (15 g/L), ampicillin (Ap, 100 g/mL), and/or arabinose 
(0.004% w/v) were added to the medium. 
 
General methods  
Techniques for restriction enzyme digestions, ligation, transformation, and other standard molecular 
biology manipulations were based on methods described elsewhere
[27]
 or as suggested by the 
manufacturer. PCR was carried out in a DNA thermal cycler (model GS-1) obtained from Biolegio 
(Nijmegen, The Netherlands). DNA sequencing was performed by Macrogen (Seoul, Korea). 
Protein was analyzed by polyacrylamide gel electrophoresis (PAGE) under either denaturing 
conditions using sodium dodecyl sulfate (SDS) or native conditions on gels containing 
polyacrylamide (10%). The gels were stained with Coomassie brilliant blue. Protein concentrations 
were determined by the Waddell method.
[28]
 Kinetic data were obtained on a V-650 
spectrophotometer from Jasco (IJsselstein, The Netherlands). The kinetic data were fitted by 
nonlinear regression data analysis by using the Grafit program (Erithacus, Software Ltd., Horley, 
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UK) obtained from Sigma Chemical Co. The CD spectra were recorded on a model 62A-DS 
spectropolarimeter from AVIV Biomedical Inc. (Lakewood, NJ, USA). 
1
H NMR spectra were 
recorded on a Varian Inova 500 (500 MHz) spectrometer using a pulse sequence for selective 
presaturation of the water signal. Chemical shifts for protons are reported in parts per million scale 
(δ scale) downfield form tetramethylsilane and are referenced to protium (H2O: δ = 4.80).  
 
Construction, expression and purification of MAL mutants 
The MAL mutants were generated by the overlap extension PCR method
[29]
 using plasmid 
pBAD(MAL-His), which contains the wild-type MAL gene under the transcriptional control of the 
araBAD promoter,
[20]
 as the template. The final PCR products were gel-purified, digested with NdeI 
and HindIII restriction enzymes, and ligated in frame with both the initiation ATG start codon and 
the sequence that codes for the polyhistidine region of the expression vector pBADN/Myc-His A. 
All mutant genes were completely sequenced (with overlapping reads) to verify that only the 
intended mutation had been introduced. Wild-type MAL and the mutant enzymes were 





Circular dichroism spectroscopy 
Circular dichroism (CD) spectra of the purified wild-type MAL and the purified mutants were 
measured in Tris-HCl buffer (5 mM, pH 8.0), containing MgCl2 (2 mM) and KCl (0.1 mM), at a 
concentration of approximately 3.0 µM in a CD cell with an optical path length of 1.0 mm. 
 
Kinetic assay  
The amination of 1 catalyzed by wild-type or mutant MAL was monitored by following the 
depletion of 1 at 240 nm or 270 nm in 500 mM Tris-HCl buffer (pH 9.0), containing 20 mM MgCl2 
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and 400 mM NH4Cl, at 30°C as described previously.
[20]
 The concentration of 1 used in the assay 
varied in the range 0.1 to 60 mM.  
 
Product analysis by 1H NMR spectroscopy 
The amino acid products of the amination of 1 catalyzed by wild-type or mutant MAL were 
identified by 
1
H NMR spectroscopy. Reaction mixtures consisted of 500 µL of a 1 M stock solution 
of NH4Cl in water (pH 9.0, containing 20 mM MgCl2), 100 µL of a 500 mM stock solution of 1 in 
water (pH 9.0, containing 20 mM MgCl2), and 100 µL of D2O. Reactions were started by the 
addition of 200 µg of freshly purified enzyme, and the reaction mixtures were incubated at 25°C. 
1
H 
NMR spectra were recorded 2 h and 7 days after the addition of enzyme. Given that MAL catalyzes 
the fast anti-addition and much slower syn-addition of ammonia to 1,
[20, 24, 25]
 leading to threo-
(2S,3S)-3-methylaspartate (2) and erythro-(2S,3R)-3-methylaspartate (3), respectively, we allowed 
the amination reactions to run for 7 days to detect the formation of low amounts of erythro product 
isomer, if present. Product amounts were estimated by integration of the signals corresponding to 2 
and 3 (if present). The 
1
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Methylaspartate ammonia lyase (MAL; EC 4.3.1.2) catalyzes the reversible addition of ammonia to 
mesaconate to give (2S,3S)-3-methylaspartate and (2S,3R)-3-methylaspartate as products. MAL is 
of considerable biocatalytic interest because of its potential use for the asymmetric synthesis of 
substituted aspartic acids, which are important building blocks for synthetic enzymes, peptides, 
chemicals, and pharmaceuticals. Here, we have cloned the gene encoding MAL from the 
thermophilic bacterium Carboxydothermus hydrogenoformans Z-2901. The enzyme (named Ch-
MAL) was overproduced in Escherichia coli and purified to homogeneity by immobilized metal 
affinity chromatography. Ch-MAL is a dimer in solution, consisting of two identical subunits (~49 




 ions for maximum activity. The optimum pH and temperature 
for the deamination of (2S,3S)-3-methylaspartic acid are 9.0 and 70°C (kcat = 78 s
-1
 and Km = 16 
mM). Heat inactivation assays showed that Ch-MAL is stable at 50°C for >4 h, which is the highest 
thermal stability observed among known MALs. Ch-MAL accepts fumarate, mesaconate, 
ethylfumarate and propylfumarate as substrates in the ammonia addition reaction. The enzyme also 
processes methylamine, ethylamine, hydrazine, hydroxylamine and methoxylamine as nucleophiles 
that can replace ammonia in the addition to mesaconate, resulting in the corresponding N-
substituted methylaspartic acids with excellent diastereomeric excess (>98% de). This newly 
identified thermostable MAL appears to be a potentially attractive biocatalyst for the stereoselective 




Enantiomerically pure amino acids constitute a significant part of the chiral building blocks for a 
range of natural products, pharmaceuticals, and agrochemicals.
[1-3]
 The synthesis of 
enantiomerically pure amino acids still remains a challenging task with traditional chemical 
catalysts.
[4, 5]
 In some cases, the use of biocatalysts is an attractive alternative option.
[6]
 Recently, 
the ammonia lyases and aminomutases (which exhibit ammonia lyase activity) have gained a lot of 
interest for the asymmetric synthesis of chiral α- and β-amino acids, with the advantage that they 
use readily available unsaturated acids as substrates.
[7-12]
 However, most known ammonia lyases 
show low stability and therefore they are not compatible with the harsh reaction conditions that are 
usually required for industrial processes, such as high temperature, high pH and high ammonia 
concentrations needed to catalyze the reverse reactions.
[7]
 Hence, there is a clear application for the 
discovery and characterization of novel ammonia lyases with increased stability. 
3-Methylaspartate ammonia lyase (MAL; EC 4.3.1.2) catalyzes the reversible amination of 
mesaconate (1) to give (2S,3S)-3-methylaspartate (2) as a major product and (2S,3R)-3-
methylaspartate (3) as a minor product (Scheme 1).
[13, 14]
 MAL was discovered initially in 
Clostridium tetanomorphum, and subsequently also in several other anearobic bacteria, where the 
enzyme forms part of the glutamate catabolic pathway that converts (S)-glutamic acid via 2 to 
finally yield acetyl-CoA.
[15]
 Recently, it has been shown that MAL also forms part of the 
methylaspartate cycle in haloarchaea, in which acetyl-CoA is oxidized to glyoxylate via 
methylaspartate. This is a novel pathway of carbon assimilation in addition to the already known 
glyoxylate cycle and ethylmalonyl-CoA pathway.
[16]
 
Microbial genome and metagenome sequencing projects have revealed that there is a large 
diversity of protein sequences that based on sequence similarities to C. tetanomorphum MAL (Ct-
MAL) might be classified as putative MALs. However, so far MALs have been isolated and 
characterized from only a few different organisms, including C. tetanomorphum, Bacterium 
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cadaveris, Morganella morganii, Citrobactor amalonaticus, Escherichia coli and Fusobacterium 
varium.
[13, 15, 17-20]
 The best studied MALs are those from C. tetanomorphum and C. amalonaticus, 
for both of which the structures have been solved by X-ray crystallography.
[21, 22]
 Based on these 
structural studies
[21, 22]
 and recent mutagenesis experiments,
[26]
 a mechanism has emerged for the 
MAL-catalyzed deamination reaction. In this proposed mechanism, a (S)- or (R)-specific catalytic 
base (Lys-331 and His-194, respectively; Ct-MAL numbering) abstracts the C-3 proton of the 
respective stereoisomer of 3-methylaspartate to generate an enolate anion intermediate that is 
stabilized by coordination to the essential active site Mg
2+
 ion. Collapse of this intermediate 
eliminates ammonia and yields the product, mesaconate. 
 
Scheme 1. MAL-catalyzed reversible amination of mesaconate to yield (2S,3S)- and (2S,3R)-3-
methylaspartate. 
 
Ct-MAL has been shown to accept a range of different nucleophiles (amines) and 
electrophiles (substituted fumarates). The broad substrate scope of Ct-MAL has been exploited for 
the stereoselective synthesis of various N-, 3-, and N,3-(di)substituted aspartic acids.
[23-25]
 A recent 
mutagenesis study on Ct-MAL has shown that the H194A, Q329A and K331A mutants display 
distinct diastereoselectivities and may be useful for the diastereoselective synthesis of (2S,3S)-3-
methylaspartic acid.
[26]
 Its broad substrate scope, high activity and stereoselectivity make Ct-MAL 
an attractive biocatalyst for organic synthesis. However, the enzyme is not stable upon long-term 
storage (at +4 or -80 C) and rapidly loses activity at elevated temperatures.
[13]
 Hence, in order to 
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use the MAL reaction for biocatalytic applications, it is essential to identify putative MAL 
isozymes with increased stability. 
In this study, we screened the microbial genomes available in the NCBI database for 
homologues of Ct-MAL with the aim to identify MALs from thermophilic microorganisms. Here, 
we report the identification of a MAL enzyme (designated Ch-MAL) from the thermophilic 
bacterium Carboxydothermus hydrogenoformans Z-2901, which was isolated from a hot spring in 
Russia and grows at very high temperatures,
[27, 28]
 that shares significant sequence identity (53%) 
with Ct-MAL. The gene encoding Ch-MAL was cloned, and the corresponding enzyme 
overproduced, purified, and subjected to kinetic and biochemical characterization. Ch-MAL shows 
optimal activity at 70°C and pH 9.0, and is stable at 50°C for >4 h, which is the highest thermal 
stability observed among reported MALs. Like Ct-MAL, Ch-MAL has a broad substrate scope, 
accepting various substituted fumarates and amines, and exhibits high activity and 
diastereoselectivity. This makes Ch-MAL an attractive enzyme for biocatalytic applications, as well 
as a promising scaffold for engineering to yield highly stable and efficient enzymes for the 
asymmetric synthesis of new aspartic acid derivatives. 
 
RESULTS 
Identification of a thermostable MAL 
A sequence similarity search in the NCBI microbial genome database was performed with the 
BLASTP program using the Ct-MAL amino acid sequence as the query. This search yielded several 
bacterial proteins that shared high sequence identity (>50%) with Ct-MAL. The top 20 hits included 
a sequence from the thermophilic bacterium C. hydrogenoformans Z-2901, which was isolated from 
a hot spring in Kunashir Island (Russia) and grows optimally at 78 C.
[27, 28]
 This bacterial protein 
(designated Ch-MAL) is annotated as a putative methylaspartate ammonia lyase and was selected 
for further study. 
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 The Ch-MAL protein is predicted to be 420 amino acids in length. Unlike the Ct-MAL 
gene, the gene encoding Ch-MAL is not located next to a gene encoding a putative glutamate 
mutase.
[15]
 In fact, the genomic context of the gene encoding Ch-MAL does not provide any clues 
about the biological function of this protein in C. hydrogenoformans Z-2901. The sequence of Ch-
MAL is 53% identical and 73% similar to that of Ct-MAL. A sequence alignment shows that nine 
of the ten active site residues of Ct-MAL are conserved in Ch-MAL
[22]
 (Figure S1, Supporting 
Information). The non-conserved residue, Thr-360, is replaced by Ser-359 in Ch-MAL. As there are 
no significant active site differences between Ch-MAL and Ct-MAL, a catalytic mechanism, with 
important roles for Lys-331 and His-194 (Ct-MAL numbering) as the S- and R-specific base/acid 
catalysts, similar to that of Ct-MAL
[26]
 may be expected for Ch-MAL. To obtain insight into the 
functional properties of this Ct-MAL homologue, Ch-MAL was overproduced, purified and 
subjected to kinetic and biochemical characterization (see below). 
 
Expression and purification of Ch-MAL 
The gene coding for Ch-MAL was amplified from genomic DNA of C. hydrogenoformans Z-2901 
and cloned into the expression vector pBADN/Myc-His A, resulting in the construct pBAD(Ch-
MAL). The Ch-MAL encoding gene in pBAD(Ch-MAL) is under transcriptional control of the 
araBAD promoter and the recombinant enzyme was produced upon induction with arabinose in E. 
coli TOP10 as a C-terminal His6-tag fusion protein. Optimal expression of the Ch-MAL gene was 
achieved when the TOP10 cells were cultivated at 22°C in an auto-induction medium
[31]
 in the 
presence of 0.05% (w/v) arabinose. The recombinant enzyme was purified by a one-step Ni-
sepharose affinity chromatography protocol, which typically provides ~200 mg of homogeneous 
enzyme per liter of culture. The purified Ch-MAL has a molecular mass of ~50 kDa when analyzed 
by SDS-PAGE. Ch-MAL was further analyzed by electrospray ionization mass spectrometry (ESI-
MS) and gelfiltration chromatography. Analysis of Ch-MAL by ESI-MS showed, upon 
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deconvolution, one major peak that corresponds to a mass of 49291 (± 3) Da. A comparison of this 
value to the calculated mass (49288 Da) indicates that, in contrast to Cys-361 in Ct-MAL,
[22]
 no 
oxidation of the active site cysteine (Cys-360) in Ch-MAL had occurred upon purification. Gel 
filtration chromatography resulted in elution of Ch-MAL as a single symmetrical peak, which 
corresponds to a native molecular mass of ~100 kDa. A comparison of this value to that of the 
subunit mass suggests that, like Ct-MAL (22), Ch-MAL is a homodimeric protein. 
 
Ammonia lyase activity of Ch-MAL 
To examine whether Ch-MAL exhibits ammonia lyase activity, the enzyme was incubated with 2 
(in 500 mM Tris-HCl buffer, pH 9.0) and the reaction was monitored by a previously described 
spectroscopic assay.
[26]
 The results show that Ch-MAL deaminates 2 to yield 1, and maximum 
activity is achieved in the presence of both Mg
2+
 (≥20 mM) and K+ (≥1 mM) ions in the assay 
buffer. Having established that Ch-MAL exhibits methylaspartate ammonia lyase activity, kinetic 
parameters were measured (at 30°C) and compared to those previously measured for Ct-MAL 







, which is ~25-fold lower than the value measured for the same reaction catalyzed by Ct-
MAL. 
 
Optimum pH and temperature for the ammonia lyase activity of Ch-MAL 
The optimum pH for the Ch-MAL–catalyzed deamination of 2 was determined at 30°C in Tris-HCl 
buffers (500 mM, containing 20 mM MgCl2 and 1 mM KCl) with pH values ranging from 6.0-9.5. 
The Ch-MAL enzyme is active in the complete pH range tested and shows maximum activity at pH 
9.0 (Figure 1a). A similar pH optimum was found for Ct-MAL (Figure 1a). The optimum 
temperature for the deamination of 2 by Ch-MAL was determined in Tris-HCl buffer (500 mM, pH 
9.0, containing 20 mM MgCl2 and 1 mM KCl) at different temperatures ranging from 10 to 90°C. 
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Ch-MAL was active at all temperatures analyzed, and showed the highest activity at 70°C (Figure 
1b). For comparison, Ct-MAL was found to be active at temperatures ranging from 10 to 70°C with 
maximum activity at 50°C (Figure 1b). The observation that Ch-MAL shows maximum activity at 
70°C, prompted us to measure kinetic parameters at this temperature. At 70°C, Ch-MAL catalyzes 
the deamination of 2 with a kcat of 78 s
-1
 and a Km of 16 mM, which results in a kcat/Km that is 
slightly higher (1.4-fold) than that measured at 30°C (Table 1). The observed 4.9-fold increase in 
kcat confirms that Ch-MAL is more active at elevated temperatures. At 70 C, Ct-MAL is almost 
completely inactive (Figure 1b). 
 













 89 ± 4 1.0 ± 0.1 8.9 x 10
4 
 
Ch-MAL (at 30°C) 16 ± 1 4.6 ± 0.4 3.5 x 10
3
 




The steady state kinetic parameters were determined in Tris-HCl buffer (500 mM, pH 9.0) containing 
MgCl2 (20 mM) and KCl (1 mM) at 30°C or 70°C. 
[b]
 These kinetic data were obtained from Raj et al.
[26]
 
Errors are standard deviations from each fit. 
 
Thermostability of Ch-MAL 
The preceding results demonstrate that Ch-MAL and Ct-MAL have different temperature-activity 
profiles, with Ch-MAL being active at higher temperatures. To compare the thermostability of these 
two MALs, they were incubated at 50°C (in separate incubations) and samples were withdrawn 
every 5 min to measure residual ammonia lyase activity. Interestingly, Ch-MAL stayed fully active 
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upon incubation at 50°C. Even after 4 h of incubation, the enzyme retained more than 95% of its 
initial activity towards 2 (Figure 2). In contrast, the ammonia lyase activity of Ct-MAL decreased 
rapidly upon incubation at 50°C, and within 30 min half of its initial activity was lost. After 4 h, Ct-
MAL retained only ~4% of its initial activity towards 2. Hence, in contrast to Ct-MAL, Ch-MAL is 
highly stable at 50°C. 
 
 
Figure 1. Effect of (a) pH and (b) temperature on the deamination activity of Ch-MAL (filled triangles) and 




Figure 2. The thermostability of Ch-MAL (filled triangles) and Ct-MAL (empty squares) upon incubation at 
50 C. 
 
Amination activity of Ch-MAL 
The rate of amination of 1 by Ch-MAL was monitored by following the depletion of 1 at 270 nm in 
Tris-HCl buffer (500 mM, pH 9.0) containing MgCl2 (20 mM) and NH4Cl (400 mM) at 30°C.
[24, 26]
 






, which is 
only 3.5-fold lower than the value measured for the same reaction catalyzed by Ct-MAL (Table 2). 
The Ch-MAL-catalyzed amination of 1 was also monitored by 
1
H NMR spectroscopy to verify that 
the products of the reaction are 2 and 3 (Scheme 1). The Ch-MAL catalyzed amination of 1 indeed 
yields 2 and 3, as indicated by signals in the NMR spectra consistent with the structures of these 
amino acid products (Figure 3a). Although the 
1
H NMR spectra showed signals for both 2 and 3, 
those corresponding
 
to 2 predominated in the initial spectra whereas signals for 3 increased in the 
later spectra. Hence, 2 is the kinetically preferred product. After a 14 day-incubation period at 
22 C, a final conversion of ~76% was achieved, giving a ~1:1 ratio of 2:3 (Figure 3a) (Table 3). For 
comparison, the Ct-MAL-catalyzed amination of 1 was also followed by 
1
H NMR spectroscopy, 
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showing the same kinetic profile of product (2 and 3) formation (Figure 3b) (Table 3). These results 
suggest that, like Ct-MAL, Ch-MAL likely catalyzes the rapid anti-addition and the much slower 

















 61 ± 1 0.7 ± 0.02 8.7  10
4
 




 The steady state kinetic parameters were determined in Tris-HCl buffer (500 mM, pH 9.0) containing 
MgCl2 (20 mM) and NH4Cl (400 mM) at 30°C. 
[b] 
These kinetic data were obtained from Raj et al.
[26]
 Errors 
are standard deviations from each fit. 
 
Electrophile scope of Ch-MAL 
It has previously been determined that Ct-MAL accepts fumarate and several of its 2-substituted 
derivatives as alternative substrates.
[23, 24]
 These observations prompted us to examine whether Ch-
MAL also catalyzes the amination of these electrophiles. The Ch-MAL-catalyzed addition reactions 
were monitored by 
1
H NMR spectroscopy. To identify the products of the reactions and to establish 
their relative configuration (threo or erythro), we compared the 
1
H NMR spectra of the products of 
the Ch-MAL-catalyzed addition reactions to those obtained for the same reactions catalyzed by Ct-
MAL, the products of which have previously been identified and their absolute configuration 
assigned.
[23]
 Representative conversions for each reaction are summarized in Table 3. Both MALs 
efficiently catalyze the amination of fumarate and ethylfumarate (in addition to the natural substrate 
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methylfumarate). While Ct-MAL has reasonable activity towards propylfumarate, this compound is 
a poor substrate for Ch-MAL. Butylfumarate is not accepted as substrate by either MAL. 
 
      
Figure 3. 
1
H NMR spectra monitoring the amination of 1 by (a) Ch-MAL and (b) Ct-MAL. The 
1
H NMR 
signals for 1, 2, and 3 were previously reported.
[26]
 Impurity (Tris):  = 3.5 (s). 
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Fumarate 99 (7) ee >99%
 
99 (7) ee >99%
 
Methylfumarate 76 (14) d.r. = 52:48 81 (14) d.r. = 51:49 
Ethylfumarate 65 (14) d.r. = 95:5 71 (14) d.r. = 72:28 
Propylfumarate ~7 (14) d.r. = 100:0 61 (14) d.r. = 100:0 
[a]
 The enantiomeric excess of the (S)-aspartic acid product was determined by chiral HPLC.
 [b]
 The 





Fumarate appears to be the best non-natural substrate for Ch-MAL, showing ~97% 
conversion after 2 h of incubation. The 
1
H NMR spectrum recorded 7 days after the addition of 
enzyme showed the nearly complete disappearance of the signals corresponding to fumarate and the 
formation of new signals corresponding to the expected product, aspartate (Figure S2). The absolute 
configuration of this product was determined by using chiral HPLC, with authentic (R)-and (S)-
aspartate for comparison, and found to be (S)-aspartate (>99% ee). Ethylfumarate is also a good 
substrate for Ch-MAL, showing ~60% conversion after 2 h of incubation. After a 14-day incubation 
period, a final conversion of ~65% was achieved and the spectrum showed signals corresponding to 
the expected products threo-(2S,3S)-3-ethylaspartate (P1) and erythro-(2S,3R)-3-ethylaspartate 
(P2). The ratio of S:P1:P2 was determined to be 35:60:5 (Figure S3). Propylfumarate is a poor 
substrate for Ch-MAL; the spectrum recorded after 14 days of incubation showed only ~7% 
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conversion of substrate with formation of threo-(2S,3S)-3-propylaspartate as the expected product 
(Figure S4). The tentative assignment of the absolute configuration of the 3-ethylaspartate and 3-
propylasparate products was made on the basis of analogy to the known configuration of the 




Nucleophile scope of Ch-MAL 
We next screened Ch-MAL for its ability to add different unnatural amines to mesaconate (1). The 
reactions were followed by using 
1
H NMR spectroscopy. The products were identified (and their 
relative configuration established) by comparing the 
1
H NMR spectra of the Ch-MAL-catalyzed 
addition reactions to those obtained for the same reactions catalyzed by Ct-MAL, the products of 
which have previously been identified and their absolute configuration assigned.
[25]
 Representative 
conversions for each reaction are summarized in Table 4. Both MALs efficiently catalyze the 
addition of hydroxylamine and hydrazine (in addition to the natural nucleophile, ammonia) to 
mesaconate. Methylamine, ethylamine and methoxylamine are also processed by both MALs, but at 
a much lower catalytic rate. Propylamine is not accepted as alternative nucleophile by either MAL. 
 Hydroxylamine and hydrazine seem to be the best alternative nucleophiles for Ch-MAL, 
showing ~80% and ~60% conversion after 2 h of incubation, respectively. For both these amines, 
1
H NMR spectra recorded 7 days after the addition of enzyme showed the nearly complete 
disappearance of the signals corresponding to mesaconate (1) and the formation of new signals 
corresponding to the expected products, threo-(2S,3S)-N-hydroxy-3-methylaspartate and threo-
(2S,3S)-2-hydrazino-3-methylaspartate, respectively (Figures S8 and S9) (Table 4). Methylamine 
and ethylamine are also accepted as substrates, showing ~12% and <1% conversion after 2 h of 
incubation, respectively. After a 14 day-incubation period, respective conversions of ~70% and 
~30% were achieved (Table 4) and the 
1
H NMR spectra showed signals corresponding to the 
expected products, threo-(2S,3S)-N,3-dimethylaspartate and N-ethyl-3-methylaspartate, respectively 
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(Figures S5 and S6). The relative configuration of the latter product has not been determined. 
Methoxylamine is a poor substrate for Ch-MAL. The spectrum recorded after 14 days of incubation 
showed only ~9% conversion of substrate with formation of threo-(2S,3S)-N-methoxy-3-
methylaspartate as the expected product (Figure S7). The tentative assignment of the absolute 
configuration of the amino acid products was again made on the basis of analogy. 
Table 4. Addition of various amines to mesaconate catalyzed by Ch-MAL or Ct-MAL
[a]
. 
Amine Ch-MAL % conversion 
(days of incubation) 
Ct-MAL % conversion 
(days of incubation) 
Ammonia 76 (14) 81 (14) 
Methylamine
[b]
 70 (14) 64 (14) 
Ethylamine
[b]
 30 (14) 14 (14) 
Methoxylamine
[b]
 9 (14) 67 (14) 
Hydroxylamine
[b]
 99 (7) 96 (7) 
Hydrazine
[b]
 100 (7) 100 (7) 
[a]
 Reactions were followed by 
1
H NMR spectroscopy. 
[b] 
The enzyme showed high diastereoselectivity in the 
formation of the corresponding amino acid product (>98% de). 
 
Preparative scale synthesis of threo-(2S,3S)-N,3-dimethylaspartic acid 
In order to demonstrate the potential of Ch-MAL for chemical synthesis, the enzyme was used to 
synthesize threo-(2S,3S)-N,3-dimethylaspartic acid at preparative scale. Accordingly, Ch-MAL was 
incubated with methylamine (1.04 g, 15.4 mmol) and mesaconate (0.2 g, 1.54 mmol) at 50°C, and 
the reaction was monitored by 
1
H NMR spectroscopy (Figure 4a); after 8 days of incubation, a final 
conversion of ~75% was achieved. The product was purified using a Dowex cation exchange 
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column, giving a final yield of 61% (white solid), and identified as threo-(2S,3S)-N,3-
dimethylaspartic acid by 
1
H NMR (Figure 4b),
13
C NMR and HRMS.
[25]
 The enzyme showed high 
diastereoselectivity in the formation of threo-(2S,3S)-N,3-dimethylaspartic acid (>98% de, as 
assessed by 
1
H NMR spectroscopy). 
 
Figure 4. Enzymatic synthesis of threo-(2S,3S)-N,3-dimethylaspartic acid. (a) Progress curve of the Ch-
MAL-catalyzed methylamine addition to mesaconate (1) as monitored by 
1
H NMR spectroscopy. (b) 
1
H 
NMR spectrum of purified threo-(2S,3S)-N,3-dimethylaspartic acid. The 
1







The thermophilic, Gram-positive bacterium C. hydrogenoformans Z-2901 has attracted much 
interest because of its unique biology: it grows at very high temperature, it lives almost entirely on a 
diet of carbon monoxide, and it converts water to hydrogen gas as part of its metabolism. The 
genome sequence of this extreme thermophile contains two open reading frames coding for putative 
MALs.
[28]
 It can be anticipated that the MALs from C. hydrogenoformans exhibit increased 
thermostability compared to known MALs from mesophilic hosts.
[13, 15, 17-20]
 
 Herein, we have described the cloning, recombinant expression and purification of Ch-MAL 
from C. hydrogenoformans Z-2901, which provided an opportunity to characterize the substrate 
specificity and thermostability of a MAL isozyme from an extreme thermophile. The enzyme can 
be highly overproduced in E. coli in a soluble and active form and rapidly purified with the help of 
a C-terminal hexahistidine tag. The thermostability, activity and substrate specificity of Ch-MAL 
were compared to Ct-MAL, the best studied MAL from a mesophilic host. As might be expected, 
Ch-MAL and Ct-MAL have different temperature-activity profiles, with Ch-MAL being active at 
much higher temperature. Ch-MAL catalyzes the deamination of (2S,3S)-3-methylaspartate (2, 












 at 70 C, which is 
somewhat lower (18- to 25-fold) than the value measured for the same conversion catalyzed by Ct-
MAL at 30°C. The lower catalytic efficiency of the Ch-MAL catalyzed reaction results mainly from 
a higher Km value, which suggests less optimal binding of 2 in the active site of Ch-MAL. A 
comparison of the kinetic parameters for the Ch-MAL and Ct-MAL catalyzed amination of 1 (Table 
2) shows similar catalytic efficiencies for both enzymes. These results indicate that Ch-MAL 
functions as an effective 3-methylaspartate ammonia lyase, catalyzing the reversible addition of 
ammonia to mesaconate to give (2S,3S)-3-methylaspartate and (2S,3R)-3-methylaspartate as 
products. Activity measurements further showed that Ch-MAL is highly thermostable and retains 





Ch-MAL can be stored at 4 C for several months without significant loss of activity. Thus, Ch-




 Ch-MAL has been shown to catalyze the regioselective addition of ammonia to several 
substituted fumarates, resulting in the corresponding 3-substituted aspartic acids with the threo-
isomers being the kinetically preferred products (Table 3). Also, the enzyme is highly 
enantioselective in the addition of ammonia to fumarate, leading to the formation of (S)-aspartic 
acid with >99% ee. While Ch-MAL efficiently processes fumarate and small substituted fumarates 
such as methylfumarate and ethylfumarate, it displays low (propylfumarate) or no (butylfumarate) 
activity with larger substrates. This suggests that the binding pocket for the C-2 alkyl substituent in 
Ch-MAL is designed to bind small alkyl chains and excludes large groups. A similar electrophile 
scope and isomer preference was found for Ct-MAL (Table 3). Ch-MAL (and Ct-MAL) also 
accepts various unnatural amines in the addition to mesaconate, yielding the corresponding N-
substituted methylaspartic acids (Table 4). The enzyme efficiently processes small substituted 
amines such as hydroxylamine and hydrazine, but displays low (methylamine, ethylamine and 
methoxylamine) or no (propylamine) activity with larger amine nucleophiles. These observations 
suggest that the amine binding pocket of Ch-MAL (and Ct-MAL) is designed to bind small amine 
compounds and excludes large nucleophiles. In contrast to the enzyme-catalyzed ammonia addition 
reactions, both MALs showed high diastereoselectivity in the amine additions to mesaconate, 
resulting in the formation of the N-substituted methylaspartic acids with high diastereomeric access 





 In conclusion, Ch-MAL from C. hydrogenoformans Z-2901 can be overproduced in E. coli 
and purified in high yield. This MAL is a promising new biocatalyst because it is highly 
thermostable and accepts various substituted fumarates and amines to produce a range of aspartic 
acid derivatives. These chiral amino acids are important building blocks for synthetic enzymes, 
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peptides, chemicals, and pharmaceuticals.
[32, 33, 34]
 To further enlarge the substrate scope of MAL 
and improve its stereoselectivity in the amination reactions, protein engineering experiments, 
guided by the previously published crystal structure of C. amalonaticus MAL in complex with 
substrate 2,
[21]
 have been initiated in our laboratory. If successful, these efforts may help to increase 
the number and diversity of enzyme applications in industry. 
 
MATERIALS AND METHODS 
Materials 
All chemicals were purchased from Sigma-Aldrich unless stated otherwise. The sources for the 
media components, buffers, solvents, Pre-packed PD-10 Sephadex G-25 columns, and molecular 
biology reagents, including PCR purification, gel extraction, and Miniprep kits, are reported 
elsewhere.
[26]
 Oligonucleotides for DNA amplification were synthesized by Operon 
Biotechnologies (Cologne, Germany). 
 
Bacterial strains, plasmids, and growth conditions  
E. coli strain TOP10 (Invitrogen) was used for cloning, isolation of plasmids and, in combination 
with the pBAD/Myc-His A vector (Invitrogen), for recombinant protein production. The genomic 
DNA of C. hydrogenoformans Z-2901, the source of the Ch-MAL gene, was kindly provided by 
Professor Frank Robb (Center of Marine Biotechnology, University of Maryland, USA). E. coli 
TOP10 cells were grown in Luria-Bertani (LB) medium containing 100 µg/mL ampicillin (Ap). Ct-




General methods  
BLASTP searches of the National Center for Biotechnology Information (NCBI) databases were 
performed using the Ct-MAL amino acid sequence (GenBank: AAB24070.1) as the query 
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sequence. Amino acid sequences were aligned using a version of the CLUSTALW multiple-
sequence alignment routines available in the computational tools at the EMBL-EBI website. 
Techniques for restriction enzyme digestions, ligation, transformation, and other standard molecular 
biology manipulations were based on methods described elsewhere
[29]
 or as suggested by the 
manufacturer. PCR was carried out in a DNA thermal cycler (model GS-1) obtained from Biolegio 
(Nijmegen, The Netherlands). DNA sequencing was performed by Macrogen (Seoul, Korea). 
Proteins were analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
under denaturing conditions on gels containing polyacrylamide (10%). The gels were stained with 
Coomassie brilliant blue. Protein concentrations were determined by the Waddell method.
[30]
 
Kinetic data were obtained on a V-650 spectrophotometer from Jasco (IJsselstein, The 
Netherlands). High Performance Liquid Chromatography (HPLC) was performed using a Waters 
510 HPLC Pump (Waters Corporation, USA) in combination with a variable wavelength UV 
detector 875-UV (Jasco) and a BD112 recorder (Kipp and Zonen, The Netherlands). 
1
H NMR 
spectra were recorded on a Varian Inova 500 (500 MHz) spectrometer using a pulse sequence for 
selective suppression of the proton signals for water by presaturation methods. 
1
H chemical shifts 
( ) are reported in parts per million (ppm) downfield from tetramethylsilane and are calibrated on 
protons in the NMR solvents (H2O:  = 4.79). 
 
Construction of the expression vector for the production of Ch-MAL 
The Ch-MAL gene was amplified from genomic DNA of C. hydrogenoformans Z-2901 (28) using 
two synthetic primers and high fidelity Phusion polymerase by following the protocol supplied with 
the polymerase (Finnzymes, Espoo, Finland). The forward primer (5’-G GAG CGG TGG CAT 
ATG AGA ATA AAA GAT G -3’) contains an NdeI restriction site (in bold) followed by 13 bases 
corresponding to the coding sequence of the Ch-MAL gene. The reverse primer (5’- CC TTC CGG 
AAG CTT ACC AAC TTT TTT CTG AAA TGT GAC C -3’) contains a HindIII restriction site (in 
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bold) followed by 25 bases corresponding to the complementary sequence of the Ch-MAL gene. 
The resulting PCR product and the pBADN/Myc-His A vector were digested with NdeI and HindIII 
restriction enzymes, purified, and ligated using T4 DNA ligase. Aliquots of the ligation mixture 
were transformed into competent E. coli TOP10 cells. Transformants were selected at 37°C on 
LB/Ap plates. Plasmid DNA was isolated from several colonies and analyzed by restriction analysis 
for the presence of the insert. The cloned Ch-MAL gene was sequenced to verify that no mutations 
had been introduced during the amplification of the gene. 
 
Expression and purification of Ch-MAL 
The Ch-MAL enzyme was produced in E. coli TOP10 using the pBADN expression system. Fresh 
TOP10 cells containing the appropriate expression plasmid were collected from a LB/Ap plate 
using a sterile loop and used to inoculate LB/Ap medium (15 mL). After growth for 8 h at 37°C, a 
sufficient quantity of the culture was used to inoculate 1 L of fresh auto-induction (ZYM) medium 
(10 g/L tryptone, 5 g/L yeast extract, 25 mM Na2HPO4 buffer, 25 mM KH2PO4, 5 mM Na2SO4, pH 
6.7), containing 0.5% (v/v) glycerol, 0.05% (w/v) glucose, MgSO4 (2 mM), ampicillin (100 µg/mL) 
and arabinose (0.05% w/v), in a 3 L Erlenmeyer flask to an initial A600 of ~0.1.
[31]
 Cultures were 
grown for 24 h at 22°C with vigorous (170 rpm) shaking. Cells were harvested by centrifugation 
(6000g, 15 min). Protein purification was performed using an immobilized metal affinity 
chromatography (IMAC) procedure as previously described.
[26]
 The elution buffer was exchanged 
against Tris-HCl buffer (50 mM, pH 8.0), containing MgCl2 (2 mM) and KCl (0.1 mM), using a 
pre-packed PD-10 Sephadex G-25 gel filtration column. The purified enzyme was stored at +4°C or 
−80°C until further use. At both temperatures, the enzyme can be stored for several months without 




Determination of the molecular mass of Ch-MAL 
The native molecular mass of Ch-MAL was determined by gel filtration chromatography. The 
purified enzyme (1 mg/mL) was applied to a Superdex 200 column (10/300; GE Healthcare, USA), 
previously equilibrated with Tris-HCl buffer (50 mM, pH 8.0), containing MgCl2 (2 mM) and KCl 
(0.1 mM). The column was eluted with the same buffer at a flow rate of 0.5 mL/min. The column 
was calibrated with the reference proteins aldolase (MW 158 kDa), bovine-serum albumin (MW 
66.7 kDa) and ovalbumin (MW 44 kDa) (GE Healthcare). The subunit molecular mass of Ch-MAL 
was determined by mass spectrometry using an API 3000 triple-quadrapole mass spectrometer 
(Applied Biosystems/MDS Sciex) connected to a LC system via a TurboIonSpray source. For this, 
the Tris-HCl buffer of the protein sample was exchanged to NH4CO2H (5 mM, pH 7.0) using a 
Nanosep centrifugal device (PALL Life Sciences). Data were collected and analyzed by using 
Analyst 1.5.1 data acquisition software (Applied Biosystems/MDS Sciex). 
 
Enzyme assays 
The rate of the MAL-catalyzed amination of 1 was monitored by following the depletion of 1 at 270 
nm (ε = 482 M-1 cm-1) in Tris-HCl buffer (500 mM, pH 9.0) containing MgCl2 (20 mM) and NH4Cl 
(400 mM) at 30°C.
[26]
 The rate of the MAL-catalyzed deamination of 2 was monitored by following 
the formation of 1 at 240 nm (ε = 3850 M-1 cm-1) in Tris-HCl buffer (500 mM, pH 9.0), containing 
MgCl2 (20 mM) and KCl (1 mM), at either 30°C or 70°C.
[24, 26]
 At 70°C, the pH of the Tris buffer 




 ions for 
its deamination activity, whereas for the amination activity only Mg
2+
 is needed. Optimal activity 





Determination of pH and temperature optima of MAL 
The pH optima of Ch-MAL and Ct-MAL were determined in Tris-HCl buffer (500 mM), 
containing MgCl2 (20 mM) and KCl (1 mM), with pH values ranging from 6.0 to 9.5 at 30°C. A 
sufficient quantity of enzyme was added and its activity assayed using 2 (15 mM) as the substrate. 
Stock solutions of 2 were made in Tris buffer (500 mM) and the pH of the stock solutions were 
adjusted to the desired pH (6.0-9.5). The normalized initial reaction rates were plotted against pH. 
 The temperature optima for Ch-MAL and Ct-MAL were determined in Tris-HCl buffer (500 
mM, pH 9.0), containing MgCl2 (20 mM) and KCl (1 mM), using a temperature range of 10 to 
90°C. At each temperature, the pH of the Tris buffer was adjusted to the desired pH (9.0). A 
sufficient quantity of enzyme was added and its activity assayed using 2 (15 mM) as the substrate. 
Stock solutions of 2 were made in Tris-HCl buffer (500 mM, pH adjusted to 9.0). The normalized 
initial reaction rates were plotted against temperature. 
 
Thermostability assay 
The thermostability of Ch-MAL or Ct-MAL was examined in Tris-HCl buffer (500 mM, pH 9.0), 
containing MgCl2 (20 mM) and KCl (1 mM). An appropriate amount of enzyme was incubated in 
the assay buffer (25 mL) at 50°C. Samples (1 mL) were withdrawn every 5 min and the residual 
activity was measured using 2 (15 mM) as the substrate. The initial reaction rates were plotted 
against time. 
 
Product analysis of the amination of 1 by MAL 
1
H NMR spectra monitoring the Ch-MAL- or Ct-MAL-catalyzed amination of 1 were recorded 
according to a protocol reported elsewhere,
[26]
 with the following modifications. Reaction mixtures 
consisted of NH4Cl (500 µL of 1 M stock solution in water, pH 9.0, containing 20 mM MgCl2), 
D2O (100 µL), and 1 (100 µL of a 500 mM stock solution in water, pH 9.0). Reactions were 
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initiated by the addition of 10-15 µL of freshly purified enzyme (400 µg of either Ct-MAL or Ch-
MAL), and each reaction mixture was incubated at 22°C. 
1
H NMR spectra were recorded 2 h, 7 
days, and 14 days after the addition of enzyme. Product amounts were estimated by integration of 
the signals corresponding to 2 and 3. The 
1





Procedure for the nucleophile screening 
The nucleophile scope of Ch-MAL was examined by using 
1
H NMR spectroscopy. Ch-MAL was 
incubated (in separate reactions) with different amines in the presence of 1. The reaction mixtures 
consisted of amine (500 µL of a 1 M stock solution in water, pH 9.0, containing 20 mM MgCl2), 1 
(100 µL of a 500 mM stock solution in water, pH 9.0), and D2O (100 µL). Reactions were initiated 
by the addition of 10-15 µL of freshly purified Ch-MAL (400 µg), and each reaction mixture was 
incubated at 22°C. 
1
H NMR spectra were recorded 2 h, 7 days, and 14 days after the addition of 
enzyme. To identify the products of the reactions and to assign their relative (threo or erythro) 
configuration, the 
1
H NMR spectra were compared to those generated for the same reactions 
catalyzed by Ct-MAL (performed as described above for Ch-MAL) as well as to previously 
published 
1
H NMR spectral data.
[23, 25]
 Relative product distributions were estimated by integration 




Synthesis of 2-substituted fumaric acids 
 
4a: 2-Propylfumaric acid. The synthesis of 4a (and 4b and 4c) is largely based on a previously 
published protocol.
[23]
 Accordingly, sodium (10 mmol, 230 mg) was dissolved in ethanol (6.0 mL). 
Ethyl acetoacetate (9.0 mmol, 1.14 mL) was added dropwise over 5 min at 5°C, followed by n-
propyl iodide (12 mmol, 1.17 mL). The reaction mixture was refluxed for 2 h and was then cooled 
to room temperature, poured on water (30 mL) and extracted with Et2O (3 x 25 mL). Organic 
fractions, containing a mixture of mono- and dialkylated product, were dried and concentrated to 
~15 mL volume. Bromine (4.0 g) was added slowly at room temperature, and the reaction mixture 
was refluxed for 3 h. The volatiles were evaporated, and the residue was slowly added to a solution 
of KOH (4.0 g) in ethanol (15 mL). The resultant mixture was heated at reflux for 30 min, after 
which 20 mL of water was added and the refluxing continued for another 20 min. The reaction 
mixture was washed with EtOAc (2 x 40 mL). The aqueous phase was acidified with aqueous HCl 
(12 N) to pH < 1 and extracted with Et2O (4 x 50 mL). The collected organic fractions were dried, 
decolourized with activated carbon and the solvent was evaporated. The resultant residue was 
triturated with pentane to yield white crystals (100 mg, 7%). Mp. 173.5-174.7°C (lit. 172-174°C, 
(23)); 
1
H NMR (400 MHz, D2O + K2CO3): δ 0.70 (t, 3H, 
3
J = 7.6 Hz, CH3), 1.19-1.25 (m, 2H, 
CH3CH2), 2.63 (t, 2H, 
3
J = 7.2 Hz, CH2C=C), 6.18 (s, 1H, vinyl H). 
1









was prepared according to the same procedure as 2-propylfumaric acid. 




H NMR (400 MHz, D2O + 
K2CO3): δ 0.71 (t, 3H, 
3
J = 7.2 Hz, CH3), 1.06-1.24 (m, 4H, CH3CH2CH2), 2.31 (t, 2H, 
3
J = 7.2 Hz, 
CH2C=C), 6.17 (s, 1H, vinyl H). 
1






was prepared according to the same procedure as 2-propylfumaric acid, 
starting with commercially available ethyl 2-ethylacetoacetate. Yield: 33%. Yellow crystals; Mp. 
197-198°C (lit.
[23]
 195 C); 
1
H NMR (400 MHz, D2O): δ 0.89 (t, 3H, 
3
J = 7.2 Hz, CH3), 2.49 (d, 2H, 
3
J = 7.2 Hz, CH2), 6.57 (s, 1H, vinyl H). 
1




Procedure for the electrophile screening 
The electrophile scope of Ch-MAL was analyzed by 
1
H NMR spectroscopy. In separate 
experiments, Ch-MAL was incubated with fumarate (or substituted fumarates) and ammonia. 
Reaction mixtures consisted of NH4Cl (500 μL of 1 M stock solution in water, pH 9.0, containing 
20 mM MgCl2), D2O (100 µL), and (substituted) fumarate (100 µL of a 500 mM stock solution in 
water, pH 9.0). Reactions were initiated by the addition of 10-15 µL of freshly purified Ch-MAL 
(400 µg), and each reaction mixture was incubated at 22°C. 
1
H NMR spectra were recorded 2 h, 7 
days, and 14 days after the addition of enzyme. To identify the products of the reactions and to 
assign their relative (threo or erythro) configuration, the 
1
H NMR spectra were compared to those 
obtained for the same reactions catalyzed by Ct-MAL (performed as described above for Ch-MAL) 
as well as to previously published 
1
H NMR spectral data.
[23, 25]
 Product amounts were estimated by 
integration of the corresponding signals. 
 The enantiomeric excess of the product of the MAL-catalyzed addition of ammonia to 
fumarate (i.e., aspartate) was determined by chiral HPLC using a Chirex 3126-(D)-pencillamine 
column (250 mm x 4.6 mm, Phenomenex, USA) with 2 mM CuSO4 solution-methanol (90:10) as 
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eluent at a flow rate of 1 mL/min. Retention times were as follows: (S)-aspartate, 23.4 min; (R)-
aspartate, 31 min. 
 
Preparative scale synthesis of threo-(2S,3S)-N,3-dimethylaspartic acid 
Purified Ch-MAL was used for the synthesis of threo-(2S,3S)-N,3-dimethylaspartic acid. A solution 
(20 mL) of 1 (0.2 g, 1.54 mmol), methylamine (1.04 g, 15.4 mmol) and MgCl2 (20 mM) was 
prepared. The pH was adjusted to 9.0 by the addition of small aliquots of an aqueous NaOH (1M) 
solution. The reaction was started by the addition of Ch-MAL (10 mg), and the reaction mixture 
was incubated at 50°C. The progress of the reaction was monitored by using 
1
H NMR (500 MHz) 
spectroscopy. After 8 days, the reaction was terminated and the reaction mixture was lyophilized, 
after which the product was purified using cation exchange chromatography (Dowex, 50W X8, 
100-200 mesh size, Merck). A Dowex column (15.0 g resin per 1 g of mesaconate) was prepared by 
pre-treatment of the resin with a solution of aqueous NH3 (2 M, 4 column volumes), aqueous HCl 
(1 N, 2 column volumes) and distilled water (4 column volumes). The lyophilized reaction mixture 
was suspended in aqueous HCl (1 N, 20 mL) and loaded on the column. The column was washed 
with distilled water (1 column volume) and the product was eluted with aqueous NH3 (2 M, 2 
column volumes). The ninhydrin positive fractions were pooled and concentrated under reduced 
pressure, followed by lyophilization. The product was obtained as a white solid in 61% (152 mg) 
yield. 
1
H NMR (200 MHz, D2O): δ 1.13 (d, 3H, 
3
J = 7.6 Hz, CHCH3), 2.75 (s, 3H, CH3NH), 2.82-
2.95 (dq, 1H, 
3
J = 7.6 Hz, 
3
J = 3.0 Hz, CHCH3), 3.79 (d, 1H, 
3
J = 3.0 Hz, CHNH); 
13
C NMR (50 
MHz, D2O): δ 11.7, 33.0, 40.8, 65.4, 172.2, 180.9. HRMS (ESI+) m/z calc. for C6H12NO4: 
162.0766 [M+H]
+
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Figure S1. Amino acid sequence alignment of the MAL proteins from Clostridium tetanomorphum (Ct-
MAL) and Carboxydothermus hydrogenoformans Z-2901 (Ch-MAL). Identical residues are shaded in gray. 











H NMR spectra monitoring the Ch-MAL and Ct-MAL catalyzed amination of fumarate. The 
spectra were taken after 7 days of incubation at 22°C. For both Ch-MAL and Ct-MAL, the ratio of S:P = 
1:99, respectively. S, fumarate; P, (S)-aspartic acid. The 
1
H NMR signals for the enzymatically generated 










H NMR spectra monitoring the Ch-MAL and Ct-MAL catalyzed ammonia addition to 2-
ethylfumarate. The spectra were taken after 14 days of incubation at 22°C. For Ch-MAL and Ct-MAL, the 
ratio of S:P1:P2 = 35:60:5 and S:P1:P2 = 29:48:23, respectively. S, 2-ethylfumarate; P1, threo-(2S,3S)-3-
ethylaspartate (major diastereoisomer); P2, erythro-(2S,3R)-3-ethylaspartate (minor diastereoisomer). The 
1
H 
NMR signals for 2-ethylfumarate and (2S,3S)-3-ethylaspartate are reported elsewhere.
[1]












H NMR spectra monitoring the Ch-MAL and Ct-MAL catalyzed ammonia addition to 2-
propylfumarate. The spectra were taken after 14 days of incubation at 22°C. For Ch-MAL and Ct-MAL, the 
ratio of S:P = 93:7 and S:P = 39:61, respectively. S, 2-propylfumarate; P, threo-(2S,3S)-3-propylaspartate. 
1
H 
NMR consistent with literature data.
[1]











H NMR spectra monitoring the Ch-MAL and Ct-MAL catalyzed methylamine addition to 
mesaconate. The spectra were taken after 14 days of incubation at 22°C. For Ch-MAL and Ct-MAL, the 
ratio of S1:P = 30:70 and S1:P = 36:64, respectively. S1, mesaconate; S2, methylamine; P, threo-(2S,3S)-N,3-
dimethylaspartate. The 
1
H NMR signals for (2S,3S)-N,3-dimethylaspartate are reported elsewhere.
[2]
 










H NMR spectra monitoring the Ch-MAL and Ct-MAL catalyzed ethylamine addition to 
mesaconate. The spectra were taken after 14 days of incubation at 22°C. For Ch-MAL and Ct-MAL, the 
ratio of S1:P = 70:30 and S1:P = 86:14, respectively. S1, mesaconate; S2, ethylamine; P, tentatively identified 
as 2-ethylamino-3-methylaspartic acid, the enzymatic synthesis of which has not been reported before. 











H NMR spectra monitoring the Ch-MAL and Ct-MAL catalyzed methoxylamine addition to 
mesaconate. The spectra were taken after 14 days of incubation at 22°C. For Ch-MAL and Ct-MAL the ratio 
of S1:P = 91:9 and S1:P = 33:67, respectively. S1, mesaconate; S2, methoxylamine; P, threo-(2S,3S)-N-
methoxy-3-methylaspartate. The 
1
H NMR signals for (2S,3S)-N-methoxy-3-methylaspartate are reported 
elsewhere.
[2]










H NMR spectra monitoring the Ch-MAL and Ct-MAL catalyzed hydroxylamine addition to 
mesaconate. The spectra were taken after 7 days of incubation at 22°C. For Ch-MAL and Ct-MAL the ratio 
of S:P = 1:99 and S:P = 4:96, respectively. S, mesaconate; P, threo-(2S,3S)-N-hydroxy-3-methylaspartate. 
The 
1
H NMR signals for (2S,3S)-N-hydroxy-3-methylaspartate are reported elsewhere.
[2]











H NMR spectra monitoring the Ch-MAL and Ct-MAL catalyzed hydrazine addition to 
mesaconate. The spectra were taken after 7 days of incubation at 22°C. For both Ch-MAL and Ct-MAL 
complete conversion of substrate to product was achieved. P, threo-(2S,3S)-2-hydrazino-3-methylaspartate. 
The 
1
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Optically pure aspartic acid derivatives are highly valuable as tools for biological research and as 
chiral building blocks for pharmaceuticals and neutraceuticals. The preparation of these amino acids 
by traditional organic synthesis still remains a challenging task. In some cases, the use of a 
biocatalytic methodology can be an important, environmentally attractive, and highly competitive 
alternative option. Aspartate ammonia lyases (aspartases) and methylaspartate ammonia lyases 
(MALs) have been explored for producing optically pure L-aspartic acid and its derivatives. In 
industry, aspartases have been used for the preparation of enantiopure L-aspartic acid, an important 
starting compound for the synthesis of the artificial sweetener aspartame. Unfortunately, the 
substrate scope of aspartases is limited to fumarate and a few small substituted amines, yielding a 
limited number of L-aspartic acid derivatives. All our engineering attempts to broaden the substrate 
scope of aspartases were unsuccessful. Recently, the three-dimensional structure of an aspartase 
(AspB) in complex with L-aspartate was determined, showing that binding of the substrate in the 
active site triggers a complex loop movement. This large (~10 Å) loop movement is essential for 
catalysis as the loop closes over the active site to form the complete catalytic machinery of the 
enzyme. This makes the engineering of the substrate specificity of aspartases a formidable 
challenge.  
MAL catalyzes the reversible addition of ammonia to mesaconate to give L-threo-(2S,3S)-3-
methylaspartate and L-erythro-(2S,3R)-3-methylaspartate as products. MAL is a homodimeric 





 ions for full catalytic activity. The MAL from the anaerobic bacterium Clostridium 
tetanomorphum is the best characterized MAL with regard to substrate scope and biochemical 
properties. It accepts a few small amines as alternative nucleophiles that can replace ammonia in the 
addition to mesaconate, yielding a limited number of N-substituted methylaspartic acids. MAL also 
accepts a few fumarate derivatives with short 2-alkyl substituents as alternative electrophiles in the 
ammonia addition reaction, yielding a small set of 3-substituted aspartic acids. Hence, the 
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biocatalytic applicability of MAL is limited by its poor diastereoselectivity and narrow substrate 
scope. Interestingly, the crystal structure of MAL in complex with the natural substrate shows that 
the catalytic machinery of MAL is intact and, unlike aspartases, it does not undergo a large 
conformational change upon substrate binding, thereby making it more amenable to protein 
engineering. In Chapter 1, we have reviewed the properties, structures, catalytic mechanisms and 
biocatalytic applications of aspartate and methylaspartate ammonia lyases. 
The aim of the work described in this thesis was to engineer MAL in order to enhance its 
diastereoselectivity and to broaden its substrate scope, and to explore the newly designed 
biocatalysts for their usefulness in the stereoselective synthesis of a wide variety of valuable 
aspartic acid derivatives. In addition, we aimed to clone and characterize a MAL from a 
thermophilic bacterium, with a view to obtain a thermostable MAL that could be exploited for large 
scale amino acid synthesis and as template in future engineering experiments. 
 
Engineering the stereoselectivity and substrate specificity of MAL 
We have focused our studies on MAL from the anaerobic bacterium Clostridium tetanomorphum, 
which is the best characterized MAL to this date, and further exploited it as template in our 
engineering experiments. The crystal structure of MAL from Citrobacter amalonaticus in complex 
with L-threo-(2S,3S)-3-methylaspartate provided the essential information about the residues that 
interact with the substrate (Figure 1). It was suggested that MAL operates via a general-base 
mechanism, where Lys-331 abstracts the 3S-proton and His-194 abstracts the 3R-proton from the 
respective isomer of 3-methylaspartic acid (Figure 1a). In Chapter 2, we have investigated the 
importance of the Lys-331 and His-194 residues for the activity and diastereoselectivity of MAL by 
site-directed mutagenesis. Kinetic studies have shown that mutations at the Lys-331 and His-194 
positions have a profound effect on the kcat and kcat/Km values, implying that these residues are 
mechanistically important. Product analysis by 
1
H NMR spectroscopy showed that the K331A and 




Figure 1. Crystal structure of MAL in complex with the natural substrate L-threo-(2S,3S)-3-methylaspartate. 
A close-up of the active site showing hydrogen bond interactions (dashed lines) or observed distances (solid 
lines) between (a) the substrate’s C4 carboxylate group and the side chains of His-194, Gln-329 and Lys-
331; (b) the substrate’s C3 methyl group and side chains of Phe-170, Tyr-356 and Leu-384; (c) the 
substrate’s C2 amino group and side chains of Gln-73 and Gln-172; and (d) the substrate’s C1-carboxylate 
group and side chains of Gln-172, Thr-360 and Cys-361. The carbon atoms of the active site residues and the 
substrate are shown in green. The magnesium ion and water molecule are shown as magenta and yellow 
spheres, respectively. The figure was prepared using PyMOL (www.pymol.org).  
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for the formation of L-threo-3-methylaspartic acid, suggesting that these residues play an important 
role in controlling the stereoselectivity of MAL. It has been suggested that the high 
diastereoselectivity of the H194A mutant can be exploited for the stereoselective synthesis of the 
threo isomers of various 3-substituted aspartic acids.  
In Chapter 3, we describe the engineering of MAL to broaden its substrate scope. Guided 
by the crystal structure of MAL in complex with the substrate, we selected the residues lining the 
substrate binding pocket of the enzyme (Figure 1). To enlarge the nucleophile scope of MAL, the 
residues which are involved in the formation of the substrate’s amine binding pocket were selected 
and subjected to saturation mutagenesis (Figure 1c). Mutants were screened for their ability to 
catalyze methylamine addition to mesaconate. This approach resulted in a single active site mutant 
(Q73A) with strongly improved activity for the methylamine addition reaction. Furthermore, the 
Q73A mutant exhibits a very broad nucleophile scope, including structurally diverse linear and 
cyclic alkylamines, in the addition to mesaconate. The enzyme-catalyzed amine addition reactions 
are highly diastereoselective, only yielding the threo isomers of the corresponding N-substituted 
methylaspartic acids (de >95%). Likewise, to expand the electrophile scope of MAL, the residues 
lining the substrate’s methyl-binding pocket were subjected to saturation mutagenesis (Figure 1b). 
Mutants were screened for their ability to catalyze ammonia addition to 2-hexylfumarate. This 
approach resulted in a single active site mutant (L384A), which showed pronounced amination 
activity towards 2-hexylfumarate. Interestingly, the L384A mutant exhibits a very broad 
electrophile scope including fumarate derivatives with alkyl, aryl, alkoxy, aryloxy, alkylthio and 
arylthio substituents at the C2 position. However, while providing high regioselectivities, the 
L384A mutant-catalyzed amination reactions provided varying degrees of diastereoselectivity. 
Structural analysis of the Q73A and L384A mutants showed that both mutants have an enlarged 
active site that accommodates the new substrates. These engineered MALs have exciting potential 
for applications in the asymmetric synthesis of various N- or 3-substituted aspartic acids.  
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Biocatalytic applications of the engineered MAL mutants 
Next, we demonstrated the preparative usefulness of the engineered MAL mutants. The use of the 
Q73A mutant for the enantioselective synthesis of a large variety of N-substituted aspartic acids by 
the addition of structurally diverse amines to fumaric acid is described in Chapter 4. The purified 
enzyme was incubated with fumaric acid and various amines in separate reaction mixtures. 
Interestingly, by using only 0.05 mol% of biocatalyst, excellent (91-100%) conversions were 




C NMR, and HRMS as the corresponding N-substituted aspartic acids. To establish the absolute 
configurations and enantiopurity of these amino acid products, authentic standards with known L- 
or D- configuration were synthesized by reductive amination. Comparative chiral HPLC analysis of 
the amino acid products and authentic standards showed that the enzyme-catalyzed amine additions 
are highly enantioselective, only yielding the L-enantiomers of the corresponding amino acid 
products (>99% ee).  
In Chapter 5, we describe kinetic resolutions and asymmetric synthesis of various 3-
substituted aspartic acids using the H194A and H194A/L384A mutant enzymes as biocatalysts. 
First, we established that the H194A-catalyzed reaction is highly regio-, enantio- and 
diastereoselective by demonstrating the preparative usefulness of the H194A enzyme in the 
selective synthesis of L-threo-(2S,3S)-3-methylaspartic acid. Then, we exploited the high regio- and 
stereoselectivity of the H194A mutant in kinetic resolutions and asymmetric synthesis to produce 
various 3-substituted aspartic acids, including threo-3-methoxyaspartic acid, an important inhibitor 
of excitatory glutamate transporters (EAAT2 and EAAT5) in the brain. We also showed that the 
biocatalytic applicability of the H194A mutant can be broadened by combining the high 
stereoselectivity of the H194A mutant with the broad electrophile scope of the L384A mutant by 
generating the double mutant H194A/L384A, which allowed the selective synthesis of threo-3-
butylaspartic acid. Thus, these engineered MALs have potential for application in the 
stereoselective preparation of various 3-substituted aspartic acids. 
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Detailed catalytic mechanism of MAL  
In Chapter 6, we describe the roles of active site residues in the catalytic mechanism of MAL. 
Based on the crystal structure of MAL in complex with L-threo-(2S,3S)-3-methylaspartic acid 
(Figure 1), we selected seven active site residues (Gln-73, Phe-170, Gln-172, Tyr-356, Thr-360, 
Cys-361, Leu-384) lining the substrate binding pocket and investigated their importance for the 
activity and diastereoselectity of MAL. The selected residues were subjected to site-directed 
mutagenesis and the mutant enzymes were characterized for their structural integrity, by using CD 
spectroscopy and native PAGE, and ability to catalyze the amination of mesaconate, using both 
kinetic assays and 
1
H NMR spectroscopy. Based on the observed properties of the mutant enzymes, 
combined with previous kinetic isotope measurements, structural studies and protein engineering 
work, we propose a detailed catalytic mechanism for the MAL catalyzed reaction. In this proposed 
mechanism, Lys-331 acts as the primary base that abstracts the 3S-proton from L-threo-3-
methylaspartate, resulting in an enolate anion intermediate. This enolic intermediate is stabilized by 
the essential Mg
2+
 ion and the Gln-329 residue. Collapse of this intermediate results in the release 
of ammonia and the formation of mesaconate. Similarly, His-194 acts as the secondary base and 
abstracts the 3R-proton from the L-erythro isomer of 3-methylaspartic acid, yielding the enolic 
intermediate. The side chains of the active site residues that form the C1 carboxylate-binding pocket 
(Gln-172, Thr-360 and Cys-361), the C2 amino-binding pocket (Gln-73 and Gln-172) and C3 
methyl-binding pocket (Phe-170, Tyr-356 and Leu-384) provide additional interactions, which are 
essential for substrate binding and activation. This detailed knowledge of the catalytic mechanism 
of MAL can serve as a guide for future engineering experiments.  
 
Cloning and characterization of a thermostable methylaspartate ammonia lyase  
In Chapter 7, we describe the cloning, heterologous expression, and purification of a 
methylaspartate ammonia lyase (designated Ch-MAL) from the thermophilic bacterium 
Carboxydothermus hydrogenoformans Z-2901. Ch-MAL is a homodimer in solution and shows 
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optimal activity at 70°C and pH 9.0. Heat-inactivation assays showed that the purified enzyme is 
stable at 50°C for several hours, which is the highest thermal stability observed among known 
MALs. Ch-MAL accepts fumarate, 2-methylfumarate, 2-ethylfumarate, and 2-propylfumarate as 
substrates in the ammonia addition reaction. The enzyme also processes methylamine, ethylamine, 
hydrazine, hydroxylamine, or methoxylamine as an alternative nucleophile that can replace 
ammonia in the addition to mesaconate, resulting in the corresponding N-substituted methylaspartic 
acids with a very high diastereomeric excess. The high thermostability and stereoselectivity, and the 
broad substrate scope, make Ch-MAL an attractive biocatalyst for large scale, asymmetric synthesis 
of aspartic acid derivatives and a promising template for future engineering experiments. 
 
Conclusions and future perspectives 
In the work described in this thesis, we have engineered both the stereoselectivity and substrate 
specificity of MAL. The structure-guided engineering of MAL led to the identification of three 
single-active-site mutants: one shows strongly enhanced diastereoselectivity (H194A), one exhibits 
a very broad nucleophile scope (Q73A), and one accepts a wide range of electrophiles (L384A). 
The usefulness of these engineered MALs for the selective synthesis of various substituted aspartic 
acids has convincingly been demonstrated. This is perhaps best illustrated by the L384A-catalyzed 
synthesis of L-threo-(2S,3S)-3-benzyloxyaspartic acid (L-TBOA in Figure 2), an important inhibitor 
of excitatory glutamate transporters in the brain. Compared to the difficult and laborious 15-steps 
chemical synthesis of L-TBOA, our 3-steps chemo-enzymatic synthesis of L-TBOA (de >98% and 
ee >99%) provides a simple and environmentally friendly method to produce this important 
compound.  
 Next, there is a need to develop second generation MAL-based biocatalysts, which have an 
even larger substrate scope and are more robust than the first generation MAL-based biocatalysts. 
For instance, the L384A mutant enzyme exhibits a broad electrophile scope, but shows poor 
diastereoselectivity. To improve the stereoselectivity of this mutant enzyme, we constructed the 
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double mutant L384A\H194A, where we combined the broad electrophile scope of the L384A 
mutant with the high stereoselectivity of the H194A mutant. Unfortunately, the double mutant 
shows very low-level amination activity. Therefore, we have initiated studies to improve the 
catalytic activity of the double mutant. If successful, the newly engineered second generation 
biocatalyst may be highly useful for the stereoselective synthesis of a wide variety of 3-substituted 
aspartic acids.  
 
Figure 2. Structures of L-TBOA and L-TFB-TBOA. 
 
Similarly, the nucleophile scope of the Q73A mutant is mainly confined to relatively small 
(C1-C7) primary amines. To synthesize large and complex N-substituted aspartic acids, which can 
be used as building blocks for low-calorie sweeteners, such as the aspartame derivatives advantame 
and neotame (Figure 3), the nucleophile scope of MAL-Q73A needs to be broadened to also include 
large and branched primary amines. Likewise, to synthesize large L-TBOA derivatives such as L-
TFB-TBOA (Figure 2), which is the most potent inhibitor of excitatory glutamate transporters in the 
brain, MAL-L384A needs to be engineered to accept very large 2-aryloxy fumarates. To further 
expand the nucleophile or electrophile scope of MAL, in silico mutagenesis combined with 
substrate docking can be an attractive strategy to reduce the sequence space that has to be covered 
to identify valuable mutants. The catalytic activity of the designed mutants can be further improved 




Figure 3. Structures of aspartame, advantame, and neotame. 
 
The results presented in this thesis suggested that combining the broad nucleophile scope of 
the Q73A mutant with the broad electrophile scope of the L384A mutant could yield a new enzyme 
with the ability to process many different combinations of substituted amines and fumarates. 
However, the MAL double mutant (Q73A/L384A) is almost completely inactive and thus not 
suitable for amino acid synthesis. In future work, we therefore aim to construct a focused library by 
saturation mutagenesis at positions 73 and 384, screening of which may yield various active 
biocatalysts optimized for unique combinations of nucleophile and electrophile. It is important to 
note that not all nucleophile-electrophile combinations are likely to be productive as very large 
substituents on both the amine and fumarate substrates may sterically hinder the addition reaction. 
Until now, we were successful in engineering the stereoselectivity and substrate specificity 
of MAL for the production of a wide range of α-amino acids. The next highly challenging step will 
be to engineer MAL for the synthesis of various β-amino acids. Unfortunately, the redesign of the 
binding pocket for the substrate’s C1 carboxylate group by saturation mutagenesis at positions Gln-
172, Thr-360 and Cys-361 (Figure 1d) did not result in mutants with amination activity towards 
unsaturated monocarboxylic acids. Therefore, we have started an engineering programme that aims 
to engineer MAL for the asymmetric synthesis of β-amino acids by targeting multiple sites at the 
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same time, with a view to benefit from synergistic effects encountered by multiple simultaneous 
mutations. This approach requires a robust and sensitive screening assay, for example detection of 




























Optisch zuivere asparaginezuurderivaten zijn uitermate waardevol voor biologisch onderzoek en 
zijn tevens belangrijke chirale bouwstenen voor farmaceutica en nutraceutica (een hypogram van de 
woorden nutriënt en farmaceutica). De bereiding van deze aminozuren door middel van traditionele 
organische synthese is tot op de dag van vandaag een enorme uitdaging. In een aantal gevallen kan 
de toepassing van een biokatalytische methode een belangrijk, milieuvriendelijk en competitief 
alternatief zijn. Aspartaat ammonia-lyases (aspartases) en methylaspartaat ammonia-lyases (MALs) 
zijn enzymen die onderzocht zijn, en worden, voor de productie van optisch zuiver L-
asparaginezuur en derivaten daarvan. In de chemische industrie worden aspartases toegepast voor 
de productie van enantiomeerzuiver L-asparaginezuur, hetgeen een belangrijke bouwsteen is voor 
de kunstmatige zoetstof aspartaam. Helaas is het aantal substraten dat door aspartases wordt 
geaccepteerd voor omzetting tot asparaginezuurderivaten beperkt tot fumaarzuur en een aantal 
kleine, gesubstitueerde amines. Wij hebben in onze onderzoeksgroep geprobeerd om, door middel 
van het muteren van aspartases, het aantal substraten dat door dit enzym wordt omgezet uit te 
breiden. Deze pogingen zijn helaas op niets uitgelopen. Recentelijk is de driedimensionale structuur 
opgehelderd van een aspartase (AspB) in complexatie met het substraat L-aspartaat (i.e. het 
carboxylaatanion van asparaginezuur; Latijn: i.e., id est, dat wil zeggen). Deze driedimensionale 
structuur maakte duidelijk dat de binding van het substraat in het actieve centrum van het enzym 
een ingewikkelde beweging van een lus van het enzym teweeg brengt. De relatief grote beweging 
(10 Å) van deze lus is essentieel voor de katalyse die het enzym uitvoert aangezien de lus het 
actieve centrum niet alleen afdicht maar tevens completeert. Deze gegevens maken dat het muteren 
van aspartases, om zodoende het aantal substraten dat voor omzetting wordt geaccepteerd te 
verhogen, een enorme uitdaging is. 
MAL katalyseert de reversibele additie van ammonia aan 2-methylfumaarzuur hetgeen de 
producten L-threo-(2S,3S)-3-methylasparaginezuur en L-erythro-(2S,3R)-3-methylasparaginezuur 
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oplevert. MAL is een homodimerisch enzym dat een rol speelt in de katabole route van glutamaat in 




 ionen nodig om maximale katalytische activiteit te 
bereiken. De MAL die voorkomt in de anaerobe bacterie Clostridium tetanomorphum is de best 
gekarakteriseerde MAL wat betreft substraatacceptatie en biochemische eigenschappen. Het enzym 
accepteert naast ammonia een beperkt aantal andere, kleine amines als nucleofiele substraten voor 
de additie aan 2-methylfumaarzuur hetgeen slechts een gelimiteerd aantal N-gesubstitueerde 
asparaginezuren als producten oplevert. MAL accepteert ook een klein aantal fumaarzuurderivaten 
met korte 2-alkylsubstituenten als alternatieve elektrofielen voor ammonia-additie hetgeen in 
slechts een beperkt aantal 3-gesubstitueerde asparaginezuurderivaten resulteert. Het gelimiteerd 
aantal nucleofiele als wel elektrofiele substraten dat door MAL wordt geaccepteerd voor 
enzymatische omzetting houdt in dat de biokatalytische toepassing van dit enzym beperkt is. Eens 
temeer omdat de producten met lage diastereomere overmaten worden verkregen. Het is interessant 
dat de kristalstructuur van MAL in complexatie met het natuurlijke substraat (i.e. L-threo-3-
methylaspartaat) laat zien dat het actieve centrum van MAL conformationeel stabiel is en, in 
tegenstelling tot aspartases, géén grote conformationele verandering ondergaat als gevolg van 
substraatbinding. Dit houdt in dat het wellicht makkelijker is om MAL te muteren dan om 
aspartases te muteren zonder dat de werking van het actieve centrum wordt aangetast. In hoofdstuk 
1 zijn de eigenschappen, structuren, katalytische mechanismen en biokatalytische toepassingen van 
aspartases en methylaspartaat ammonia-lyases (MALs) op een rij gezet.  
De doelen van de onderzoeken die in dit proefschrift zijn beschreven zijn om door middel 
van het muteren van MAL enerzijds het aantal substraten dat door MAL wordt geaccepteerd voor 
omzetting te verhogen en anderzijds de optische zuiverheid (i.e. diastereomere en enantiomere 
overmaten) waarmee de producten worden verkregen te verhogen. Het vervolgdoel is om te testen 
of deze nieuw ontworpen biokatalysatoren bruikbaar zijn voor de stereoselectieve synthese van een 
breed scala aan asparaginezuurderivaten. Een aanvullend doel is om een MAL uit een thermofiele 
bacterie te kloneren en te karakteriseren om zodoende een (thermo)stabiel MAL te verkrijgen dat 
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inzetbaar is voor grote-schaal-synthese van aminozuren en dat als een uitgangspunt kan dienen voor 
toekomstige mutatie-experimenten. 
  
Mutaties van MAL om stereoselectiviteit en acceptatie van aantal substraten te verhogen 
Wij hebben onze onderzoeken gefocust op MAL verkregen uit de anaerobe bacterie Clostridium 
tetanomorphum, de meest uitvoerig gekarakteriseerde MAL tot op dit moment, en het aangewend 
als uitgangspunt (template) voor onze mutatie-experimenten. De kristalstructuur van MAL uit 
Citrobacter amalonaticus in complexatie met L-threo-(2S,3S)-3-methylaspartaat gaf essentiële 
informatie over welke aminozuurresiduen interactie aangaan met het substraat (Figuur 1). Er is 
geopperd dat katalyse in MAL via een algemeen zuur-base-mechanisme werkt waarin Lys-331 het 
3S-proton en His-194 het 3R-proton abstraheert van het betreffende isomeer van 3-
methylasparaginezuur (Figuur 1a). In hoofdstuk 2 is beschreven hoe het belang van de residuen 
Lys-331 en His-194 voor katalytische werking en stereoselectiviteit van MAL is onderzocht door 
middel van gerichte mutaties (site-directed mutagenesis) op posities 331 en 194. Kinetiek-
experimenten hebben laten zien dat mutatie van zowel Lys-33 als His-194 een aanmerkelijk effect 
heeft op de kcat en kcat/Km waarden van de natuurlijke activiteit hetgeen duidelijk maakt dat beide 
residuen een belangrijke rol spelen in het katalyse mechanisme. Productanalyse met behulp van 
1
H 
NMR spectroscopie heeft aangetoond dat de K331A- en de H194A-mutant de diastereoselectiviteit 
van de aminering van 2-methylfumaarzuur hebben veranderd en zeer sterke voorkeur geven aan 
formatie van L-threo-3-methylasparaginezuur. Dit resultaat geeft aan dat de residuen op posities 
331 en 194 een grote invloed hebben op de diastereoselectiviteit. Wellicht kan de hoge 
diastereoselectiviteit van de H194A-mutant benut worden voor de stereoselectieve synthese van de 





Binding site = bindingslocatie 
Figuur 1. Kristalstructuur van MAL in complexatie met het natuurlijke substraat L-threo-(2S,3S)-3-
methylaspartaat. Uitvergrotingen van het actieve centrum laten waterstofbruginteracties (stippellijnen) en 
atoomafstanden (ononderbroken lijnen) zien tussen (a) de C4-carboxylaatgroep van het substraat en de 
zijketens van de residuen His-194, Gln-329 en Lys-331; (b) de C3-methylgroep van het substraat met de 
zijketens van de residuen Phe-170, Tyr-356 en Leu-384; (c) de C2-aminogroep van het substraat met de 
zijketens van de residuen Gln-73 en Gln-172; en (d) de C1-carboxylaatgroep van het substraat en de 
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zijketens van de residuen Gln-172, Thr-360 en Cys-361. De koolstofatomen van de residuen in het actieve 
centrum en het substraat zijn groen gekleurd. Het magnesium ion en het watermolecuul zijn met, 
respectievelijk, magenta en geel gekleurde bollen afgebeeld. De afbeeldingen zijn gemaakt met behulp van 
het programma PyMOL (www.pymol.org). 
 
In hoofdstuk 3 staan de mutatie-experimenten met MAL beschreven met als doel de acceptatie van 
het aantal substraten te verhogen. Aan de hand van de kristalstructuur van MAL met het natuurlijke 
substraat zijn de residuen geselecteerd die verantwoordelijk zijn voor substraatbinding binnen het 
enzym (Figuur 1). Om het aantal substraten dat door MAL wordt geaccepteerd voor omzetting te 
vergroten zijn de residuen die verantwoordelijk zijn voor binding met de aminogroep van het 
substraat (residuen 73 en 172, Figuur 1c) onderworpen aan gerandomiseerde mutatie-experimenten 
(saturation mutagenesis). De op deze manier verkregen mutanten zijn vervolgens getest op hun 
vermogen om methylamine te adderen aan 2-methylfumaarzuur. Met deze aanpak is er een 
enkelvoudige mutant (Q73A) gevonden met een sterk verhoogde katalytische activiteit voor de 
additiereactie van methylamine. Bovendien accepteert de Q73A-mutant een breed scala van lineaire 
en cyclische alkylamines als nucleofiele substraten voor de additie aan 2-methylfumaarzuur. Het 
enzym katalyseert de amine-addities met hoge diastereoselectiviteit (de >95%) waarbij de threo-
isomeren van de N-gesubstitueerde methylasparaginezuren in overmaat verkregen werden. Dezelfde 
strategie (saturation mutagenesis) is toegepast op de residuen die een rol spelen in de binding van 
de methylgroep van het substraat (Phe-170, Tyr-356 en Leu-384) om zodoende het aantal 
elektrofiele substraten te verhogen dat door MAL wordt geaccepteerd (Figuur 1b). De mutanten zijn 
onderzocht op hun vermogen om de additie van ammonia aan 2-hexylfumaraat te katalyseren. Er 
werd één enkelvoudige mutant gevonden (L384A) met een sterk verhoogde activiteit. Interessant 
genoeg accepteert deze mutant ook een ruime, aanvullende collectie van fumaarzuren met alkyl-, 
aryl-, alkoxy-, aryloxy-, alkylthio- en arylthiosubstituenten op de C2-positie, als elektrofiele 
substraten. Echter, ondanks dat de L384A-mutant de amine-addities met hoge regioselectiviteit 
uitvoert, variëren de diastereoselectiviteiten. Structuuranalyses van de Q73A- en de L384A-mutant 
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lieten zien dat beide mutanten een vergroot actief centrum hebben dat in staat is om de collectie van 
nieuwe, grotere substraten te accommoderen en te binden. Deze gemuteerde MALs hebben de 
aansprekende potentie om toegepast te worden in de asymmetrische synthese van N- en 3-
gesubstitueerde asparaginezuren. 
 
Biokatalytische toepassingen van de MAL-mutanten 
In een volgende serie experimenten is de bruikbaarheid van de MAL-mutanten in preparatieve 
schaalexperimenten aangetoond. Het aanwenden van de Q73A-mutant voor de enantioselectieve 
synthese van een groot aantal N-gesubstitueerde asparaginezuren door middel van additie van 
verschillende amines aan fumaarzuur is beschreven in hoofdstuk 4. Het gezuiverde enzym werd 
geïncubeerd met fumaarzuur en de verschillende amines in afzonderlijke experimenten. Met slechts 
0,05 mol% biokatalysator (i.e. Q73A) werden uitstekende conversies (91-100%) bereikt na 
reactietijden die variëren van 30 minuten tot 48 uur. In alle afzonderlijke experimenten werd slechts 
één aminozuurproduct gevonden. De producten werden gezuiverd en geïdentificeerd als N-




C NMR en HRMS spectroscopie. Om 
de absolute configuraties en de enantiomere zuiverheden van deze aminozuurproducten te 
achterhalen werden er referentiestoffen met bekende L- of D-configuratie gesynthetiseerd door 
middel van reductieve aminering. Analyses met HPLC, met een chirale vaste fase, van de 
aminozuurproducten en de referentieverbindingen toonden aan dat de enzym-gekatalyseerde amine-
addities met hoge enantioselectiviteiten (ee >99%) plaatsvinden en dat de L-enantiomeren in 
overmaat worden verkregen.  
In Hoofdstuk 5 zijn de kinetische resoluties en asymmetrische syntheses van verschillende 
3-gesubstitueerde asparaginezuren met behulp van de H194A- en de H194A/L384A-mutant 
beschreven. Ten eerste hebben we aangetoond dat L-threo-(2S,3S)-3-methylasparaginezuur op 
preparatieve schaal met hoge regio-, enantio- en diastereoselectiviteit verkregen kan worden door 
middel van katalyse met de H194A-mutant. Vervolgens zijn de hoge regio- en stereoselectiviteit 
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van de H194A-mutant benut voor kinetische resolutie-experimenten en asymmetrische synthese van 
meerdere 3-gesubstitueerde asparaginezuren. Onder andere van threo-3-methoxyasparaginezuur 
hetgeen een belangrijke inhibitor is van excitatorische glutamaattransporters (EAAT2 en EAAT5) 
in de hersenen. Er is tevens aangetoond dat de biokatalytische toepasbaarheid van de H194A-
mutant uitgebreid kan worden wanneer de hoge stereoselectiviteit van H194A gecombineerd wordt 
met de brede substraatacceptatie van de L384A-mutant (i.e. de hoeveelheid aan substraten die door 
L384A wordt geaccepteerd). De dubbelmutant H194A/L384A kan inderdaad selectief de vorming 
van threo-3-butylasparaginezuur katalyseren en aan de hand hiervan kan geconcludeerd worden dat 
gemuteerde MALs de potentie hebben om toegepast te worden in de stereoselectieve synthese van 
een veelheid aan 3-gesubstitueerde asparaginezuren. 
 
Gedetailleerd katalytisch mechanisme van MAL 
In hoofdstuk 6 worden de individuele rollen van de residuen in het actieve centrum van MAL 
beschreven in het katalytische mechanisme. Aan de hand van de kristalstructuur van MAL in 
complexatie met L-threo-(2S,3S)-3-methylaspartaat (Figuur 1) zijn er zeven residuen in het actieve 
centrum geselecteerd (Gln-73, Phe-170, Gln-172, Tyr-356, Thr-360, Cys-361 en Leu-384) en 
onderzocht op hun rol in de activiteit en diastereoselectiviteit van MAL. De geselecteerde residuen 
zijn onderworpen aan gerichte mutagenese (site-directed mutagenesis) en de mutanten zijn 
geïdentificeerd op basis van hun structuureigenschappen met behulp van CD-spectroscopie en 
native PAGE (PAGE met niet-gedenatureerd proteïne). De mutanten zijn tevens met een kinetisch 
onderzoek (kinetic assay) en met 
1
H NMR spectroscopie getoetst op hun vermogen om de 
aminering van 2-methylfumaarzuur te katalyseren. Gebaseerd op de eigenschappen van de 
mutanten, eerder uitgevoerd kinetisch isotoop onderzoek, structuurstudies en enzymmutaties is er 
een gedetailleerd katalytisch mechanisme van MAL voorgesteld. In dit voorgestelde mechanisme 
acteert Lys-331 als een primaire base dat het 3S-proton van L-threo-3-methylaspartaat abstraheert 





 ion en het Gln-329 residu. Verval van dit intermediair resulteert in het vrijkomen 
van ammonia en de formatie van 2-methylfumaarzuur. Op eenzelfde wijze acteert His-194 als een 
secundaire base en abstraheert het het 3R-proton van de L-erythro-isomeer van 3-methylaspartaat 
eveneens resulterend in het enolisch intermediair. De zijketens van de residuen die tezamen in het 
actieve centrum de bindingslocatie vormen voor de C1-carboxylaatgroep (Gln-172, Thr-360 en 
Cys-361), de C2-aminefunctionaliteit (Gln-73 en Gln-172) en de C3-methylgroep (Phe-170, Tyr-
356 en Leu-384) gaan bijkomende interacties aan die essentieel zijn voor substraatbinding en 
activering. Deze gedetailleerde informatie over het katalytische mechanisme van MAL geeft de 
richting aan voor toekomstige mutatie-experimenten.  
 
Het kloneren en karakteriseren van een thermostabiel methylaspartaat ammonia-lyase 
In hoofdstuk 7 wordt het kloneren, de heterologische expressie en de zuivering beschreven van een 
methylaspartaat ammonia-lyase (genoteerd als Ch-MAL) die verkregen is uit de thermofiele 
bacterie Carboxydothermus hydrogenoformans Z-2901. Ch-MAL is een homodimeer in oplossing 
en heeft een optimale activiteit bij 70°C en een pH van 9.0. Hitte-inactivatie-studies hebben laten 
zien dat het gezuiverde enzym enkele uren stabiel is bij 50°C hetgeen betekent dat Ch-MAL de 
meest stabiele en hittebestendige is van alle bekend zijnde MALs. Ch-MAL accepteert fumaraat, 2-
methylfumaraat, 2-ethylfumaraat en 2-propylfumaraat als substraten voor ammonia-additie. Het 
enzym accepteert bovendien methylamine, ethylamine, hydrazine, hydroxylamine en 
methoxylamine als alternatieve nucleofielen in plaats van ammonia voor de additie aan 2-
methylfumaarzuur. De corresponderende N-gesubstitueerde methylasparaginezuurproducten 
werden met zeer hoge diastereomere overmaten verkregen. De hoge thermostabiliteit en 
stereoselectiviteit tezamen met de uitgebreide substraatacceptatie maken dat Ch-MAL een 
aantrekkelijke biokatalysator is voor asymmetrische grote-schaal-synthese van 




Conclusies en toekomstperspectief 
Gedurende het onderzoek dat in dit proefschrift beschreven wordt is het enzym MAL zodanig 
gemuteerd dat zowel de stereoselectiviteit als wel het aantal substraten dat geaccepteerd wordt voor 
omzetting zijn verhoogd. Op basis van kristalstructuren zijn mutaties van verschillende residuen in 
het actieve centrum van MAL doorgevoerd. Deze hebben geleid tot de identificatie van drie 
enkelvoudige mutanten: één met een sterk verbeterde diastereoselectiviteit (H194A), één die een 
uitgebreide hoeveelheid aanvullende nucleofiele substraten accepteert voor omzetting (Q73A) en 
ten slotte één die een significante hoeveelheid aanvullende elektrofiele substraten accepteert voor 
omzetting (L384A). De bruikbaarheid van deze MAL-mutanten voor de selectieve synthese van 
diverse gesubstitueerde asparaginezuren is overtuigend aangetoond. Dit wordt wellicht het best 
geïllustreerd met de door de L384A-mutant gekatalyseerde synthese van L-threo-(2S,3S)-3-
benzyloxyasparaginezuur (L-TBOA in Figuur 2), een belangrijke inhibitor van excitatorische 
glutamaattransporters in de hersenen. Vergeleken met de moeilijke en tijdrovende 15-staps 
chemische synthese van L-TBOA is onze 3-staps chemo-enzymatische synthese van L-TBOA (de 
>98% en ee >99%) een simpele en milieuvriendelijke methode voor het vervaardigen van deze stof. 
 Op basis van de resultaten beschreven in de voorgaande alinea ontstond er de behoefte om 
een tweede generatie op MAL gebaseerde biokatalysatoren te ontwikkelen die een nóg grotere 
hoeveelheid substraten accepteert voor omzetting en tevens meer robuust is dan de eerste generatie 
MAL-afgeleide biokatalysatoren. De L384A-mutant accepteert bijvoorbeeld een grote hoeveelheid 
substraten voor omzetting maar heeft een lage diastereoselectiviteit. Om de stereoselectiviteit van 
deze mutant te verhogen werd de dubbelmutant L384A\H194A geconstrueerd. Op deze manier 
werd een poging gedaan om de uitgebreide substraatacceptatie van de L384A-mutant te combineren 
met de hoge diastereoselectiviteit van de H194A-mutant. Helaas bleek de dubbelmutant een lage 
amineringsactiviteit te hebben. Vanwege dit resultaat zijn we met een onderzoek begonnen om de 
katalytische activiteit van de dubbelmutant te verbeteren. Wanneer dit succesvol verloopt zou deze 
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tweede generatie biokatalysatoren, met nieuwe mutaties, bruikbaar kunnen zijn voor de 
stereoselectieve synthese van een brede variëteit van 3-gesubstitueerde asparaginezuren.  
 
Figuur 2. Structuren van L-TBOA en L-TFB-TBOA. 
 
Op vergelijkbare wijze beperkt zich het aantal nucleofielen dat door de Q73A-mutant wordt 
geaccepteerd tot een aantal relatief kleine (C1-C7) primaire amines. Om grote en complexe N-
gesubstitueerde asparaginezuren te synthetiseren, die kunnen dienen als bouwstenen voor lage-
calorie zoetstoffen zoals de aspartaamderivaten advantaam en neotaam (Figuur 3), zal het palet aan 
nucleofielen dat door MAL-Q73A geaccepteerd wordt voor omzetting uitgebreid moeten worden 
met grotere en vertakte amines. Vergelijkbaar hiermee zal MAL-L384A op zodanige wijze 
gemuteerd moeten worden dat het relatief grote 2-aryloxyfumaraten accepteert als substraten om 
zodoende grote L-TBOA-derivaten te synthetiseren zoals L-TFB-TBOA (Figuur 2), de meest 
potente inhibitor van excitatorische glutamaattransporters in de hersenen. De combinatie van in 
silico mutagenese en substraat-accommodatie (substrate docking) is wellicht een aantrekkelijke 
strategie om de essentiële mutaties te vinden die in vitro doorgevoerd moeten worden om het aantal 
nucleofiele als wel elektrofiele substraten te verhogen dat door MAL wordt geaccepteerd én om er 
voor te zorgen dat het aantal mutanten dat in vitro gescreend moet worden (sequence space), om 
een verbeterde mutant te vinden, niet te hoog wordt. Vervolgens kan gepoogd worden om de 
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katalytische activiteit van de op deze manier ontworpen mutanten verder te verbeteren met 
gerandomiseerde mutagenese (i.e. error-prone PCR) en activiteitsonderzoeken. 
 
Figuur 3. Structuren van aspartaam, advantaam en neotaam. 
 
De resultaten die in dit proefschrift gepresenteerd worden suggereren dat de combinatie van 
het gevarieerd aantal nucleofielen dat door de Q73A-mutant wordt geaccepteerd en de collectie 
elektrofielen die door de L384A-mutant wordt geaccepteerd een nieuw enzym (Q73A/L384A) kan 
opleveren dat in staat is om vele verschillende combinaties van amines en fumaraten om te zetten. 
Echter, de MAL-dubbelmutant Q73A/L384A is vrijwel inactief en daarom ongeschikt voor de 
synthese van aminozuren. Met toekomstig onderzoek zullen we daarom door middel van saturation 
mutagenesis een doelgerichte bibliotheek construeren van dubbelmutanten die gemuteerd zijn op 
posities 73 en 384. Het onderzoeken van deze bibliotheek levert hopelijk verschillende 
biokatalysatoren op die ieder een optimale activiteit hebben voor omzetting van een unieke 
combinatie van een nucleofiel en een elektrofiel substraat. Het is belangrijk om te beseffen dat 
hoogstwaarschijnlijk niet alle nucleofiel-elektrofiel-combinaties succesvol zullen worden omgezet 
aangezien grote substituenten op zowel het amine- als het fumaarzuursubstraat de additiereactie 
sterisch kunnen hinderen.  
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Op dit moment hebben we MAL succesvol gemuteerd zodat de stereoselectiviteit en de 
hoeveelheid substraten die geaccepteerd worden, voor de synthese van een grote collectie -
aminozuren, zijn verhoogd. De volgende grote uitdaging zal zijn om MAL zodanig te muteren dat 
het de synthese van -aminozuren kan katalyseren. Helaas heeft een herontwerp van de 
bindingslocatie van de C1-carboxylaatgroep van het substraat door middel van saturation 
mutagenesis van posities Gln-172, Thr-360 en Cys-361 (Figuur 1d) niet tot mutanten geleid die de 
amine-additie aan onverzadigde monocarbonzuren kunnen katalyseren. Dit is de reden dat we zijn 
begonnen om verschillende groepen van residuen van MAL tegelijkertijd te muteren om zodoende 
één of meerdere mutanten te verkrijgen die de asymmetrische synthese van -aminozuren kunnen 
katalyseren. De achterliggende gedachte is dat er wellicht een synergistisch effect optreedt wanneer 
er verschillende groepen residuen tegelijkertijd worden gemuteerd. Deze onderzoeksopzet vereist 
een pragmatische, en ook gevoelige, manier van detectie van de gewenste activiteit, bijvoorbeeld 
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